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 1. Background 
Bones are rigid organs that constitute part of the endoskeleton of vertebrates. The adult 
human skeleton contains 213 bones that are vitally important to support and protect the 
various organs of the body. Clinically, the occurrence of bone defects is common and can 
be caused by a variety of factors, including congenital deformity, trauma/injuries, infec-
tion, osteoporosis, and tumorectomy. In daily life, bone defects have a significant impact 
on an individual’s life quality, as well as on overall health care cost. For example, the 
estimated cost of treating all musculoskeletal injuries in 2004 was $127.4 billion in the 
United States1. In addition, treatment of fractures and other musculoskeletal injuries will 
continue to increase as a result of population aging and growth, which might be a major 
cost to the medical community and society. 
A conventional strategy to reconstruct bone defects (particularly large bone gaps and 
composite defects) involves transplantation of bone grafts, which can be harvested from 
the iliac crest, fibula, scapula or radius (either autogenous or allogenous)2. This approach 
has established itself as the “gold standard” in bone reconstructive surgery because of 
its high success rates owing to the osteogenic, osteoinductive and osteoconductive prop-
erties of autologous bone3. However, the inherent drawbacks of this approach, including 
insufficient autogenous resources, contour irregularities and donor-site morbidity2, 
strongly urge clinicians and researchers to explore alternative treatment options. 
2. Bone tissue engineering 
In view of the drawbacks of conventional bone graft strategies, bone tissue engineering 
recently has emerged as a promising approach for bone reconstruction. The fundamen-
tal concept behind bone tissue engineering is to utilize the body’s own biological capaci-
ty for bone healing in conjunction with engineering principles. There are three important 
elements for bone tissue engineering, namely scaffolds, cells and biomolecules (Figure 
1). A conventional tissue engineering strategy starts with pre-culturing progenitor cells 
on synthetic scaffolds, followed by transplantation of cell/scaffold complexes into the 
defect site. In this approach, the progenitor/stem cells isolated from bone marrow, 
which have been recognized as the most efficient cell type for osteogenic differentia-
tion4, provide the main resource to form new bone tissue; while the scaffolds mainly 
provide physical accommodation to cells to enable them secrete extracellular bone ma-
trix and form new bone tissues. 
In principle, an optimal tissue engineering scaffold should mimic the structural and func-
tional characteristics of bone extracellular matrix (ECM). Natural bone ECM is composed 
of nanoscale collagen fibers, in which biomolecules (e.g. cytokines and growth factors) 
are incorporated. The nanoscale architecture of the ECM influences the adhesion and 
orientation of cells5, while the release of biomolecules from the ECM regulates cellular  
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proliferation and differentiation6. In view of this, an optimal tissue engineering scaffold 
should provide more than only physical support for cells; it should also direct the local 
biological processes (e.g. via the release of biomolecules) in order to modulate optimal 
cell and tissue responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Electrospun scaffolds for bone tissue engineering 
Tissue engineering scaffolds have been prepared using a multitude of different tech-
niques, such as gas foaming, emulsion freeze drying and rapid prototyping7. Recently, 
electrospinning has emerged as a popular technique to prepare tissue engineering 
scaffolds due to its relative simplicity regarding the generation of fibrous scaffolds with 
nanoscale dimensions. In addition, due to the nanoscale properties, electrospun 
scaffolds have been considered as an effective delivery system owing to the stereological 
porous structure and high specific surface area8. 
Electrospinning utilizes electrostatic forces to spin polymer solutions or melts into 
whipped jets, resulting in continuous fibers with diameters from a few nanometers to 
micrometers after solvent evaporation in the spinning process9. A typical electrospinning 
set up contains four parts: (1) a syringe pump, which controls the feeding rate of poly-
mer solution to be electrospun; (2) a needle, through which the solution goes into a high 
electric field; (3) a high voltage source, which stretches the polymer solution into ul-
trathin fibers; and (4) a grounded fiber collector, where electrospun fibers can be collect-
ed in a static or dynamic way.- 
There is a wide range of material choices to prepare electrospun scaffolds for tissue engi- 
Figure 1. Three key elements for tissue engineering, namely cells, scaffolds and biomolecules 
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neering applications, which mainly includes two categories: natural polymers and syn-
thetic polymers. In principle, the material choice for scaffold preparation depends on the 
purpose of application and feasibility of electrospinning. Compared to the natural poly-
mers, synthetic polymers (especially the polyesters) are much easier to be optimized for 
electrospinning, and hence are more commonly applied. Among multiple choices of syn-
thetic polymers, poly(ε-caprolactone) (PCL), poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA) and their copolymers poly(lactic-co-glycolic acid) (PLGA) are most extensively used 
for biomedical applications, as they are constituents of many products approved by the 
US Food and Drug Association (FDA) and have demonstrated suitable biocompatibility as 
well as biodegradability. 
4. Bioactive electrospun scaffolds with biomolecules incorporation 
As aforementioned, a successful tissue engineering approach requires scaffolds to pro-
vide biological functionality in addition to simple physical support. Consequently, it is 
important to enhance the biological functionality of electrospun scaffolds by incorpo-
rating biomolecules that can stimulate bone regeneration process.  
Multiple kinds of biomolecules play important roles in regulating recruitment, prolifera-
tion, and differentiation of osteogenic progenitor cells. Chapter 2 comprehensively de-
scribes various biomolecules with potential for application in bone regeneration. Based 
on their molecular weight, therapeutic biomolecules can be divided as macromolecules 
and small molecules. Macromolecules include growth factors, cytokines as well as their 
corresponding encoding nucleic acids, which mainly regulate the morphogenesis and 
regeneration of bone tissue. Comparatively, small molecules, predominantly drugs, pep-
tides, and oligonucleotides, are emerging in recent years as an effective adjuvant therapy 
to improve the conditions for bone regeneration10. 
Currently, the mainstream of research interest in tissue engineering still focuses on 
growth factor/cytokines incorporation, as these biomolecules are the most straightfor-
ward candidates to modulate bone regeneration. For example, stromal cell derived fac-
tor-1 alpha (SDF-1α) has shown to be a powerful chemokine involved in cell recruitment 
in a variety of tissues10; bone morphogenetic protein-2 (BMP-2) is critically involved in 
mediating mesenchymal condensation that appears prior to the formation of mature 
bony structures11; while vascular-endothelial growth factor (VEGF) plays important roles 
in the regulation of angiogenesis during bone healing11. In view of this, the focus of this 
thesis is to functionalize electrospun scaffolds with aforementioned growth factors/
cytokines. 
In order to incorporate electrospun scaffolds with biomolecules, there currently are four 
fabrication techniques, i.e. physical adsorption, blend electrospinning, coaxial electro-
spinning, and covalent immobilization. The principles, their application as well as pros  
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and cons of these techniques are extensively described in Chapter 3. Among these four 
techniques, physical adsorption is the easiest way to load biomolecules, albeit that it 
generates a large burst release and a relatively short release period. Blend and coaxial 
electrospinning are the most commonly used methods to generate electrospun scaffolds 
with slow and sustained release profiles, since the biomolecules are embedded within 
polymeric scaffolds during electrospinning. In contrast, covalent immobilization is not a 
routine way to deliver biomolecules from electrospun scaffolds due to its technical com-
plexity. In addition, some researchers also doubt the uniformity loss of the scaffolds dur-
ing surface modification processes12, which might affect topographical and mechanical 
properties of the scaffolds. In consequence, this thesis particularly focuses on biomole-
cule incorporation within electrospun scaffolds through physical adsorption, blend elec-
trospinning, and coaxial electrospinning. 
5. Objectives of this thesis 
This thesis aimed to cover research on the development of bioactive electrospun 
scaffolds with biomolecule incorporation via different techniques. In addition, the evalu-
ation of the efficacy of obtained bioactive electrospun scaffolds for guided bone regener-
ation was an objective. Finally, this thesis also aimed to explore strategies to improve 
host tissue responses upon implantation of nanofibrous electrospun scaffolds. 
The following research questions were covered: 
1. What is the current state of the art in local delivery of biomolecules for bone re-
generation? 
2. What are current available methods to functionalize electrospun scaffolds with 
biomolecules, and what are pros and cons for different methods?  
3. Can electrospun scaffolds be functionalized with SDF-1α by physical adsorption to 
achieve cell recruitment? 
4. What is the superior method to generate bioactive electrospun scaffolds with 
sustained release of biomolecules, in respect of spinnability, release profiles, and 
bioactivity preservation? 
5. What is the application potential for coaxial electrospun nanofibrous scaffolds 
with growth factor release? 
6. What are biocompatibility and degradation characteristics of PLGA-based nano-
fibrous electrospun scaffolds?  
Chapter 1 
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1. Introduction 
The bones of the craniomaxillofacial (CMF) skeleton include the neurocranium and facial 
bones. These bony structures provide the foundation for oral-facial soft tissues and pro-
tections for organs (i.e. brain, nerve, and vasculature) located inside, and are thus func-
tionally and aesthetically important. The occurrence of CMF bone defects are common 
and can be caused by a variety of factors, including congenital deformity, trauma, infec-
tion, and tumorectomy. For example, in 2007 over 400.000 people in the United States 
required maxillofacial surgery for injuries to the face and jaw1. Affected patients suffer 
from functional disorder, social incapacitation, and biomedical and economical burden. 
This patient population ultimately demands an effective restoration strategy to fulfil aes-
thetic and functional requirements. 
Current state of the art reconstruction of bony defects in the CMF area involves trans-
plantation of bone grafts harvested from the iliac crest, fibula, scapula or radius (either 
autogenous or allogenous), which inherently contain microvascular structures2, 3. This 
approach has established itself as the “gold standard” in bone reconstructive surgery 
because of high success rates due to the osteogenic, osteoinductive and osteoconductive 
properties of autologous bone4. However, the inherent drawbacks of this approach, in-
cluding insufficient autogenous resources, contour irregularities, and donor-site morbidi-
ty5, strongly urge clinicians and researchers to explore alternative treatment options. 
With an improved understanding of CMF biology as well as progress in biomedical thera-
peutic techniques, an alternative strategy in CMF reconstruction termed regenerative 
craniofacial surgery emerged, which aims to repair CMF defects by inducing the regener-
ation of autogenous bone instead of using exogenous transplants with their inherent 
shortcomings6. An important approach for regenerative craniofacial surgery is based on 
the concept of tissue engineering, which aims to utilize the body’s natural biological re-
sponse to tissue damage in conjunction with engineering principles7.  
There are three key factors involved in tissue engineering, namely cells, scaffolds, and 
biomolecules8. In recent years, an increasing trend toward the combination of scaffolds 
and biomolecules became obvious9-12, in which scaffolds with controlled release of bio-
molecules induce ((pre)seeded) cells to proliferate and differentiate during an ex vivo pre
-culture period, thereby encouraging tissue formation after implantation in vivo. Upon 
implantation, those scaffolds continue to release signal molecules to enhance the de-
sired biological response, and hence enhance tissue regeneration in the defect area13. 
Bone regeneration involves a complex cascade of processes during which resident or 
bone marrow-derived precursor cells migrate to the site of damage and undergo differ-
entiation into the osteogenic lineage14. As such, a large number of small and large bio-
molecules (including hormones, cytokines, and growth factors) are involved in bone 
regeneration that modulate the cellular behavior of progenitor and inflammatory cells  
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in terms of migration, proliferation, and differentiation15. Considering the importance of 
these biomolecules during bone regeneration, it is not surprising that exogenous deliv-
ery of a single or multiple biomolecules at the defect site has been heavily explored as a 
promising therapeutic strategy in CMF bone regeneration.  
Based on the molecular weight, a threshold can be set at 5 kDa to divide therapeutic 
biomolecules in CMF bone into either macromolecules or small molecules. Macromole-
cules include growth factors, cytokines as well as their corresponding encoding nucleic 
acids, which mainly regulate the morphogenesis and regeneration of CMF skeleton and 
have been investigated extensively in the past to promote bone regeneration. Compara-
tively, small molecules, predominantly including drugs, peptides, and oligonucleotides, 
are emerging in recent years as an effective adjuvant therapy to interfere with infection, 
osteoporosis and tumor metastasis in CMF bone, thereby improving the conditions for 
CMF bone regeneration.  
In general, biomolecules can be administered either systemically or locally. Due to the 
low oral and transdermal bioavailability, short biological half-life, tissue specificity, and 
potential dose-dependent carcinogenicity16, 17, systemic administration of biomolecules 
is often not effective. Consequently, localized controlled delivery via a carrier material is 
advantageous for therapeutic applications in order to optimize efficacy of biomolecules 
and increase the comfort, convenience, and compliance of involved patients17. 
This review will focus on the effects of locally delivered small and large biomolecules for 
the clinical treatment of CMF bone defects. We will describe biomolecules that are in-
volved in the process of CMF bone healing with specific emphasis on small molecule 
drugs, followed by a description of currently explored carrier materials and their re-
quirements to achieve optimal biomolecule delivery. Finally, we will provide a perspec-
tive on the applicability of biomolecule delivery in CMF repair by reviewing the pre-
clinical studies carried out so far in various animal models. 
2. Lessons from biology: biomolecules involved in CMF bone healing 
2.1. Biomedical fundamentals for CMF bone 
From a biological point of view, it should be realized that several differences can be dis-
cerned between CMF bone formation and axial skeleton formation. First of all, the CMF 
bone and axial bone arise from different embryonic lineages, in which the CMF bone is 
formed by cranial neural crest cells, whereas the axial skeleton is derived from paraxial 
mesoderm (somites)18. Secondly, the CMF bone and axial bone undergo different bone 
formation pathways. Two different pathways are involved in skeletogenesis, i.e. in-
tramembranous ossification and endochondral ossification19. During embryonic devel- 
opment, the CMF bones, including the cranial vault, maxilla, mandible, and frontal re- 
gion of the facial skeleton, undergo intramembraneous formation, which involves a  
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direct differentiation of mesenchymal precursors into osteoblasts as well as direct dep-
osition of bone matrix by osteoblasts20.  
In contrast, long bone structures are formed by endochondral ossification21, which 
starts with the condensation of mesenchymal precursors into the chondrogenic lineage, 
which then go into hypertrophy before finally entering terminal chondrogenic differen-
tiation resulting in a mineralized cartilage matrix22. Many morphogenetic factors play 
important roles in CMF bone development18, which will be explained in detail in section 
2.2.2.  
From a clinical therapeutic point of view, the unique location of the CMF skeleton raises 
another consideration in treatment compared to axial bone. The CMF skeleton is inter-
connected with the oral cavity, which hosts over 700 species of bacteria23. This unique 
location makes that the infection risk is high in bone tissue close to the oral cavity (e.g. 
alveolar bone, mandible, and maxilla). For example, in clinics, osteomyelitis of the jaws 
is a common infectious disease, leading to surgical debridement of the infected bone 
and long-term antibiotic therapy24. The main causes for osteomyelitis are odontogenic 
microorganisms25. In addition to the high risk of infection, the numerous lymph nodes, 
nerves and vasculature structures in the CMF area increase the risk of tumor metasta-
ses to CMF bone from surrounding tissues. It has been reported that 1% of oral cancers 
metastases to the mandible, while the occurrence of other mandible metastases is 
mainly caused by malignant tumors from breast, lung, kidney, and colon26. Therefore, 
when treating the CMF bony lesions caused by tumorectomy, an indispensible therapy 
to the routine bone regeneration is the administration of anti-tumor drugs to prevent 
further metastasis. 
2.2. Candidate biomolecules for CMF bone defect therapy 
As aforementioned, a highly promising therapy for reconstruction of CMF bone is to 
induce bone regeneration in the defect site, rather than simply fill the defect with graft-
ing materials. The regeneration processes in CMF bone are initiated in response to inju-
ry followed by normal bone development coordinated by cells derived from perioste-
um, bone, and external soft tissues surrounding the defect site27. As aforementioned, 
candidate biomolecules for therapeutic applications in CMF bone regeneration can be 
categorized into two groups according to their  molecular weight (threshold: 5 kDa): (i) 
large molecules, including growth factors, cytokines as well as their corresponding en-
coding nucleic acids, and (ii) small molecules, including drugs, peptides, and oligonucle-
otides. The large molecules can be further subcategorized by their functions in the pro-
cess of craniomaxillofacial bone regeneration: (i) inflammatory cytokines and chemo- 
kines, which orchestrate inflammatory responses and chemotaxis of regenerative cells; 
(ii) morphogenetic factors which regulate skeleton formation and morphogenesis; (iii)  
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angiogenic factors, which direct vascularisation to allow transport of nutrients, oxygen  
and waste during bone formation; The small molecules also include different subgroups 
based on their functions such as (i) short peptides derived from therapeutic proteins, 
which play similar roles as proteins in physiological process of CMF bone regeneration, 
(ii) anti-infection molecules, (iii) anti-tumor molecules, as well as the (iv) antiosteopo-
rotic molecules. The latter three groups of small molecules have intrinsic capacity to 
alleviate compromised conditions that may hinder CMF bone regeneration (Figure 1).  
 
 
 
 
 
 
 
 
 
 
2.2.1. Large molecules 
2.2.1.1. Inflammatory cytokines and chemokines. Bone healing is initiated with hemato-
ma formation and activation of the immune system15. During this initial stage, a number 
of cytokines are secreted by macrophages and inflammatory cells, which regulate the 
healing process. The detailed categories of cytokines and their function during immune 
response have already been clearly reviewed28. Among different kinds of cytokines, in-
terleukin 1 (IL-1) and tumor necrosis factor-α (TNF-α) are known to be the most im-
portant pro-inflammatory cytokines, as they play an important role in initiating the in-
flammatory cascade28, whereas interleukin-4 (IL-4), and interleukin-13 (IL-13) are consid-
ered as pro-wound healing cytokines, as they suppress the production of pro- 
inflammatory cytokines hence promoting wound healing29, 30. 
Figure 1. Classification and controlled release of biomolecules involved in therapeutic applications in CMF 
bone regeneration. Macromolecules, primarily including proteins and DNA, can be loaded by carrier devices 
and released extracellularly or intracellularly to guide cell behaviors and regulate bone healing process; 
while small molecules, hereby defined as biomolecules with molecular weight lower than 5kDa, mainly 
target bone regeneration under compromised conditions such as infection, skeletal malignancies and me-
tastases in CMF bone and osteoporosis. 
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In recent years, the chemotactic capacity of cytokines has gained interest rapidly, as re-
searchers realized that recruitment of precursor cells plays a critical role during bone 
repair. Stromal cell derived factor-1 alpha (SDF-1α) has shown to be a powerful chemo-
kine involved in cell recruitment in a variety of tissues31. It has been demonstrated that 
SDF-1α is critical to migration of hematopoietic stem cells (HSCs) and can be used to tar-
get stem cells to a desired site within the body32. Furthermore, recent studies revealed 
that SDF-1α improves the efficiency of BMPs in vivo by increasing the number of oste-
oprogenitor cells that are mobilized from the bone marrow33. In addition to SDF-1α, TNF-
α has also been reported to promote recruitment of mesenchymal stem cells (MSCs), 
induce apoptosis of hypertrophic chondrocytes, and stimulate osteoclastic function34. 
2.2.1.2. Morphogenetic factors. During the morphogenetic process, several soluble fac-
tors, including TGF-β superfamily members, fibroblast growth factors (FGFs), sonic 
hedgehog (SHH), and Wingless- and Int-related proteins (Wnts), participate in a complex 
series of events that guide mesenchymal precursor cells in the skull through patterning, 
proliferation, and differentiation to form the craniofacial skeleton. Previous studies have 
already comprehensively reviewed the detailed molecular mechanisms of TGF-β super-
family35, FGFs36, SHH37, and Wnts38 in CMF skeleton development, for which only key 
functions of these biomolecules are highlighted below. 
TGF-β superfamily members are the most extensively studied growth factors in recent 
years. This family includes five TGF-β isoforms (TGF-β1-5), bone morphogenetic proteins 
(BMPs), the inhibins/activins, and a number of distantly-related molecules39. BMPs (BMP
-2, 4, 7), have been demonstrated to play important roles in determination, migration, 
condensation, proliferation, and apoptosis of skeletal cells. More particularly, BMP-4 and 
BMP-7 have been reported to be responsible for neural crest cell induction35, whereas 
BMP-2 is critically involved in mediating mesenchymal condensation that appears prior 
to the formation of mature bony structures in both intramembranous and endochondral 
ossification6. The other members of the TGF-β superfamily (TGF-β 1-3) also participate in 
bone formation induction40, but the osteoinductive activity of TGF-β proteins is specifi-
cally found in heterotopic sites in primates41. 
Fibroblast growth factors (FGFs) are humoral factors originally identified by their ability 
to stimulate cell proliferation42. The family of FGFs consists of twenty-two members that 
are involved in diverse biological roles in the regulation of cell proliferation, differentia-
tion, and function42. During craniofacial bone development, FGFs are required for the 
regulation of intramembranous ossification, and absence of FGF-2 was reported to inhib-
it osteogenesis in cranial vault development43. During bone healing, FGFs can be secret-
ed by monocytes, macrophages, mesenchymal cells, osteoblasts, and chondrocytes, in 
the early stages of fracture healing27. 
Compared to the morphogenetic molecules mentioned above, Wnts and SHH are less  
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known to clinicians, but gained increasing interest in recent years because of their im-
portant function during the process of craniofacial development. Wnts are associated 
with the maintenance and proliferation of mesenchymal stem cells during craniofacial 
development44. SHH is involved in regulating the transdifferentiation of epithelial cells to 
a mesenchymal cell fate, as well as the proliferation of mesenchymal cells during cranio-
facial patterning, and this process is indispensible for fusions between the palatal 
shelves45. 
Furthermore, insulin-like growth (IGFs), platelet-derived growth factor (PDGF), growth 
hormone, parathyroid hormone, and vitamine D have also been demonstrated to medi-
ate osteoblast activity during the process of bone remodeling46.  
2.2.1.3. Angiogenic factors. Optimal bone healing requires adequate blood supply to 
transport nutrients and oxygen. Two separate pathways are involved in the regulation of 
angiogenesis during bone healing: a vascular-endothelial growth factor (VEGF)-
dependent pathway, and an angiopoietin (Ang)-dependent pathway47. VEGF isoforms 
are involved in the regulation of the interaction between angiogenesis and osteogene-
sis48. It has been demonstrated that VEGF promotes endochondral bone formation via 
synergistically acting with BMP-4 for the recruitment of mesenchymal stem cells49. A 
previous study showed that the expression of Ang-2 and its receptor Tie-1 significantly 
increased during the chondrogenic phase of fracture repair50, which might indicate the 
participation of Ang-2 in endochondral ossification. On the other hand, the role of the 
angiopoietin pathway and its contribution in bone healing process are still not fully un-
derstood47. 
2.2.2. Small molecules 
2.2.2.1. Peptides derived from therapeutic proteins. Short peptides derived from thera-
peutic proteins can exert similar biological functions without involving complicated 
structures of the entire proteins and are delicate in the biological environment. A vivid 
example for this category are synthetic peptides corresponding to the knuckle epitope of 
BMPs. It has been reported previously that a synthetic peptide derived from BMP-2 
knuckle epitope, NSVNSKIPKACCVPTELSAI (residues 68–87), recruited osteocalcin posi-
tive osteoblasts, and induced ectopic calcification when a peptide-conjugated alginate 
gel was implanted into a rat’s muscle51. Another synthetic peptide, KIP-
KASSVPTELSAISTLYL (residues 73–92, C78,79S and M89T) has been demonstrated to in-
duce differentiation of osteoblast precursor cells and activate osteoblasts to promote 
repair of bone defects52. Beside peptides derived from BMP-2, synthetic peptides from 
BMP-7, including SNVILKKYRN, (residues 121-130), KPSSAPTQLN (residues 101-110), and 
KAISVLYFDDS (residues 110- 120) have been reported to promote proliferation and calci- 
um deposition of osteoblasts53. Recently, Bergeron et al54 incorporated a 23-residue syn- 
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thetic peptide Ac-CGGKVGKACCVPTKLSPISVLYK-NH2 derived from human BMP-9 
(residues 68–87) into collagen and chitosan gels and investigated effects on ectopic bone 
formation. Their results indicated that chitosan gels containing 100 μg of BMP-9 peptides 
induced lamellar bone formation in mouse quadriceps after 24 days, although bone for-
mation was not as strong compared to the same gel containing full length of BMP-9. To-
gether, these studies suggest a promising future for the application of short peptides 
instead of entire proteins in the field of regenerative medicine. 
2.2.2.2. Anti-infection molecules. It is generally accepted that resistant microbial infec-
tion, due to periodontitis23 or osteomyelitis55, is the main cause for alveolar bone loss. 
Therefore, an effective anti-microbial infection treatment is indispensible to achieve 
bone regeneration. Antibiotic therapy is the mainstay of treating microbial infection in 
CMF skeleton. Several types of antibiotics have become commercially available in the 
past decades, and the most commonly used antibiotics in clinics include tetracyclines, 
penicillins (amoxicilin), metronidazole  and cephalosporins55, 56. However, the increasing 
microbial resistance following the use of antibiotics remains a critical concern for thera-
peutic application of antibiotics in clinics57. Beside commercially available antibiotics, 
antimicrobial peptides (AMPs) from saliva and gingival crevicular fluid are recently 
emerging as effective therapeutic molecules. These AMPs constitute a diverse class of 
host-defense molecules ranging from small cationic peptides to enzymes that play a role 
in balancing oral pathogens and commensals23.  
2.2.2.3. Anti-tumor molecules. In clinics, anti-tumor therapy is often required for recon-
struction of the skeletal malignancies and surgical removal of metastases to slow down 
tumor growth and metastasis outgrowth. Classical drugs include cyclophosphamide, 
methotrexate, and 5-fluorouracil, while new generation agents include anthracyclines 
and texanes, such as epirubicin, doxorubicin and paclitaxel58. It needs to be emphasized 
that the combined usage of these drugs may also weaken the bone further, hence the 
dosage and administration route should be well controlled. Nowadays, RNA interference 
(RNAi) provide a new perspectives in disease treatment by targeted degradation of 
mRNA with the introduction of small interfering RNAs (siRNAs) or small hairpin RNAs 
(shRNAs)59. To date, RNAi for therapeutic purposes has been explored in different appli-
cations including anti-cancer and antiviral treatment in different organs60. For instance, it 
is well established that the VEGF-receptor pathway is important in the pathogenesis and 
angiogenesis of human cancers61, for which the introduction of a VEGF-targeted shRNA 
was hypothesized to inhibit angiogenesis in the progression of cancers. This therapeutic 
approach has recently been shown to result in a significant delay of tumor growth62.  
2.2.2.4. Anti-osteoporotic molecules. Anti-osteoporotic treatment is another increasing 
issue in view of regenerative treatments of CMF bone defects, as osteoporosis systemi- 
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cally influences general bone formation and remodelling. It is generally accepted that 
systemic osteoporosis and its milder form osteopenia, can cause substantial bone loss in 
alveolar and jaw bone63. Currently, an effective pharmaceutical treatment for osteoporo-
sis is the application of use anti-resorptive drugs, including bisphosphonates, calcitonin, 
estrogen, and estrogen agonist/antagonist. All of these biomolecules inhibit (directly or 
indirectly) osteoclast activity to diminish bone loss and hence mainly act to stabilize the 
balance of bone turnover. Recently, N-methylpyrrolidone (NMP) was found to inhibit 
osteoclast differentiation and attenuate bone resorption64 .In addition, the combination 
of genistein, zinc, and vitamin D has also been shown to improve bone mineral density65. 
On the other hand, the anabolic agents that enhance bone mass and improve bone archi-
tecture are clinically very important in treating established osteoporosis. The most fre-
quently used anabolic agent is parathyroid hormone (PTH), for which it has been report-
ed previously that it promotes osteoblast function to increase new bone formation65. 
Currently, several PTH analogs are being investigated, and finally human (h) PTH (1-34) 
has been approved for use in osteoporosis treatments in the United States66. Recently, 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), which have been 
principally used as the most effective class of drugs to reduce serum cholesterol concen-
trations, were found to have anabolic effects on bone metabolism. It was discovered that 
treatment with statins can stimulate cellular osteogenic differentiation by enhancing 
BMP-2 mRNA expression and increasing trabecular bone volume when orally adminis-
tered to ovariectomized rats67-69. Although statins are considered as potential therapeu-
tic agents for anti-osteoporotic treatment, due to different kinds of statins available on 
the market and different dosages and administration methods, controversial results still 
exist regarding their biological effect on bone metabolism (see also review by Horiuchi et 
al66).  
3. Carrier material requirements for the delivery of biomolecules in CMF 
bone regeneration 
After discovery of the important biological function of above-described small and large 
biomolecules during CMF bone healing, extensive research efforts have been dedicated 
to enable delivery of these biomolecules into the defect site to enhance bone healing. 
Regardless of the delivery form, the fragile nature of biomolecules demands for con-
trolled delivery carriers to achieve an optimal therapeutic application. Generally, carrier 
systems for biomolecule delivery should be biocompatible and biodegradable. In addition 
to these general requirements, an optimal carrier device should also ensure the biologi-
cal activity of biomolecules as well as allow for controlled release profiles in line with the 
time window of tissue regeneration70. Compared to the small molecule drugs, delivery of  
proteins and genes is more challenging due to their complicated structure and fragile   
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structure. Therefore, we will specifically list some important considerations for those 
biomolecules delivery. 
3.1. Preservation of biological activity 
Carrier devices for delivery of proteinaceous biomolecules should preserve the confor-
mational stability of these proteins. The conformational stability of proteins can be com-
promised at different stages: (i) during carrier/protein construct fabrication, (ii) during 
carrier/protein storage, and (iii) after implantation71. Two main pathways towards loss of 
conformational stability of proteins can be discerned: (i) physical or noncovalent degra-
dation, which leads to changes in secondary or tertiary structures; and (ii) chemical inac-
tivation, which results from changes in primary structure.  
Noncovalent degradation mainly refers to the destruction of noncovalent interactions 
(i.e., hydrogen bonds, van der Waals interactions, salt bridges, and hydrophobic interac-
tion) in the native protein structure caused by elevated temperature, extremes of pH, 
denaturants, and adsorption to hydrophobic surfaces72. Due to noncovalent degradation, 
a protein may unfold locally and globally from its native structure to yield an inactivation 
or aggregation state17. Chemical inactivation includes hydrolysis of the peptide bonds, 
deamidation, oxidation, β-elimination, isomerization, and disulfide bond breakage and 
formation, which are mainly influenced by the temperature and pH value of the solu-
tion72. In view of this, the overall strategy for preserving protein stability is to prevent 
protein inactivation or aggregation from above-mentioned environmental conditions.  
Different from proteinaceous molecules, which act extracellularly by binding to corre-
sponding cell surface receptors, gene-based biomolecules will only work intracellularly. 
Based on this principle, the prerequisite for successful gene delivery is that the target 
gene can be released from the carrier, after which it needs to be to be taken up by the 
host cell and remain functional to be transcribed and translated to generate proteins. As 
naked genes are vulnerable to ubiquitously available extracellular DNA-degrading en-
zymes and intracellular lysozymes73, the target gene is commonly protected by chaper-
one vectors, which can be categorized into either viral or non-viral vectors74, 75. 
3.2. Controlled release kinetics 
Another important issue for biomolecule delivery is to control the spatiotemporal availa-
bility at the defect site. Logically, mimicking release kinetics of multiple biomolecules in 
different time windows during bone regeneration will provide attractive options. As, the 
release kinetics related to the in vivo efficacy is difficult to investigate, mainly extensive 
studies have been performed to evaluate the effect of dual and multiple biomolecules 
release on cellular behavior in order to optimize the delivery systems76, 77. 
Optimally, the release of biomolecules from a carrier should initially release a substantial 
part of loaded amount, termed as “burst release”78, to rapidly obtain the effective thera- 
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peutic concentration, followed by a well-defined release to prolong the time window of a 
supra-threshold dosage79. However, it needs to be emphasized that this burst release 
should be controlled to achieve an optimal therapeutic efficacy, thereby avoiding su-
praphysiological concentrations of biomolecules (e.g., BMPs, etc) at the defect site that 
may cause adverse effects80, 81. 
Similar to protein delivery, gene delivery relies on efficient concentrations for sufficient 
duration. In view of this, too low concentrations of plasmid82, 83, or too fast release of 
plasmid83 have been demonstrated to result in low gene transfection efficiency, mainly 
because the surrounding cells cannot capture sufficient gene-vector complexes or super-
abundant gene complexes may lose activity when transfection is not achieved in due 
time. 
3.3. Targeted delivery 
Besides the biological activity preservation and controlled release kinetics, tissue-target 
releasing becomes nowadays another important issue for the local delivery of biomole-
cules to improve the efficacy and safety of biomolecules delivery, especially for the anti-
cancer drug delivery. In a clinical oncological situation, it is difficult to exactly localize the 
drug delivery vehicles solely within the tumor tissue because tumor tissue is usually adja-
cent to healthy tissue. In order to make the anticancer drugs only target tumor cells, it is 
necessary to make the delivery vehicles specific or targeted for the diseased cells. Two 
strategies can be discerned to obtain targeted local delivery of biomolecules: (i) ligand-
free strategy, and (ii) ligand-functionalization strategy. Ligand-free strategy is to increase 
the affinity of incorporated biomolecules to the target tissues by mixing with other addi-
tives. For example, some groups reported that growth factors can be mixed with 
bisphosphonates, tetracyclines, glutamic and aspartic oligopeptides, and peptides de-
rived from non-collagenous proteins, which have high affinity to bone70 to achieve bone-
targeting function. Ligand-functionalization strategy is to modify the surface structure of 
the carrier device by conjugating a cell-specific ligand to direct the biomolecules to be 
released more or less exclusively in close association with the target cells. For example, 
PEG-tethered ligands are reported as a potential platform technology to delivery bone 
cell-specific biomolecules for bone repair purpose70. Various molecules that specifically 
bind to an antigen or receptor that is either uniquely expressed or overexpressed on the 
tumor cell surface can be conjugated to the carrier device to selectively deliver anti-
cancer biomolecules to tumor cells84. 
4. Mechanisms for biomolecule release from carrier devices 
To optimize the pharmacokinetics of biomolecule delivery, it is of paramount importance 
to understand the mechanisms of biomolecule loading and release in various delivery  
systems, which may directly influence the resulting efficacy of delivery.  
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In general, the release of biomolecules in various delivery systems can be regulated by (i) 
desorption, (ii) diffusion, (iii) carrier degradation, and (iv) environmental stimuli, or con-
trolled by the combination of the abovementioned factors85-88 (Figure 2). 
4.1. Desorption-controlled release 
Typical desorption-controlled delivery vehicles are carriers consisting of dense or non-
swollen biomaterials, in which biomolecules cannot penetrate through or be entrapped 
inside the carrier network. Since adsorption/desorption happens at the interface be-
tween a biomaterial surface and its physiological environment, surface properties and 
design/geometry of delivery systems are main factors that affect the resulting release 
profiles89. Most delivery systems using particulate carriers are based on desorption-
controlled release owing to more active surface properties allowing high loading capacity 
and ease of surface functionalization90. However, limitations of this strategy are obvious, 
including the tendency of biomolecules to deactivate during adsorption, poor capacity of 
delivering hydrophilic molecules, and poor control over delivery, retention, orientation, 
or desorption rate of biomolecules91.  
4.2. Diffusion-controlled release 
Diffusion occurs in numerous delivery systems, in which small biomolecules are self-
propelled by thermal energy and spread into/out of carrying vehicles when dispersed 
into media. This process is a physical entrapment strategy, which can be affected by the 
characteristics of either biomolecules to be released (e.g. size, solubility and diffusion 
efficiency) or delivery vehicles (e.g. geometry, mesh size of network and affinity to small 
molecules). Typical carriers of this kind include hydrogels and polymeric fibrous mem-
branes that allow diffusional loading of biomolecules into polymer networks, thus provid-
ing a protective environment for biomolecules and prolonging their retention at treat-
ment sites. The release profile for diffusion-controlled delivery systems is normally char-
acterized by an initial burst release, followed by a phase of sustained release that can be 
further regulated by fine-tuning the physicochemical properties of carrier materials92. 
4.3. Degradation-controlled release 
Degradation-controlled release systems are defined as erodible systems, where biomole-
cules can be either: (i) physically entrapped in the carrier and released by carrier’s degra-
dation, or (ii) chemically immobilized to a polymer backbone and released upon hydro-
lytic or enzymatic cleavage of the bond85, 87, 88. By physical or chemical immobilization, 
fragile biomolecules can be preserved from harsh environmental factors, and released 
with high degree of controllability by tailoring molecular weight, crosslinking and mor-
phology of the carrier materials. Generally, these degradation-controlled release systems  
are favored over other release mechanisms since biomolecules are presented at the  
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treatment site in a so-called matrix-bound manner, similar to the way in which biomole-
cules are presented in the physiological environment93-96. 
4.4. Stimuli-triggered release 
Recently, intelligent delivery systems have gained considerable attention owing to their 
capacity to release biomolecules governed by environmental factors (e.g. pH, protein, 
glucose) or by external stimuli (e.g. temperature, ultrasound and irradiation)88, 94. These 
devices are referred to as “programmed” or “triggered” release systems, which show 
great potential for use in sequentially or spatiotemporally controlled delivery of multiple 
biomolecules88, 94. For example, self-exploding microcapsules based on a biodegradable 
microgel core surrounded by a bio-polyelectrolyte membrane have been developed, 
which can release their content in a pulsatile manner after a certain incubation time at 
physiological conditions97, 98. 
 
 
Figure 2.Schematic diagram of various mechanisms for biomolecules release from carrier devices. (A-D) and 
typical corresponding pharmacokinetics (a-d). (A) and (a), desorption-controlled release; (B) and (b), diffusion
-controlled release; (C) and (c), degradation-controlled model; (D) and (d), stimuli-triggered release. 
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5. Carrier devices for delivery of biomolecules 
From a materials perspective, the design of delivery systems plays a critical role for con-
trolled delivery of biomolecules with respect of chemical composition (including poly-
mer, ceramics and composites) and geometry (such as micro/nanoparticles, membrane 
and bulk materials. Therefore, in this section, we particularly focus on the classification 
of delivery carriers by reviewing the delivery systems that have been extensively used in 
CMF bone regeneration. 
Microparticles (MP) and, more recently, nanoparticles (NP), are the most extensively 
used platforms for controlled delivery of biomolecules, owing to their inherently small 
size and corresponding large specific surface area, a high drug loading efficiency, a high 
reactivity towards surrounding tissues in vivo as well as a high diffusibility and mobility of 
drug-loaded particles94, 99-103. 
The basic strategy of using particles for biomolecules delivery is to simply adsorb them 
onto the particle surface or encapsulate them inside the particle, and release their pay-
load by desorption, diffusion, or degradation depending on the chemical composition 
and geometry of the delivery vehicle. Recently, microcapsules have been developed to 
physically encapsulate labile biomolecules and prevent them from the harsh environ-
ment. Release profiles of encapsulated biomolecules normally display sustained release 
kinetics favorable for long-term delivery in comparison to molecules adsorbed onto bio-
material surfaces104, 105. Another strategy is to incorporate biomolecule-loaded (via ad-
sorption or encapsulation) particles into a continuous matrix of monolithic biomaterials, 
and hence gain prolonged retention of biomolecules, and simultaneously provide bulk 
materials with enhanced features for sustained release of biomolecules94, 99, 100, 106-108. 
Moreover, the use of particles facilitates programmable delivery of multiple biomole-
cules with precise spatiotemporal control over the distribution through carrier materials 
and release profiles of various molecules109, 110. 
Membranes have been extensively used in CMF tissue regeneration by acting as scaffold-
ing matrix supporting cell adhesion and proliferation, as well as effective biomolecules 
delivery carriers likely due to the large tissue-biomaterial interface. Especially, guided 
bone regeneration (GBR) technique has recently emerged as a promising approach by 
employing membrane materials, which mechanically exclude non-osteogenic cell popula-
tions from the surrounding soft tissues, thus securing the population of osteogenic cells 
and osteoconduction events111, 112. More importantly, therapeutic components can be 
loaded to GBR membranes via different strategies, aiming to improve bone healing. Di-
rect incorporation of biomolecules normally leads to a desorption-controlled release 
profile with complete release of loaded agents within days, while the introduction of 
additional carriers (such as MP/NPs) as molecules delivery vectors gives rise to a more 
sustained release, which is typically tailored by a combination of biomolecules diffusion  
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and membrane degradation113. 
Hydrogels are one of the most important groups of biomaterials for tissue regeneration 
and controlled delivery. Hydrogels are widely used in the biomedical field because of 
their favorable biological performance, hydrophilic nature, mild preparation conditions, 
versatility for biomolecule encapsulation, tunable release characteristics, and injectabil-
ity/moldability114. The three-dimensional hydrophilic network of hydrogels facilitates 
absorption of large volumes of aqueous solutions, allowing either physical or chemical 
immobilization of molecules into the polymer network, thereby protecting biomolecules 
from detrimental conditions115. Hydrogels have been increasingly advocated as promising 
devices for delivery of biomolecules and stem cells, which can be obtained via minimally 
invasive methods to fill shape-specific defects116. Injectable hydrogel precursors can be 
easily delivered and subsequently solidified in situ via either physical or chemical cross-
linking116, 117. Especially, physical gels undergoing gelation based on physical interactions 
(e.g. electrostatic or hydrophobic interactions) are highly suitable for carrying biomole-
cules92. Colloidal gels comprising electrostatically crosslinked PLGA nanocapsules have 
recently been developed as injectable carrier material for release of dexamethasone ac-
cording to a zero-order manner in vitro118. However, it needs to be emphasized that due 
to their poor mechanical properties, hydrogels are barely used for load-bearing applica-
tions. 
Ceramic materials such as calcium phosphate (CaP) ceramics also showed potential for 
use in localized delivery of biomolecules as granules, bulk scaffolds or injectable ce-
ments119. Due to the high affinity of ceramics for biomolecules, ceramic carriers can easi-
ly adsorb biomolecules, thus resulting into strong retention of biomolecules. Alternative-
ly, CaP nanoparticles display an extremely high surface-to-volume ratio which -in addition 
to their tunable phase composition and capacity to permeate cell membranes- offers 
specific advantages for controlled delivery of biomolecules120-123. On the other hand, in-
jectable calcium phosphate cements (CPC) have been investigated as injectable reser-
voirs of biomolecules. Biomolecules can be added to the cement by simply adding bio-
molecules to the liquid hardener, thereby obtaining homogeneous distribution through-
out the cement matrix. Further, additional carriers (e.g. PLGA microspheres) can be 
mixed with cement to encapsulate biomolecules124-126 in order to protect the biological 
activity and obtain a more controlled release profile of loaded biomolecules. 
6. Preclinical evaluation of different carriers with biomolecules delivery 
Although different categories of carrier devices have been developed in the past decades 
to achieve local delivery of different biomolecules, the functional evaluation of these 
carrier devices is mostly based on in vitro model systems (i.e. model protein release, bio 
activity assay). However, in vitro cell-based systems cannot fully reflect the in vivo re-  
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lease kinetics of biomolecules as well as the tissue performance evoked by the biomole-
cule gradients. Therefore, it is necessary to set up animal models and use these preclini-
cal models127 to fully understand the biological performance of these devices in an entire 
organism and as such make a translational step from bench-side to organism128. Although 
different animal models for biomolecule delivery have been recently reviewed regarding 
long bone defects129, it has to be emphasized that the biological performance of biomol-
ecules has to be evaluated under similar conditions as present in the intended applica-
tion due to e.g. differences in the bone formation process in different anatomical loca-
tions, effect of local conditions on biomolecule release and efficacy, and effect of local 
conditions on the response to the carrier material. Therefore, the next section of this 
review will summarize the biological performance of the biomolecules delivered by the 
afore-mentioned carriers in representative animal models specifically for CMF bone re-
construction. 
6.1. Animal models used in CMF bone reconstruction 
For studies investigating CMF bone reconstruction, it is important to understand the spe-
cies-specific bone characteristics, including bone microstructure and composition, as well 
as bone modelling and remodelling properties when generalizing the obtained results to 
the clinical situation130. Since no single animal model will be appropriate to meet all re-
quirements, as a consequence, different animal models, including small and large size 
animals have both been involved in the evaluation of CMF bone reconstruction. Small 
animals mainly include rodents such as mouse, rat, and guinea pig as well as non-
rodents, such as rabbits. Due to their easy maintenance and relatively low cost, small 
animal models are frequently used in CMF bone regeneration research to obtain funda-
mental and applied knowledge about the performance of biomaterials. However, the 
limited CMF area obtained from those animals raises difficulties in surgery. Compared to 
the small animal models, large animals (e.g. sheep, minipig, dog, and non-human pri-
mate) provide larger defect sizes for more control in the surgical area 5, and more close 
physiology to humans, but the expensive housing cost, as well as the related ethical is-
sues hinder their usage in biomedical research. 
6.1.1. Calvarial defects 
Calvarial defects represent the most commonly used defect model in CMF bone recon-
struction because calvarial defects provide good first phase (non-load bearing) bone 
healing models with relative biological inertness due to poor blood supply and limited 
bone marrow, which is thought to resemble the atrophic mandibular bone in humans130. 
The standard rodent calvarial bone defect is typically created by using a trephine drill 
that makes a circular defect in the cranial skeleton on the midline5 (Figure 3). Research- 
ers recognized that the defects are critical sized depending on their size (5 mm diameter  
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in mouse, and 8 mm in rat)131, which means that these are “above the threshold size 
intraosseous defect dimensions that will not heal spontaneously during the lifetime of 
the animal”132. However, in recent years, some researchers suggested that the use of the 
term of “critical sized defect” had to be discontinued131, because the definition of a criti-
cal sized defect is based on the size of the defect that will not heal within the life time of 
the animal, whereas most studies in reality are of limited duration. Consequently, many 
calvarial defects below the threshold of critical sized have been investigated in previous 
studies. Instead of creating one defect in the center of the skull, a bilateral calvarial de-
fect model was also developed by creating one defect (5 mm diameter in rat133, 8 mm 
diameter in rabbit134) in each parietal (cranial) bone next to the middle line, which reduc-
es the risk of significant trauma to the sagittal suture. 
In addition to studying the healing pattern in the CMF skeleton, calvarial defect models 
also enable monitoring the in vivo release kinetics of loaded biomolecules by using fluo-
rescent or gamma radioactive signals135, 136 owing to its superficial location. On the other 
hand, this model also involves additional requirements for the surgical techniques as 
well as the mechanical properties of filling materials. It is suggested the sagittal suture 
and the dura mater underlying the defect have to be carefully protected during the sur-
gery, which is important for the cranial skeleton healing131. Furthermore, the filling mate-
rial should be strong and resistant enough to avoid the dilation of brain tissue beneath 
the defect. 
6.1.2. Periodontal and mandibular bony defects 
Besides the calvarial defect, the periodontal and mandibular bony defect models are also 
very useful in the evaluation of periodontal bone regeneration as well as mandibular 
reconstruction. Periodontal and mandibular bone defect models include the suprain-
frabony defect, periodontal fenestration defect, artificial furcation defects, guided bone 
regeneration (GBR) defect, as well as the segmental defect in the mandible. Due to the 
small size of the surgical area, periodontal and mandibular bone defects are usually cre-
ated in relatively large-size animals (e.g. rat, rabbit, dog, etc.) in order to gain sufficient 
surgical field view and practical surgical access. Further, the unique location of this de-
fect model also requires the carrier device to be adaptable to provide space mainte-
nance as graft materials, and to support the mucoperiosteal flap or to restrict the epithe-
lial down growth as barrier membrane137. 
The surprainfrabony defect was developed by Nemcovsky et al138 to investigate perio-
dontal tissue regeneration. In this model, bone defects of reasonable dimensions were  
created at the mesial aspect of the mesial root of the first maxillary molar in rats. Perio- 
dontal fenestration defects were usually created bilaterally at the first and second mo-
lars in the mandible using an ultrasonic device to remove the alveolar bone (Figure 3), to 
gether with the periodontal ligament and cementum, and followed by preparation of a  
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square shape bone window (e.g. 4×4 mm in rabbit)139. Artificial furcation defects were 
performed by removing 5 mm of coronal bone and 2 mm of horizontal bone within the 
furcation site of the third molar to mimic the class II furcation defect, which is a common 
symptom for periodontitis140. Additionally, Salata et al141 produced 3-mm diameter bilat-
eral transcortical defects in the mandibular ramus as an effective model to evaluate the 
biological performance of a GBR membrane. Beside the aforementioned models that 
mainly focus on the periodontal bone regeneration, the mandibular segmental defect is 
an important model, which aims specifically at mandibular reconstruction. Mandibular 
segmental defects are often created in ruminating animals, like sheep and goats are, be-
cause these animals have mandibles that come close to the human anatomy as far as the 
gonial region is concerned142. Fennis et al142 created a 3 mm wide segmental defect in 
goat mandible after careful ligation of neurovascular bundle that enters the mandible. It 
needs to be mentioned that mandibular segmental defect was performed unilaterally in 
order to avoid malocculsion and subsequent jaw function disturbance of animals. Fur-
ther, the bone stumps at each side of the defect were stabilized with specially designed 
fixation plates. 
6.1.3. Sinus elevation  
Sinus elevation is a frequently used model to study bone augmentation by using bone 
grafting materials, because it is commonly used in dental clinics to improve the height of 
sinus floor to support dental implant placement. Preclinical models for sinus elevation 
are usually set in large animals, including rabbits143, goat144, sheep145 and pigs146. The 
basic approach to the sinus (Caldwell-Luc operation) involves an osteotomy performed 
on the lateral maxillary wall, elevation of the Schneidarian membrane, and placement of 
bone graft material, which can be derived from autogenous bone, allografts (harvested 
from human cadavers), alloplasts (synthetic materials), and xenografts (grafts from a 
nonhuman species)147 (Figure 3). 
6.2. Biological performance of locally delivered biomolecules 
Given the multiple types of candidate biomolecules involved in CMF bone healing, cur-
rent preclinical studies still mainly focus on the morphogenetic molecule and angiogenic 
molecule delivery, and only limited research involves local application of small molecule 
drugs. 
Among different types of morphogenetic molecules, recombinant human BMPs (rhBMPs) 
are the most commonly used for the animal study because of its dominant osteoinduc- 
tion. It is reported that rhBMP-2 coated onto titanium porous oxide implant surfaces 
induced clinically relevant local bone formation including vertical augmentation of the  
alveolar ridge and osseointegration148. Successful in vivo rhBMP-2 delivery has been  
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achieved using particles149, hydrogels150, 151, electrospun membranes152, as well as CaP 
cement153. The local delivery of rhBMP2 using different carriers has been evaluated in 
calvarial defect149, 152, 153, mandibular-alveolar defect150, 154 as well as sinus elevation mod-
els144, 151, which all concluded that bone formation was enhanced in the defect site after 
local delivery of rhBMP-2. Instead of directly BMPs delivery, Jiang et al recently reported 
the use of adenovirus encoding BMP-2 (AdBMP-2) transfected bone marrow cells seeded 
onto a β-TCP carrier155 and ceramic scaffolds143, and the BMP-2 gene transfected cells 
significantly improved sinus floor bone augmentation in New Zealand White rabbits after 
8 weeks compared to the bare materials. Instead of using BMP-2, Zhang et al156 recently 
reported that adenovirus encoding BMP-7 (AdBMP-7) could be delivered via silk fibroin 
scaffolds prepared by solid-liquid phase separation and improved new bone formation in 
mouse calvarial defect compared to the silk scaffold containing virus alone. Besides the 
BMPs, TGF-β1 has also been evaluated in vivo to improve the CMF bone formation. Blom 
et al.135 mixed rhTGF-β1 in CaP-cement during setting and implanted the mixture in a rat 
calvarial defect. Their results indicated that TGF-β1 loaded CaP stimulated bone growth 
in the defect site after 8 weeks of implantation compared to non-loaded scaffolds, alt-
hough the effect was minimal. In addition to the commercial recombinant growth fac-
tors, enamel matrix derivates (EMDs), which are commercially available as Emdogain®, 
have already been clinically applied and are considered to enhance bone regeneration. It 
has also been hypothesized that EMDs show osteopromotive capability because of the 
presence of bone growth stimulating factors157. On the other hand, Nemcovsky et al138 
achieved local delivery of Emdogain® via propylene glycol alginate in suprainfrabony de-
fect in rat, and showed that Emdogain® induced new cementum formation, but limited 
new bone formation compared to plain alginate. 
Delivery of angiogenic molecules is also explored in preclinical studies of CMF bone re-
generation in recent research, because it was found that exogenous VEGF enhanced 
BMP2-induced bone formation and bone healing by improving angiogenesis, which in 
turn led to accelerated cartilage resorption and enhanced mineralized bone formation158. 
The single VEGF delivery or dual delivery of VEGF combined with BMP2 in calvarial defect 
has been achieved using calcium phosphate ceramics159, and gelatin particles160, 161. It has 
been reported that VEGF release at low concentration from ceramic scaffolds is benefi-
cial for bone regeneration159. However, the addition of VEGF did not affect the amount of 
bone formation achieved by BMP-2160, 161, which confirmed the dominant osteoinductive 
function of BMPs. Previous research also revealed that the local application of platelet-
rich plasma (PRP), which is considered to be a rich source of autologous growth factors, 
also improved bone formation in rabbit cranial defects162. 
As mentioned above, published reports on the in vivo efficacy of small molecules delivery 
in CMF bone regenerative therapy are rather limited. Most of such studies have been  
Chapter 2 
 38 
conducted to explore the local delivery of antibiotics163-166 to reduce bone loss in alveolar 
and jaw bone caused by infectious disease. Local antibiotic therapy via antibiotic-
impregnated cement was used for osteomyelities55. As an alternative to introducing large 
deposits of antibiotic-impregnated cement at sites of chronic osteomyelitis, gentamicin-
impregnated cement beads can temporarily fill the dead space created by the debride-
ment of infected bone55. Besides the osteomyelitis, the local delivery of doxycycline in an 
alveolar bone defect was reported by using membrane167 and nanoparticles166, and it 
was shown that the topical application of doxycycline resulted in a more pronounced 
new bone formation in the defects compared to the group without antibiotics, which 
indicated that the local delivery of antibiotics is beneficial for the treatment of periodon-
titis related bone loss. Furthermore, a recent study revealed that the combined delivery 
of antibiotics and BMP-2 resulted in more new bone formation and a modest infection 
compared to BMP-2 delivery alone in rat calvarial defects168. Most importantly, the incor-
porated antibiotics did not interfere with the biological activity of BMP-2169, demon-
strating that anti-infection therapy is important to improve the clinical outcome of con-
taminated open fractures. 
In addition to antibiotics, anti-osteoporotics such as bisphosphonates170-176 have been 
delivered into alveolar bone defects to reduce bone resorption. Yaffe et al171 reported 
that the  topical application of 20 mg/ml of alendronate, as applied at the surgical muco-
periosteal site, produced a striking reduction of alveolar bone loss in the rat model. They 
also found that the alendronate gave an adequate distribution of bisphosphonate to the 
bone, because of the high affinity to bone mineral176. In addition, the effect of alendro-
nate can be synergistically enhanced when combined with local delivery of tetracy-
cline170. However, concern is emerging related to the potential risks of alendronate appli-
cation. Bodde et al177 discovered that a high dose of alendronate (8.8 mg per implant) 
resulted in cell death of fibroblasts surrounding the alendronate specimen after 72h incu-
bation. Recently, osteonecrosis of the jaw (ONJ) has been linked to the use of bisphos-
phonates, which raises another critical concern for bisphosphonates delivery. Bisphos-
phonate-related ONJ is defined as the presence of “exposed, necrotic bone” of the jaw or 
face that has been present for at least 8 weeks in a patient who has received bisphospho-
nate treatment but has not been exposed to radiation therapy178. A total of 481 patients 
with ONJ were reported in previous studies in the 44 case reports179. Although the re-
ported cases were mostly associated with intravenous or oral administration of bisphos-
phonates, it stresses the fact that the efficacy and safety of topical application of 
bisphosphonates should be studied in more details.  
Considering the potential risks of bisphosphonates, the topical delivery of NMP and 
statins appears to be a promising approach to enhance bone generation. Miguel et al180 
investigated the in vivo performance of PLGA-based guided bone regeneration mem-
brane with or without NMP treatment in rabbit calvarial defects (6 mm in diameter), and  
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their results showed that the membrane with NMP resulted in significantly enhanced 
bone regeneration after 4 weeks via increased BMP-2 activity. These results highlighted 
NMP as a novel, locally applicable drug for accelerated bone regeneration. Besides NMP, 
the osteopromotive effect of local delivery of statins has been investigated using differ-
ent carriers in various animal models. Previous research revealed that gelatin sponges 
with incorporated statins resulted in 2-fold increased new bone formation compared to 
plain materials in 3 mm diameter defects in the angulus mandibular region of rats181. 
Nyan et al182, 183 implanted calcium phosphate loaded with statins in rat calvarial defects, 
and their results showed that the combination of statins and calcium phosphate remark-
ably stimulated bone regeneration after 8 weeks of implantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Future perspective 
Surgical interventions based on the concepts of tissue engineering and regenerative 
medicine are evolving as promising strategies for the reconstruction of bony defects in  
 
Figure 3. Animal models used in CMF bone reconstruction. (A) Critical-sized calvarial bone defect (diameter 
8 mm) was created using rat, and (B) filled with pre-set calcium phosphate cement (CPC) containing PLGA 
microspheres. (C) Mandibular bone defect (4 mm depth, 5 mm height) was created in Beagle dog, and (D) 
treated using CPC containing growth factor loaded PLGA microspheres. (E) Sinus elevation in sheep. A bony 
window (diameter 10mm) was created to access to the maxillary sinus, and (F) filled with CPC. 
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the CMF area. Controlled local delivery of therapeutic biomolecules is a particularly pow-
erful tool to this end by combining local pharmacotherapy with tissue-engineered carrier 
devices. In this way, the clinical success of regenerative craniofacial surgery can be con-
siderably improved, especially in patients with compromised healing conditions. Among 
the various choices for certain bioactive molecules, small molecules (< 5kDa) are particu-
larly promising for future biomedical applications due to their therapeutic efficacy, rela-
tively simple synthesis and long-term stability, thus allowing for cost-effective industrial 
upscaling of production and commercialization. 
However, despite a substantial number of in vivo studies, the vast majority of studies 
that report on local delivery of biomolecules in CMF bone are still the pre-clinical testing 
phase, whereas data from clinical trials is limited. This infantile status can be attributed 
to two main reasons. First of all, although systemic delivery of biomolecules has been 
extensively investigated, local delivery of such biomolecules from carrier devices still 
needs to be optimized. For instance, optimal in vivo dosing of biomolecules for local de-
livery is still largely unknown. Furthermore, translation of data on dosing from preclinical 
to clinical studies is hardly possible. Secondly, the aforementioned drug delivery vehicles 
generally are categorized as medical devices incorporating, as an integral part, an ancil-
lary medicinal substance. As a result, these medical delivery devices belong to the ‘Class 
III’ devices, which are usually those that support or sustain human life, are of substantial 
importance in preventing impairment of human health, or which present a potential, un-
reasonable risk of illness or injury (General and Special Controls. Medical Devices. FDA. 
Retrieved 2010-10-15). It is obligatory to obtain a premarket approval (PMA) for a ‘Class 
III’ device to fully prove its safety and efficacy prior to final clinical application. The regu-
latory pathway for these devices is rather complicated which has hampered translation 
of basic knowledge towards clinical applications. 
Compared to cell therapy and tissue engineering strategies that employ encapsulated 
cells, clinical application of local delivery of biomolecules is still far more feasible from a 
regulatory and ethical point of view. Therefore, extensive research needs to be carried 
out to optimize local delivery of biomolecules, particularly small molecules, in terms of 
loading, dosing, and controlled release from suitable carrier biomaterials.  
8. Conclusions 
Currently, a wide interest exists in local delivery of small and large biomolecules for CMF 
bone regeneration. In addition to inflammatory cyto- and chemokines, morphogenetic 
and angiogenic factors, small molecules are rapidly emerging in recent years as an inter-
esting adjunct for upgrading the clinical treatment of CMF bone regeneration under com-
promised healing conditions. Small molecules (including antibiotics, AMPs, antitumor  
drug, siRNA and shRNA, as well as anti-osteoporotics) can effectively interfere with infec- 
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tion, tumor-metastasis and osteoporosis, thereby considerably improving conditions for 
bone regeneration. 
Regardless of the biomolecules, the carrier device should be able to preserve the biologi-
cal activity of biomolecules and offer controlled release kinetics to yield an optimal tissue 
response. Different materials have been investigated as carrier device, including parti-
cles, membranes, hydrogels, and ceramic scaffolds. The release of biomolecules from 
these carrier devices can be controlled via desorption, diffusion, degradation, and stimuli
-triggered mechanisms. 
So far, different kinds of preclinical models have been developed to evaluate the efficien-
cy and efficacy of biomolecules-loaded carrier devices in CMF bone regeneration, in 
which calvarial defects, mandibular and alveolar bony defects and sinus elevation are 
included. Most of the preclinical studies have so far been focused on the morphogenetic 
molecules and angiogenic molecules delivery, and quite limited research involved deliv-
ery of small molecules.  
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1. Introduction  
Tissue engineering is an interdisciplinary field that applies the principles of engineering 
and life sciences toward the development of functional substitutes for damaged tissues. 
The fundamental concept behind tissue engineering is to utilize the body’s natural bio-
logical response to tissue damage in conjunction with engineering principles1. To achieve 
successful tissue regeneration, three key factors are to be considered: cells, scaffolds, 
and biomolecules (e.g., growth factor, gene, and etc.). Currently, two strategies have 
emerged as most promising tissue engineering approaches (Figure 1)2. One is to implant 
pre-cultured cells-synthetic scaffolds complexes into the defect place. In this approach, 
the seeded cells are generally isolated from host target tissues, for which they provide 
main resource to form newly born tissue. The synthetic scaffolds, on the other hand, 
provide porous three dimensional structures to accommodate the cells to form extracel-
lular matrix (ECMs) and regulate the cell growth in vivo3, 4. These synthetic scaffolds are 
biodegradable and degrade in accordance with the tissue regeneration time frame. The 
other approach is to place acellular scaffolds immediately after injury. The governing 
principle of this approach is using scaffolds to deliver appropriate biomolecules to the 
defect area; the biomolecules are released from the scaffolds in a controlled manner and 
may recruit progenitor cells toward the defect area and promote their proliferation and 
differentiation, thereby enhancing tissue regeneration. 
 
 
 
 
 
 
 
 
 
Figure 1. Current tissue engineering approaches. (a) To implant pre-cultured cells-scaffolds complex into the 
defect place. In this approach, cells are isolated from biopsy and then cultured in vitro for expansion. Then the 
cells are seeded onto synthetic scaffolds, which provide porous three dimensional structure to accommodate 
seeding cells to form extracellular matrix; (b) To place acellular scaffolds with biomolecules delivery immediate-
ly after injury. In this approach, the biomolecules are released from scaffolds in a controlled manner and they 
may recruit the progenitor cells in wound area and promote their proliferation and differentiation. 
In recent years, an increasing trend toward the combination of these two approaches is 
observed5-8, because the scaffolds with controlled release of biomolecules can induce the 
seeded cells to proliferate and differentiate during an ex vivo pre-culture period, thereby 
encouraging tissue formation after implantation in vivo. Meanwhile, the scaffolds will 
continue to release signal molecules after implantation to enhance the desired physio- 
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logical response, and consequently enhance tissue regeneration in the defect area. In 
view of these strategies, to achieve successful and efficient tissue engineering, an in-
creasing demand for bioactive scaffolds that can provide more than only physical support 
for cells but also a local release of biomolecules to influence surrounding tissue regener-
ation is observed. This type of scaffold is termed as “bioactive scaffold”1. 
The importance of bioactive scaffolds in tissue engineering has been comprehensively 
reviewed9. Various biomolecules can be incorporated within tissue engineered scaffolds 
to enhance their functional properties for biomedical applications The most frequently 
used biomolecules are proteins (e.g., growth factors or cytokines) and growth factor cod-
ing-genes. Growth factors (GFs) are endogenous proteins capable of binding cell-surface 
receptors and directing cellular activities involved in the regeneration of new tissue10. 
Localized delivery of exogenous GFs is suggested to be therapeutically effective for pro-
duction of cellular components involved in tissue development and the healing process, 
thus making them important factors for tissue regeneration11. Nevertheless, it has to be 
emphasized that the success of direct growth factor delivery from scaffolds depends on 
the large-scale production of recombinant GFs, which is quite expensive. Additionally, 
protein bioactivity after incorporation within scaffolds also needs to be considered in 
view of efficacy issues. Instead of growth factor delivery, gene therapy presents a new 
paradigm in tissue engineering. This concept gives birth to gene-activated scaffolds 
(GASs), which are defined as scaffolds incorporating therapeutic protein encoding 
genes12. GASs ensure the delivery of genes at the desired site13, after which transfection 
into target cells is required to produce therapeutic proteins14. Compared to growth fac-
tor delivery, gene delivery is advantageous in its long-time effect as well as relatively low 
cost, which makes it promising for tissue engineering application.  
Since the last decade, huge efforts have been made to explore strategies for the 
preparation of bioactive scaffolds to deliver therapeutic proteins or genes, and a series of 
comprehensive reviews has provided detailed information for these strategies14-16. In 
general, proteins or genes can be delivered by micro/nano-particles17, hydrogels18 or 
electrospun fibrous matrices19, 20. For micro/nano-particles, due to their fluidity, it is diffi-
cult to keep them localized in the defected area giving new tissues enough support21. 
Therefore, such particles can only be used as carriers for biomolecules rather than 
scaffolds for tissue engineering. Comparably, hydrogels have been used as drug delivery 
systems for many years, but the poor mechanical properties of hydrogel-based scaffolds 
limits their use for load-bearing applications, and this disadvantage can even result in the 
premature dissolution or displacement of the hydrogel from a targeted local site22. Elec-
trospinning is a popular technique to prepare tissue engineering scaffolds due to its rela-
tive simplicity regarding the generation of fibrous scaffolds with nano- or submicron-
scale dimensions, which morphologically resemble the natural ECM. Due to the possibil- 
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ity of ultrathin fiber diameters, electrospun fibrous matrices can have a large specific 
surface area, which enables effective delivery of biomolecules. Furthermore, the loose 
bonding between fibers is beneficial for tissue growth and cell migration23. These charac-
teristics endue electrospinning with superiority in preparation of bioactive scaffolds. In 
2003, electrospinning has been first used to prepare bioactive scaffolds with gene re-
lease24, and thereafter, this technique has gained an exponentially increasing popularity 
in this area (Figure 2). The aim of this paper is to review the techniques to incorporate 
growth factors or genes into electrospun scaffolds. Additionally, the existing challenges 
of using electrospinning in the area of tissue regeneration will be discussed.  
 
 
 
 
 
 
 
 
 
2. Basics relevant to electrospinning 
Electrospinning is a cost-efficient technique to prepare ultra fine polymeric fibers, which 
can be easily employed in the laboratory and scaled up to an industrial process. It utilizes 
electrostatic forces to spin polymer solutions or melts into whipped jets, resulting in con-
tinuous fibers with diameters from a few nanometers to micrometers after solvent evap-
oration in the spinning process25, 26. A typical electrospinning apparatus consists of four 
major components: (1) a syringe pump, which controls the feeding rate of polymer solu-
tion to be electrospun; (2) a needle, through which the solution goes into a high electric 
field; (3) a high voltage source, which stretches the polymer solution into ultrathin fibers; 
and (4) a grounded fiber collector, where electrospun fibers can be collected in a static 
or dynamic way (Figure 3).  
The technique of electrospinning has been comprehensively reviewed25, 27: when high 
voltage is applied, the polymer solution droplet from the needle becomes highly electri-
fied and tends to form a conical shape known as the Taylor cone depending on the sur-
face tension of the liquid and the force of electric field; once the electric field surpasses a 
threshold, the electric force overcomes the surface tension and viscoelastic force of  the  
Figure 2. Publications and citations report from ISI web of Science®, as at August 18, 2010. 
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polymer droplet, which results in a finely charged jet from the tip of the Taylor cone; 
then the jet sprays into one continuous ultrathin fiber. The random or aligned fibers can 
be collected on a grounded metallic collector, in the form of a plate, cylinder or disc 
type27. Based on this theory, it is clear that the electrospinning process can be manipulat-
ed by a number of variables. These variables include solution properties (polymer con-
centration, polymer molecular weight), system set up (applied voltage, feeding rate and 
collecting distance), and environmental factors (temperature and humidity)20, 25. Among 
these variables, solution properties are crucial for a successful electrospinning. Further, 
literature indicates that low polymer weight, high fluidity or high density of the polymer 
solution will cause instabilities, including whipping and droplet instead of uniform fiber 
formation 28. In addition, sub-optimal voltage is another key factor that could lead to 
bead-like defects in the spun fibers or even failure in jet formation20, 25.  
 
 
 
 
 
 
 
 
 
There is a wide range of material choices to prepare electrospun scaffolds for tissue engi-
neering applications, which mainly includes two categories: natural polymers and syn-
thetic polymers. In principle, the material choice for scaffolds preparation depends on 
the purpose of application and feasibility of electrospinning. Electrospun fibrous 
scaffolds prepared from natural polymers, especially collagen, are mostly used because 
these can mimic the properties of natural ECM for engineered tissues29. However, some 
natural polymers are not easy to handle during electrospinning, as they tend to display 
poor processibility, which needs to be modified to achieve better electrospinning30. Fur-
thermore, it is difficult to confirm that native structure and biological characteristics of 
natural polymers are still preserved after electrospinning31. In contrast, synthetic poly-
mers (especially the polyesters) are much easier to be optimized for electrospinning pro-
cess, and hence are more commonly applied. Dong et al.32 gave a comprehensive review 
listing different synthetic polymers that can be used to prepare electrospun scaffolds. 
Among multiple choices of synthetic polymers, poly(ε-caprolactone) (PCL), poly(lactic- 
Figure 3. Scheme for electrospinning apparatus. 
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acid) (PLA), poly(glycolic acid) (PGA) and their copolymers poly(lactic-co-glycolic acid) 
(PLGA) are most extensively used for biomedical applications because they are approved 
by US Food and Drug Association (FDA) for their good biocompatibility as well as biodeg-
radability. 
3. Current progress of electrospun scaffolds with biomolecule delivery 
3.1. General considerations for growth factor and gene delivery  
There are two important aspects to achieve a successful delivery: (1) to ensure the bioac-
tivity of the biomolecules incorporated within the scaffolds; (2) to fit the release profile 
of biomolecules with time frame of tissue regeneration. 
3.1.1 Principles for growth factor delivery 
Growth factors easily lose their activity upon chemical or physical processing. Therefore, 
the preservation of protein activity is a prerequisite for successful growth factor delivery. 
There are three stages during which the stability of a growth factor incorporated in a 
scaffold must be preserved: (i) scaffold fabrication, (ii) scaffold storage, and (iii) scaffold 
degradation. The source of the protein stability in each stage and available strategies to 
improve the protein stability will be explained in detail in section 4.1. 
The release profile is another important issue to take into account when designing elec-
trospun scaffolds to deliver growth factors. Considering the half-lives of most growth 
factors in serum are very short, it is essential for bioactive scaffolds to maintain a desired 
temperospatial growth factor concentration to direct tissue regeneration. For this pur-
pose, an optimal growth factor delivering scaffold should be able to initially release part 
of the dosage contained, which is typically termed “burst release”33, to rapidly get the 
effective therapeutic concentration. Subsequently, well defined release kinetics follow in 
order to provide the maintenance dosage enabling the attainment of the desired concen-
tration34.  
3.1.2 Principles for gene delivery 
Different from growth factors, which act extracellularly and initiate biological response 
by binding to cell surface receptors, target genes will only have an intracellular effect by 
integrating into the host genome of endogenous cells and transformed the transfected 
cells into local bio-activated actors to enhance tissue formation. Consequently, a prereq-
uisite for a successful gene delivery scaffold is that the active gene can be released from 
the scaffold, after which it needs to be integrated into the host genome. To achieve this 
goal, the target gene is always packed within vectors before incorporated into the 
scaffolds, because vectors can protect the target genes from extracellular DNA-degrading  
enzymes and intracellular lysosomes that contain digestive enzymes in the process of 
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being taken up by surrounding cells13. On the other hand, vectors can transport genes 
through the lipid bilayer of the cell membrane, and the latter is the biggest obstacle in 
gene transfection. Currently, two categories of vectors are used: viral and non-viral vec-
tors. The strategies of effective vectors have been clearly reviewed by Storrie et al. and 
Kootstra et al.14, 35.  
Similar to growth factor delivery, an important issue for gene delivery is to modulate 
both the concentration and duration of the gene particles released from scaffolds, which 
dictates a well controlled release profile. To achieve successful gene transfection, the 
effective concentration of target gene-vector complexes should be released into the cell 
surrounding microenvironment within an optimal time frame. It is found that low con-
centration of DNA always results in low transfection efficiency36, 37 and much too fast 
gene release leads to a low transfection efficiency, because superabundant gene com-
plexes may lose activity if transfection is not achieved in due time37. 
3.2. Fabrication techniques for electrospun scaffolds with biomolecule delivery capacity  
In general, biomolecules can be delivered either directly from the electrospun scaffolds 
or from additional separate release system (i.e., micro/nanospheres) loaded into the 
scaffolds, where the electrospun scaffolds behave only as a supporting structure. Since 
using micro/nano-spheres to deliver biomolecules has been comprehensively reviewed38-
41, this topic will not be addressed in this review. Different proteins and genes that have 
been loaded in electrospun scaffolds are listed in Table I & II, respectively. 
3.2.1. Physical adsorption 
The easiest way to load biomolecules into electrospun scaffolds is to dip the scaffolds 
into an aqueous phase containing biomolecules (Figure 4a). In this approach, biomole-
cules can be in the form of pure solution or emulsions and they can attach to the 
scaffolds via electrostatic forces. Although this approach gives little interference with the 
activity of loaded biomolecules, it is seldom used to load protein or genes in electrospun 
scaffolds due to the uncontrolled release profiles. It has been shown that bone morpho-
genetic protein-2 (BMP2) adsorbed to PLGA scaffolds reached over 75% release within 5 
days and nearly complete release within 20 days This release rate was much faster than 
that of the same amount of protein loaded in PLGA scaffolds using blend electrospin-
ning21. Similar evidence is available for gene delivery using this approach. Although some 
researchers could obtain transfected cells in an early stage (most likely due to a large 
amount of target gene bulk release36, 37, the released gene exhausted within a short time 
and over 95% of incorporated  DNA released within 10 days37. 
3.2.2. Blend electrospinning 
In blend electrospinning, biomolecules are mixed within the polymer solution, after  
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which the mixed solution is used in the electrospinning process to fabricate a hybrid 
scaffold (Figure 4b). Some researchers made emphasis on the preparing process of sus-
pending the protein solution in polymer solution by emulsifying using ultra-sonication or 
homogenizer, therefore named the process as “emulsion electrospinning”42. The idea for 
emulsification arises from the improvement of biomolecule suspension in organic sol-
vents. Considering its same principle, we assume that it still belongs to blend electrospin-
ning approach.  
As blend electrospinning localizes biomolecules within the fibers of the scaffolds rather 
than simply adsorb them superficially to the scaffolds, it is assumed that this approach 
allows more sustained release profiles compared to physical adsorption. Researchers 
have used blend electrospinning to incorporate various types of proteins and genes in 
scaffolds, including bovine serum albumin (BSA)43-45, lysozyme42, 46 and growth factors 
e.g., BMP221, 47, epidermal growth factor (EGF)48. In general, a sustained release profile 
can be obtained over several weeks using this technique. 
 
 
Figure 4. Fabrication techniques of bioactive electrospun scaffolds (a) physical adsorption; (b) 
blend electrospinning; (c) coaxial electrospinning; (d) covalent immobilization 
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Although blend electrospinning is assumed to be relatively easy to perform, an inconven-
ient issue is the activity loss of incorporated biomolecules. This is especially vital for pro-
teins, because they may lose their bioactivity due to conformational changes in the or-
ganic solution environment. On the other hand, the process to prepare protein emul-
sions, which involves mechanical stirring, homogenization or ultrasonication, can also 
damage protein function49. In previous studies, several strategies have been applied to 
improve protein stability. A strategy is to use salt complexation instead of emulsification 
to improve protein solubility in organic solvents. Li et al.46 incorporated lysozyme-oleate 
complex into electrospun membranes and their results showed that the released lyso-
zyme retained over 90% of bioactivity. Another strategy is to use hydrophilic additives to 
minimize the hydrophobic interaction of protein and organic solvents during electrospin-
ning50-52. It has been reported that hydrophilic polymers, such as poly(ethylene glycol) 
(PEG) and poly(ethylene oxide) (PEO) added in the aqueous protein solution46, 47, 53 are 
beneficial for improving protein stability. Futhermore, a recent study showed that hy-
droxyapatite (HAp) particles were able to preserve the activity of BMP2 loaded in elec-
trospun PLGA scaffolds, as proteins can attach to these hydrophilic particles so as to es-
cape the harsh electrospinning process21. 
A typical protein release profile from blend electrospun scaffolds is an initial burst re-
lease followed by a sustained release close to a linear mode24, 44, 46, 54, 55. The burst re-
lease usually occurs within 24 hours, regardless of polymer type for scaffolds prepara-
tion. This initial burst release may be related to the migration of protein during drying 
and storage steps, which localizes a certain fraction of protein molecules near the fiber 
surface56. The high solubility and partition coefficients of the incorporated protein can 
lead to a rapid release through short diffusion pathways due to thermodynamic imbal-
ances33. After burst release, the protein release behavior is mainly driven by protein 
diffusion or the effect of polymer degradation and protein diffusion. For slowly degrada-
ble polymers, such as PCL, the protein release profile behaves as a relatively linear 
mode56; whereas for PLGA, a polymer with relatively short degradation time, the protein 
release profile shows a sustained mode followed by an obvious increased release rate 
once the polymer starts to degrade21, 54 The protein release profile can be modulated by 
additives loaded together with protein during blend electrospinning. The addition of hy-
drophilic additives, such as hydroxyapatite particles21, 54 and PEG46, will improve the hy-
drophilicity of scaffolds and hence enhance water uptake of the scaffolds as well as ac-
celerate protein release from electrospun scaffolds.  
The first gene delivery using blend electrospinning approach was reported by Luu et al.24. 
In this study, the authors mixed pCMVβ plasmid (7164 bp) encoding b-galactosuchsidase 
with PLA–PEG–PLA tri-block copolymer and high molecular weight (75kDa) PLGA (LA/
GA=75/25). Since then, many groups have used this approach to incorporate bmp2 with  
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different plasmids into electrospun scaffolds
37, 47
. In this approach, the plasmid gene is 
able to withstand the electrospinning process because of the protection from complexa-
tion with vectors. Luu et al.24 found that DNA kept its structural integrity after release 
out of PLGA scaffolds. Nie et al.36 also showed that the incorporated bmp2 was still capa-
ble to induce BMP2 expression in vivo after 4 weeks.  
Different from protein release, gene release shows two types of profiles from blend elec-
trospun scaffolds, which might be related to different fiber compositions. Luu et al.24 
reported a burst release within 2 hours followed by a sustained DNA release until 20 
days using PLA-PEG block copolymers blended with different variations of PLGA, whereas 
others obtained a linear release profile up to 2 months from composite PLGA electro-
spun scaffolds37, 57. 
3.2.3. Coaxial electrospinning 
Coaxial electrospinning, also known as co-electrospinning, was first demonstrated by Sun 
et al.58. In coaxial electrospinning, two solutions (i.e. polymer solution and biological so-
lution) are coaxially and simultaneously electrospun through different feeding capillary 
channels in one needle to generate composite nano-fibers with core-shell structures 
(Figure 4c). Coaxial electrospinning is a very dynamic process, and many factors such as 
feeding rate of the inner and outer fluids, interfacial tension and visco-elasticity of the 
two solutions affect the entrapment of components in the core part58, 59. Although this 
technique was developed more than ten years ago60, the application of coaxial electro-
spinning to deliver biomolecules has only been explored since five years 24, 44 due to the 
complexity of this technique.  
Recently, coaxial electrospinning has gained increased popularity in the protein delivery 
field because the produced core-shell fibers have great potential in preserving proteins 
during the electrospinning process. In addition, it provides homogeneous protein distri-
bution throughout the fibers and proteins can be delivered in a controlled manner due to 
the shell barrier (Figure 5). Researchers have achieved encapsulation of different types of 
proteins in coaxially electrospun scaffolds, including BSA56, 61-63, lysozyme62, platelet-
derived growth factor-bb (PDGF-bb)64, 65, nerve growth factor (NGF)66 and fibroblast 
growth factor (FGF)67. These studies indicated that released growth factors had efficient 
bioactivity to stimulate corresponding cell growth. Some authors attribute this bioactivity 
preservation only to the superiority of coaxial electrospinning, as during coaxial electro-
spinning, the electric charges are located predominantly at the outer fiber surface so 
that the inner protein solutions are not charged at all25. In contrast, we compared the 
effect of blend and coaxial electrospinning on protein activity by using alkaline phospha-
tase (ALP) as a model protein, and our results indicated that both electrospinning tech-
niques depressed the biological activity of the incorporated ALP, suggesting that high  
Chapter 3 
 61 
voltage and contact with organic solvents are harmful to the loaded biomolecules; the 
ALP through coaxial electrospinning without PEG loaded maintained significantly lower 
enzyme activity, than the one with PEG loaded regardless of electrospinning method68. 
 
 
 
 
 
 
 
 
 
 
 
The protein release profile from coaxial electrospun fibers also includes an initial burst 
release followed by a sustained release stage56, 61, 62, 66, 67, which is similar to the one from 
blend electrospun scaffolds. However, compared to blend electrospinning, the burst re-
lease from coaxial fibers is significantly lower and the entire release profile is more sus-
tained56, 68, because core-shell-structured fibers provide a protein reservoir system with a 
barrier membrane that controls the protein diffusion rate68. 
To date, only a limited number of studies on gene delivery via coaxial electrospinning 
scaffolds has been published. Saraf et al.69 incorporated pDNA into an aqueous poly
(ethylene glycol) (PEG) solution to fabricate the core of fibers, and loaded hyaluronic acid 
(HA) derivative of poly(ethylenimine) (PEI) as gene delivery vector into an organic sheath 
polymer solution of poly(ε-caprolactone) (PCL) to form the shell part. Their results sug-
gested that the plasmid diffusing out of the fiber cores could complex with the positively 
charged vector PEI-HA released from the fiber shells. In addition, the released gene-
vector complex could sustainedly transfect cells present on the scaffolds over 60 days 
with 15% transfection efficiency on average. The authors concluded that transfection 
efficiency was related to the concentration and molecular weight of the core polymer 
PEG. However, the pDNA release was not directly measured in their study. Liao et al.70 
used core-shell fibers to deliver the adenovirus (Ad) encoding gene of green fluorescence 
Figure 5. Protein distribution and core-shell structure of coaxial electrospun fibers. (a) Laser scanning 
confocal microscopy images to visualize protein distribution in coaxial electrospun fibers. The panels in 
each image are: upper left: fitc labelled protein (green); upper right: rhodamin B labelled polymer (red); 
bottom left: natural light; bottom right: the merger of fitc and rhodamin B. (b) Transmission electron 
microscopy image to visualize core-shell structure of the same coaxial electrospun fibers. Arrows indi-
cate the core and shell parts within the fiber. 
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(GFP) in vitro. They succeeded to detect cells expressing GFP for more than 30 days and 
the cell transfection efficiency could reach over 80%. However, the high transfection effi-
ciency only sustained for two weeks, which is related to the initial burst release. Their 
results showed that different polymer compositions have different pore formation ability 
on the fiber surface, which contributed to different release profiles and cell transfection 
efficiencies.  
3.2.4. Covalent immobilization 
Covalent immobilization immobilizes biomolecules onto the fiber surface via chemical 
bond, for instance forming peptide bond through amino groups71 (Figure 4d). Compared 
to the above mentioned strategies, this approach is predominantly used to improve the 
surface properties of electrospun fibers72, but some researchers are applying this ap-
proach to deliver protein aiming to achieve controlled release profiles, because the re-
lease rate of the immobilized biomolecules can be controlled by the external enzymes.  
Choi et al.73 reported that BSA-immobilized nanofibers showed no obvious burst release, 
although the authors only observed the release within one week. Using the same strate-
gy, they prepared electrospun scaffolds with epidermal growth factor (EGF) delivery and 
succeeded in effective application of these bioactive scaffolds in vivo74. 
Kim et al.71 introduced a matrix metalloproteinases (MMPs)-cleavable linker between 
gene-vector complex and the electrospun scaffolds, so that gene release can be con-
trolled by external MMPs cleavage. Their results showed that a fast gene release can be 
achieved in presence of MMP-responsive peptides, for which the maximum released 
amount was 82% within 12 hours, whereas less than 40% of incorporated gene was re-
leased if MMPs were absent. 
So far, covalent immobilization is not a routine way to deliver protein or genes from elec-
trospun scaffolds due to its technical complexity. In addition, some researchers also 
doubt the uniformity loss of the scaffolds during surface modification process75, which 
might affect mechanical properties of the scaffolds. In addition, the manipulation of pro-
tein configuration and function by choosing specific binding sites in the protein molecule 
is still a big challenge. However, surface covalent immobilization represents an option to 
achieve delivery of multiple biomolecules in combination with the biomolecules directly 
incorporated within the scaffolds11.  
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Fabrication 
technique 
Loaded 
Protein 
Scaffold 
material 
Biological application Ref 
  
Physical  
BMP2 PLGA BMP2 release in vitro & human bone marrow 
stem cell culture 
21 
adsorption  BMP2 PLGA Implantation of tibia defect in nude mice 54 
  BSA PEO --- 43 
  BSA PVA BSA release in vitro 44 
  BSA PDLLA BSA release in vitro & structural integrity 
analysis 
45 
  lysozyme PDLLA Lysozyme release in vitro,  structural integrity 
& enzymatic  analysis 
42 
  lysozyme PCL Lysozyme release in vitro & enzymatic analysis 46 
Blend electro-
spinning 
bFGF PLGA bFGF release in vitro & rat bone marrow cell 
culture to test bioactivity of released bFGF 
67 
  EGF Silk fibroin EGF release in vitro & human dermal fibro-
blasts culture 
48 
  BMP2 Silk fibroin Human bone marrow stem cell culture 47 
  BMP2 PLGA BMP2 release in vitro & human bone marrow 
stem cell culture 
21 
  BSA PCL BSA release in vitro 61, 62, 
64, 68 
  BSA PLCL BSA release in vitro 63 
  lysozyme PCL Enzymatic analysis of released lysozyme 62 
  PDGF-bb 
  
PCL NIH3T3 cell culture to test bioactivity of re-
leased PDGF-bb 
64 
Coaxial electro-
spinning 
PDGF-bb 
  
PLCL PDGF-bb release in vitro & vascular smooth 
muscle cells to test bioactivity of released 
PDGF-bb 
65 
  NGF PLCL Rat pheochromocytoma cell line culture to 
test bioactivity of released NGF 
66 
  bFGF PLGA bFGF release in vitro & rat bone marrow cell 
culture to test bioactivity of released bFGF 
67 
  ALP -- Enzymatic analysis of the post-electrospun 
ALP 
68 
  BSA PEG-b-
PDLLA 
In vitro culture of human dermal fibroblast 76 
  BSA PCL/PCL-b-
PEG mixture 
In vitro culture of  NIH3T3 cells 73 
Covalent immo-
bilization 
EGF PCL/PCL-b-
PEG mixture 
In vitro culture of human primary keratino-
cytes 
74 
  bovine  
collagen I 
PMMAAA In vitro culture of cortical neural stem cells 72 
  BSA PSU --- 75 
Table I. Proteins that have been loaded into electrospun scaffolds 
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Fabrication 
technique 
Loaded gene 
particles 
Scaffold 
material 
Application Ref 
  pGL3 PLA Deliver gene into  COS-7 cell line in vitro 77 
Physical 
 adsorption 
pBMP-2 PLGA/HAp Deliver gene into hMSC in vitro & bone re-
generation in nude mice 
36, 37
 
  
  pBMP-2 PLGA/HAp Deliver gene into hMSC in vitro & bone re-
generation in nude mice 
36, 37 
Blend electro-
spinning 
pBMP-2 Silk/PEO/
nHAp 
Deliver gene into hMSCs in vitro for bone 
tissue engineering 
47 
  Adenovirus E1 Chitosan/
PEG/FA 
Deliver gene into HEK293 cell line for cancer 
therapy 
78 
  pCMVβ PLA-PEG/
PLGA 
In vitro gene delivery into MC3T3-E1 cell 
line 
24, 57 
  pCMV-EGFP PEI-HA/PCL Non-viral gene delivery into CRL1764 cell line 
in vitro 
69 
Coaxial electro-
spinning 
Adenovirus E1/
E3 
PCL/PEG Viral gene delivery into HEK293 cell line in 
vitro 
70 
  
  
  
  
  
  
Deliver gene into NIH3T3 cell line in vitro & 
animal 
  
  
Covalent immo-
bilization 
LPEI-pEGFP-N1 PCL-PEG study in vivo for local gene therapy of dia-
betic ulcers 
  
71 
 
Table II. Genes that have been loaded into electrospun scaffolds 
4. Challenges and outlook 
Although electrospinning shows huge potential and promising application possibilities to 
prepare tissue engineering scaffolds with biomolecule delivery, challenges still exist for 
further application of such bioactive scaffolds, which includes concerns about (i) protein 
instability, (ii) low gene transfection efficiency, and (iii) difficulties in release kinetics con-
trol. 
4.1. Protein instability 
Maintaining protein conformation within the scaffolds will be essential for further bio-
medical application of protein delivery from electrospun scaffolds, because the loss of 
conformation of a protein might not only be detrimental to the bioactivity and hence 
therapeutic potential, but also causes immunogenic effects related to exposure of non-
native peptide epitopes79. Although it has been reported that protein released from 
freshly prepared electrospun scaffolds was capable to induce various cellular respons-
es21, 42, 45, 54, 65, indicating the preservation of protein activity after the electrospinning 
process, it is too easy to claim that proteins incorporated within electrospun scaffolds 
will behave similar to the virgin proteins. As aforementioned, the threat for protein in- 
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stability regarding electrospun scaffolds might arise from fabrication, storage or degrada-
tion period. Also, it needs to be mentioned that the instability of protein during storage 
and degradation period is a general problem for polymeric protein delivery system. 
Therefore, the development of methods to optimize protein stability during these three 
stages is a major challenge for effective protein delivery from electrospun scaffolds.  
During the scaffold preparation process, high voltage and contact with organic solvents 
may be harmful to the growth factor activity42, 53, 80. Although using coaxial electrospin-
ning and adding hydrophilic additives (e.g. PEG, hydroxyapatite) was reported to mini-
mize the interaction between protein and organic phase21, 42, the protein still loses 20% 
bioactivity due to the loss of α-helix in secondary structure compared with virgin protein 
solution68.  
Once the scaffolds are prepared, normally they are lyophilized for storage before applica-
tion. It has been recognized that protein stresses may also arise from the drying process 
without appropriate stabilizing excipients81. As a result, it is wise to include protein stabi-
lizer within the electrospun scaffolds to avoid the protein degradation during lyophiliza-
tion. The commonly used lyoprotectants include sugars (e.g. sucrose) and polymers with 
relative high collapse temperature (e.g. dextran) 81, Some authors used PEG 56 or dextran 
61 as protein stabilizer during coaxial electrospinning, but they rarely mentioned the 
effect of these additives on protein stability during lyophilization. Sucrose is suggested to 
be effective at inhibiting unfolding during lyophilization81, but its effect on electrospun 
scaffolds fabrication and protein stabilization still needs further investigation.  
When the synthetic polymeric electrospun scaffolds start to degrade, the acidic microen-
vironment induced by hydrolysis products of polyesters is also likely to be destructive to 
growth factor integrity82, 83. This is especially a serious concern for PLGA, which is attrac-
tive for biomolecules delivery because of its tailored degradation rate to achieve con-
trolled release. The instability of incorporated proteins comes from deamidation at as-
paragine residues, peptide bond hydrolysis and acylation of protein primary amines (e.g., 
N-terminus, Lysine group) in degrading PLGA systems. All these instabilities are related to 
the acidic microclimate pH produced by the accumulation of acidic monomers and oligo-
mers during PLGA degradation83. In consequence, it is necessary to maintain the pH dur-
ing scaffold degradation to stabilize the protein incorporated within PLGA delivering sys-
tems. Currently, there are two effective approaches to maintain pH within a PLGA pro-
tein delivery system. One is using hydrophilic polymer PEG as porogen in PLGA scaffolds 
to enhance acidic degraded products release84, but this approach will decrease the me-
chanical properties of electrospun scaffolds, which might limit its further application. The 
other approach is adding poorly water-soluble basic salts such as Mg(OH)2 to neutralize 
acidic microenvironment during scaffolds degradation85. However, it is interesting that 
the use of this approach is not widespread in spite of its apparent simplicity.  
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4.2. Low gene transfection efficiency 
Although many studies showed that it is feasible to deliver target genes at the desired 
tissue site via electrospun scaffold implantation24, 36, 47, 71, the low gene transfection effi-
ciency remains a drawback. Basically, the low efficiency is not only an obstacle for elec-
trospun scaffolds with gene release, but a key technical barrier for full exploitation of the 
potential of gene therapies. In order to improve gene transfection efficiency, viral vec-
tors seem to be a straightforward option, as viral vectors have natural tropism for living 
cells. However, their immunogenic potential and the threat of disturbing normal gene 
function from retroviruses and adeno-associated viruses limit their further clinical appli-
cation86, 87. In recent years, other options for improving transfection efficiency have been 
experimented, including nano-scaled delivery carriers88, gene gun89, disulfide linkages in 
cationic polymers90 and bioresponsive polymers68. Unfortunately, those methods are 
difficult to combine with electrospun scaffolds. 
The poor interaction between released gene particles and cells is another possible rea-
son for the low gene transfer efficiency via electrospun scaffolds. It is known that the 
released gene dose has to reach a threshold to induce gene transfection in cells, as re-
cent studies have demonstrated that low concentrations of released gene always yield a 
low transfection efficiency36, 37. 
4.3. Release kinetics control 
In order to achieve an effective dose and a target release profile, it is necessary to use 
mathematical models to predict release kinetics on the basis of good estimates of the 
required composition, geometry, and dimensions of the biomolecular delivery system. A 
mechano-realistic mathematical model is based on equations that describe real phenom-
ena, e.g. mass transport by diffusion, dissolution of biomolecules, and/or the transition 
of a polymer from a glassy to rubbery state91. The mathematical modelling of biomole-
cule delivery from polymeric matrices have been clearly reviewed34, 91. Among different 
models, a simple and useful empirical equation is the so-called power law equation34: 
Mt/M∞ =kt
n,  
where M∞ is the amount of drug released after an infinite time, k is a constant related to 
the structure and geometric characteristics of the system, and n is the release exponent 
indicating the mechanism of protein release91. However, it needs to be mentioned that, 
in practice, the release kinetics are likely affected by many factors, including polymer 
swelling, polymer erosion, biomolecular dissolution/diffusion characteristics, biomole-
cules distribution inside the matrix, biomolecule/polymer ratio and system34. Apparently, 
it is impossible for a single mathematic model to consider all variables. Therefore, devia-
tion will always exist between theoretical prediction and practical realization. Further-
more, in vivo biomolecule delivery from degradable polymeric scaffolds will be strongly  
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affected by the surrounding tissue environment (e.g. pH value and cellular tissue reac-
tion). Nevertheless, there is no mathematical model available that estimates biomolecule 
release from biodegradable vehicles under physiological conditions. Consequently, it is 
necessary to design advanced mathematical models considering in vivo conditions. 
5. Summary 
Tissue engineering is a promising research area for present and future regenerative med-
icine, and the fundamental concept behind tissue engineering is to utilize the body’s nat-
ural biological response to tissue damage in conjunction with engineering principles1. In 
order to achieve successful and efficient tissue engineering applications, there is an in-
creasing demand for bioactive scaffolds that can provide more than only physical support 
for cells but also local release of biomolecules to direct tissue regeneration in the defect 
area. Growth factors and growth factor coding-genes are the most straightforward bio-
logical stimuli to promote tissue regeneration. Consequently, studies related to the con-
trolled delivery of growth factors and genes from bioactive scaffolds show an exponen-
tial increase over the last decade. Bioactive scaffolds with growth factor or gene delivery 
can be prepared in the form of micro/nano-spheres, hydrogel, as well as electrospun 
fibers. In recent years, electrospun fibrous scaffolds have attracted increasing  attention 
due to the relative simplicity regarding the generation of fibrous scaffolds with nanoscale 
dimensions.  
Electrospinning utilizes electrostatic forces to spin polymer solutions or melts into 
whipped jets, revealing continuous fibers with diameters from a few nanometers to mi-
crometers after solvent evaporation in the spinning process. Because of the ultrathin 
fiber diameter, electrospun scaffolds are considered as an effective delivery system for 
biomolecules due to the stereological porous structure and high specific surface area. 
Biomolecules can be incorporated within electrospun scaffolds by physical adsorption, 
blend electrospinning, coaxial electrospinning as well as covalent immobilization after 
scaffolds fabrication. Although there has been a substantial number of studies dedicated 
to the methodology of preparing electrospun scaffolds to achieve biomolecules delivery, 
further studies are needed to improve the stability of incorporated protein, gene trans-
fection efficiency as well as the accuracy of release kinetics control. 
Until now, only a limited number of research efforts have focused on in vivo applications 
of electrospun scaffolds with protein or gene delivery. Consequently, more animal stud-
ies are needed to fully explore the potential of these bioactive scaffolds for clinical appli-
cations. Close cooperation between laboratory and clinics might eventually help to trans-
late this promising technique from bench to bed, and it is likely that biomolecule delivery 
from electrospun scaffolds will provide therapeutic benefit in regenerative medicine in 
the near future. 
Chapter 3 
 68 
6. References 
1. Porter, J. R.; Ruckh, T. T.; Popat, K. C. Biotechnol Prog 2009, 25, 1539-1560. 
2. Langer, R.; Vacanti, J. P. Science 1993, 260, 920-926. 
3. Rosenberg, M. D. Science 1963, 139, 411-412. 
4. Ma, Z.; Kotaki, M.; Inai, R.; Ramakrishna, S. Tissue Eng 2005, 11, 101-109. 
5. Martins, A.; Duarte, A. R. C.; Faria, S.; Marques, A. P.; Reis, R. L.; Neves, N. M. Biomaterials 
2010, 31, 5875-5885. 
6. Wang, F.; Li, Z. Q.; Khan, M.; Tamama, K.; Kuppusamy, P.; Wagner, W. R.; Sen, C. K.; Guan, J. 
J. Acta Biomater 2010, 6, 1978-1991. 
7. Murphy, W. L.; Peters, M. C.; Kohn, D. H.; Mooney, D. J. Biomaterials 2000, 21, 2521-2527. 
8. Moioli, E. K.; Clark, P. A.; Xin, X.; Lal, S.; Mao, J. J. Adv Drug Deliv Rev 2007, 59, 308-324. 
9. Tabata, Y. Pharm Sci Technolo Today 2000, 3, 80-89. 
10. Varkey, M.; Gittens, S. A.; Uludag, H. Expert Opin Drug Deliv 2004, 1, 19-36. 
11. Chen, F. M.; Zhang, M.; Wu, Z. F. Biomaterials 2010, 31, 6279-6308. 
12. Lu, Z.; Zreiqat, H. Tissue Eng Part A 2010, 16, 3075-3084. 
13. Roy, K.; Wang, D.; Hedley, M. L.; Barman, S. P. Mol Ther 2003, 7, 401-408. 
14. Storrie, H.; Mooney, D. J. Adv Drug Deliv Rev 2006, 58, 500-514. 
15. Babensee, J. E.; McIntire, L. V.; Mikos, A. G. Pharm Res 2000, 17, 497-504. 
16. De Laporte, L.; Shea, L. D. Adv Drug Deliv Rev 2007, 59, 292-307. 
17. Basmanav, F. B.; Kose, G. T.; Hasirci, V. Biomaterials 2008, 29, 4195-4204. 
18. Censi, R.; Vermonden, T.; van Steenbergen, M. J.; Deschout, H.; Braeckmans, K.; De Smedt, 
S. C.; van Nostrum, C. F.; di Martino, P.; Hennink, W. E. J Control Release 2009, 140, 230-
236. 
19. Abbas, A. O.; Donovan, M. D.; Salem, A. K. J Pharm Sci 2008, 97, 2448-2461. 
20. Sill, T. J.; von Recum, H. A. Biomaterials 2008, 29, 1989-2006. 
21. Nie, H.; Soh, B. W.; Fu, Y. C.; Wang, C. H. Biotechnol Bioeng 2008, 99, 223-234. 
22. Hoare, T. R.; Kohane, D. S. Polymer 2008, 49, 1993-2007. 
23. Li, W. J.; Laurencin, C. T.; Caterson, E. J.; Tuan, R. S.; Ko, F. K. J Biomed Mater Res 2002, 60, 
613-621. 
24. Luu, Y. K.; Kim, K.; Hsiao, B. S.; Chu, B.; Hadjiargyrou, M. J Control Release 2003, 89, 341-
353. 
25. Pham, Q. P.; Sharma, U.; Mikos, A. G. Tissue Eng 2006, 12, 1197-1211. 
26. Yang, F.; Both, S. K.; Yang, X.; Walboomers, X. F.; Jansen, J. A. Acta Biomater 2009, 5, 3295-
3304. 
27. Murugan, R.; Ramakrishna, S. Tissue Eng 2006, 12, 435-447. 
28. Yarin, A. L.; Koombhongse, S.; Reneker, D. H. J Appl Phy 2001, 89, 3018-3026. 
29. Venugopal, J.; Low, S.; Choon, A. T.; Ramakrishna, S. J Biomed Mater Res B Appl 
Biomater 2008, 84, 34-48. 
30. Agarwal, S.; Wendorff, J. H.; Greiner, A. AdvMater 2009, 21, 3343-3351. 
31. Zeugolis, D. I.; Khew, S. T.; Yew, E. S.; Ekaputra, A. K.; Tong, Y. W.; Yung, L. Y.; Hutmacher, D. 
W.; Sheppard, C.; Raghunath, M. Biomaterials 2008, 29, 2293-2305. 
 
Chapter 3 
 69 
32. Dong, Y.; Liao, S.; Ngiam, M.; Chan, C. K.; Ramakrishna, S. Tissue Eng Part B Rev 2009, 15,  
333-351. 
33. Huang, X.; Brazel, C. S. J Control Release 2001, 73, 121-136. 
34. Grassi, M.; Grassi, G. Curr Drug Deliv 2005, 2, 97-116. 
35. Kootstra, N. A.; Verma, I. M. Annu Rev Pharmacol Toxicol 2003, 43, 413-439. 
36. Nie, H.; Ho, M. L.; Wang, C. K.; Wang, C. H.; Fu, Y. C. Biomaterials 2009, 30, 892-901. 
37. Nie, H.; Wang, C. H. J Control Release 2007, 120, 111-121. 
38. Cleland, J. L. Pharm Biotechnol 1997, 10, 1-43. 
39. Vasir, J. K.; Labhasetwar, V. Adv Drug Deliv Rev 2007, 59, 718-728. 
40. Giteau, A.; Venier-Julienne, M. C.; Aubert-Pouessel, A.; Benoit, J. P. Int J Pharm 2008, 350, 
14-26. 
41. Shi, Y.; Huang, G. Crit Rev Ther Drug Carrier Syst 2009, 26, 29-84. 
42. Yang, Y.; Li, X.; Qi, M.; Zhou, S.; Weng, J. Eur J Pharm Biopharm 2008, 69, 106-116. 
43. Kowalczyk, T.; Nowicka, A.; Elbaum, D.; Kowalewski, T. A. Biomacromolecules 2008, 9, 2087
-2090. 
44. Zeng, J.; Aigner, A.; Czubayko, F.; Kissel, T.; Wendorff, J. H.; Greiner, A. Biomacromolecules 
2005, 6, 1484-1488. 
45. Yang, Y.; Li, X.; Cui, W.; Zhou, S.; Tan, R.; Wang, C. J Biomed Mater Res A 2008, 86, 374-385. 
46. Li, Y.; Jiang, H.; Zhu, K. J Mater Sci Mater Med 2008, 19, 827-832. 
47. Li, C.; Vepari, C.; Jin, H. J.; Kim, H. J.; Kaplan, D. L. Biomaterials 2006, 27, 3115-3124. 
48. Schneider, A.; Wang, X. Y.; Kaplan, D. L.; Garlick, J. A.; Egles, C. Acta Biomater 2009, 5, 2570
-2578. 
49. Kim, B. S.; Oh, J. M.; Kim, K. S.; Seo, K. S.; Cho, J. S.; Khang, G.; Lee, H. B.; Park, K.; Kim, M. S. 
Biomaterials 2009, 30, 902-909. 
50. Knoll, D.; Hermans, J. J Biol Chem 1983, 258, 5710-5715. 
51. Michel, R.; Pasche, S.; Textor, M.; Castner, D. G. Langmuir 2005, 21, 12327-12332. 
52. Wang, Y.; Annunziata, O. J Phys Chem B 2007, 111, 1222-1230. 
53. Casper, C. L.; Yamaguchi, N.; Kiick, K. L.; Rabolt, J. F. Biomacromolecules 2005, 6, 1998-
2007. 
54. Fu, Y. C.; Nie, H.; Ho, M. L.; Wang, C. K.; Wang, C. H. Biotechnol Bioeng 2008, 99, 996-1006. 
55. Chew, S. Y.; Wen, J.; Yim, E. K.; Leong, K. W. Biomacromolecules 2005, 6, 2017-2024. 
56. Zhang, Y. Z.; Wang, X.; Feng, Y.; Li, J.; Lim, C. T.; Ramakrishna, S. Biomacromolecules 2006, 
7, 1049-1057. 
57. Liang, D.; Luu, Y. K.; Kim, K.; Hsiao, B. S.; Hadjiargyrou, M.; Chu, B. Nucleic Acids Res 2005, 
33, e170. doi:10.1093/nar/gni171 
58. Sun, Z. C.; Zussman, E.; Yarin, A. L.; Wendorff, J. H.; Greiner, A. Adv Mater2003, 15, 1929-
1932. 
59. Chakraborty, S.; Liao, I. C.; Adler, A.; Leong, K. W. Adv Drug Deliv Rev 2009, 61, 1043–1054. 
60. Doshi, J.; Reneker, D. H. J Electrostat 1995, 35, 151-160. 
61. Jiang, H.; Hu, Y.; Zhao, P.; Li, Y.; Zhu, K. J Biomed Mater Res B Appl Biomater 2006, 79, 50-
57. 
62. Jiang, H.; Hu, Y.; Li, Y.; Zhao, P.; Zhu, K.; Chen, W. J Control Release 2005, 108, 237-243. 
 
 
Chapter 3 
 70 
63. Li, X. Q.; Su, Y.; Chen, R.; He, C. L.; Wang, H. S.; Mo, X. M. J Appl Polym Sci 2009, 111, 1564-
1570. 
64. Liao, I. C.; Chew, S. Y.; Leong, K. W. Nanomed 2006, 1, 465-471. 
65. Li, H.; Zhao, C. G.; Wang, Z. X.; Zhang, H.; Yuan, X. Y.; Kong, D. L. J Biomat Sci-Polym Ed 21, 
803-819. 
66. Wang, J. G.; Liu, J. J.; Fan, C. Y.; Mo, X. M.; He, C. L.; Chen, F. J Clinical Rehabilitative Tissue 
Eng Res 2008, 12, 4440-4444. 
67. Sahoo, S.; Ang, L. T.; Goh, J. C.; Toh, S. L. J Biomed Mater Res A 2009, 93A, 1539-1550. 
68. Ji, W.; Yang, F.; van den Beucken, J. J.; Bian, Z.; Fan, M.; Chen, Z.; Jansen, J. A. Acta Bio-
mater 2010, 6, 4199-4207. 
69. Saraf, A.; Baggett, L. S.; Raphael, R. M.; Kasper, F. K.; Mikos, A. G. J Control Release 2010, 
143, 95-103. 
70. Liao, I. C.; Chen, S.; Liu, J. B.; Leong, K. W. J Control Release 2009, 139, 48-55. 
71. Kim, H. S.; Yoo, H. S. J Control Release 2010, 145, 264-271. 
72. Li, W.; Guo, Y.; Wang, H.; Shi, D.; Liang, C.; Ye, Z.; Qing, F.; Gong, J. J Mater Sci Mater Med 
2008, 19, 847-854. 
73. Choi, J. S.; Yoo, H. S. J Bioact Compat Polym 2007, 22, 508-524. 
74. Choi, J. S.; Leong, K. W.; Yoo, H. S. Biomaterials 2008, 29, 587-96. 
75. Ma, Z. W.; Kotaki, M.; Ramarkrishna, S. J Membrane Sci 2006, 272, 179-187. 
76. Grafahrend, D.; Calvet, J. L.; Klinkhammer, K.; Salber, J.; Dalton, P. D.; Moller, M.; Klee, D. 
Biotechnol Bioeng 2008, 101, 609-621. 
77. Sakai, S.; Yamada, Y.; Yamaguchi, T.; Ciach, T.; Kawakami, K. J Biomed Mater Res A 2009, 88, 
281-287. 
78. Park, Y.; Kang, E.; Kwon, O. J.; Hwang, T.; Park, H.; Lee, J. M.; Kim, J. H.; Yun, C. O. J Control 
Release 2010, 148, 75-82. 
79. van der Walle, C. F.; Sharma, G.; Ravi Kumar, M. Expert Opin Drug Deliv 2009, 6, 177-186. 
80. van de Weert, M.; Hennink, W. E.; Jiskoot, W. Pharm Res 2000, 17, 1159-1167. 
81. Carpenter, J. F.; Pikal, M. J.; Chang, B. S.; Randolph, T. W. Pharm Res 1997, 14, 969-975. 
82. Estey, T.; Kang, J.; Schwendeman, S. P.; Carpenter, J. F. J Pharm Sci 2006, 95, 1626-1639. 
83. Houchin, M. L.; Topp, E. M. J Pharm Sci 2008, 97, 2395-2404. 
84. Jiang, W.; Schwendeman, S. P. Pharm Res 2001, 18, 878-885. 
85. Zhu, G.; Mallery, S. R.; Schwendeman, S. P. Nat Biotechnol 2000, 18, 52-57. 
86. Mahr, J. A.; Gooding, L. R. N Engl J Med 2003, 348, 193-194. 
88. Fernandez, C. A.; Rice, K. G. Mol Pharm 2009, 6, 1277-1289. 
89. Yang, N. S.; Burkholder, J.; Roberts, B.; Martinell, B.; McCabe, D. Proc Natl Acad Sci USA 
1990, 87, 9568-9572. 
90. Lin, C.; Engbersen, J. F. Expert Opin Drug Deliv 2009, 6, 421-439. 
91. Siepmann, J.; Siepmann, F. Int J Pharm 2008, 364, 328-343. 
Chapter 3 
 71 
Appendix 
ALP: alkaline phosphatase 
BMP2: bone morphogenic protein 2 (protein form) 
bmp2: bone morphogenic protein 2 (gene form) 
BSA: bovine serum albumin 
EGF: epidermal growth factor 
FA:  folic acid 
HA: hyaluronic acid 
HAp: hydroxylapatite 
NGF: nerve growth factor 
PCL: poly(ε-caprolactone) 
PCL-b-PEG: poly(ε-caprolactone)-block-poly(ethylene glycol)  
PDGF-bb: platelet-derived growth factor-bb 
PDLLA: poly (D,L-lactide) 
PEG-b-PDLLA: poly (ethylene glycol)-block-poly(D,L-lactide) 
PLCL: poly(L-lactide-co-epsilon-caprolactone) 
PLGA: poly(lactide-co-glycolide) 
PMMAAA: copolymer of methyl methacrylate (MMA) and acrylic acid (AA) 
PSU: polysulphone 
PVA: poly(vinyl alcohol) 
pDNA: plasmid deoxyribonucleic acid 
pGL3: plasmid DNA encoding luciferase 
pBMP-2: plasmid DNA encoding bone morphogenic protein-2 
pCMVβ: plasmid DNA encoding β-galactosidase 
pCMV-EGFP: plasmid DNA encoding enhanced green fluorescent protein with a cytomeg-
alovirus promoter 
pEGFP-N1: plasmid DNA encoding a red shifted variant of wild-type green fluorescent 
protein 
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1. Introduction 
Guided bone regeneration (GBR) is a frequently used strategy to treat bony defects in 
the craniomaxillofacial region. The principle of GBR is to create and maintain a secluded 
space by using a barrier membrane to prevent the invasion of fast growing epithelial and 
other soft tissues from migrating into the osseous defect, thereby allowing time for oste-
ogenic cell populations originating from the parent bone to inhabit the osseous defect1. 
Conventionally, GBR membranes require flexibility to adapt to and optimally cover a 
bone defect, to maintain the space for bone formation and to connect with the soft tis-
sues2, and biodegradability to eliminate the need for membrane removal surgery3. To 
date, most of the available biodegradable GBR membranes present the required compe-
tence as barrier membranes for space provision, yet the amount of regenerated bone is 
limited due to the relatively low regenerative capacity of bone tissue4. Consequently, the 
current research efforts focus on developing a bioactive GBR membrane that not only 
functions as a barrier membrane, but also exerts biological activity to stimulate in situ 
bone regeneration in the defect site. 
In the past decades, many attempts have been made to enhance the biological activity of 
GBR membranes. One frequently used approach is to incorporate osteogenic (growth) 
factors into GBR membranes, hence to encourage the differentiation of osteogenic pro-
genitor cell types in the secluded space under the membrane. Among the various choices 
of osteogenic factors, bone morphogenetic protein 2 (BMP-2) has been most frequently 
used to functionalize GBR membranes, withstanding its recently reported adverse effects 
(e.g. local inflammation and heterotopic ossification) related to uncontrolled release 
profiles5. Danesh-Meyer et al.6 previously reported that GBR membranes absorbed with 
BMP-2 promoted osseous repair compared to conventional GBR membranes, either with 
or without the use of various osseous grafting materials. In addition, Park et al.7 reported 
that BMP-2 conjugated chitosan membranes significantly increased osteoblastic cell 
attachment, proliferation as well as calcium deposition, indicating that BMP-2 conjugat-
ed membranes would be applicable for inducing bone formation in future GBR proce-
dures.  
Recently, an alternative approach has emerged as a promising strategy for in situ tissue 
regeneration, which focuses on cell recruitment. This cell recruitment approach maximiz-
es the body’s own regenerative capacity by recruiting endogenous stem/progenitor cells 
to the injury site to (i) exert local functional and reparative effects, and (ii) to synchronize 
the biological functions of other cell types via paracrine mechanisms8, 9. In view of the 
bone healing process, tissue regeneration in a bony defect is dependent on the recruit-
ment of progenitor cells either derived from bone marrow or present at the defect site, 
for which these cells “sense” tissue injury, migrate to the injured sites, and undergo spe-
cific differentiation to form mature bone tissue10. Multiple types of progenitor cells re- 
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side within the bone marrow, and amongst them, the non-haemopoietic progenitor cells, 
which are commonly referred to as bone marrow stromal cells (BMSCs), are considered 
most potent during bone regeneration because these cells exhibit multi-lineage differen-
tiation capacity11. Additionally, the migratory capacity of BMSCs to sites of bone fracture 
has been reported previously10. In view of this, development of a bioactive membrane 
that can increase recruitment of BMSCs to the defect area in addition to simple space 
provision holds huge potential for an enhanced bone regeneration in clinical GBR appli-
cations.  
To induce BMSCs recruitment, a commonly used strategy is to increase local concentra-
tions of cytokines and/or chemokines at the target site12, because cytokines and chemo-
kines are important factors in regulating mobilization, trafficking and homing of stem/
progenitor cells13. Among various cytokines or chemokines, stromal cell derived factor-
1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12), is particularly 
important in BMSCs homing and localization within the bone marrow14. Previous studies 
indicated that SDF-1α activates cell recruitment mainly through its receptor CXCR414, 15, 
suggesting that the SDF-1α/CXCR4 axis plays an important role in stem cell/progenitor 
cell migration. Wynn et al.16 reported that SDF-1α regulates the migration of human 
BMSCs in a dose-dependent manner by using a transwell migration assay. Recently, 
Kitaori et al.10 discovered that the SDF-1α/CXCR4 axis plays a crucial role in the migration 
of BMSCs to a fracture site, and the recruited cells actively participated in endochondral 
bone repair observed in a segmental bone defect model.  
On the basis of the aforementioned, a straightforward approach to generate bioactive 
GBR membranes with BMSCs recruitment capacity is to incorporate SDF-1α into conven-
tional barrier membranes. Nevertheless, limited research has been performed to explore 
the feasibility and performance of such a bioactive membrane with local delivery of SDF-
1α in GBR applications. Among the rare cases which investigated in vivo performance of 
locally delivered SDF-1α, Thevenot et al.17 and Schantz et al.18 used mini-osmotic pumps 
and a customized apparatus comprising a reservoir and microneedle, respectively, to 
achieve sustained SDF-1α delivery in vivo. However, these approaches are apparently not 
sufficiently sophisticated to be applied in clinical GBR procedures. 
The current study aimed to (i) develop membranes absorbed with SDF-1α as bioactive 
GBR membranes, and (ii) investigate their biological effects on BMSCs recruitment and 
bone regeneration using a rat cranial defect model. To this end, GBR membranes were 
prepared by blends of poly(ε-caprolactone) (PCL) and type B-gelatin using an electrospin-
ning technique19, and the obtained membranes were further loaded with SDF-1α via 
physical adsorption. PCL was chosen due to its good spinnability, flexibility, and biocom-
patibility20, and the addition of type B-gelatin was to provide electrostatic affinity for 
loaded SDF-1α21 in order to improve SDF-1α release kinetics. Our hypothesis was that 
the electrospun PCL/gelatin membrane loaded with SDF-1α would stimulate BMSCs re-
cruitment and enhance bone regeneration in the defect site. 
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2. Materials and Methods 
2.1. Membrane preparation  
GBR membranes were prepared using an electrospinning technique. To prepare the elec-
trospinning solution, PCL (inherent viscosity 1.0-1.3 dl/g), gelatin powder from bovine 
skin (Type B, ~225 g Bloom), and organic solvent 2,2,2-trifluoroethanol (TFE) (purity ≥ 
99.8%) were obtained from Durect (Cupertino, USA), Sigma-Aldrich (St. Louis, USA) and 
Acros Organics (Geel, Belgium), respectively. PCL and type B-gelatin (w/w=1/1) were dis-
solved in 90% TFE in deionized H2O at a concentration of 16% w/v. A commercially availa-
ble electrospinning set-up (Advanced Surface Technology, Bleiswijk, The Netherlands) 
was used for the membrane preparation. The feeding rate for the solution was 2.0 ml/h, 
and the collection distance was 18 cm. A high voltage of 20 kV was applied to generate a 
stable polymer jet. 
The membranes were collected on a rotating mandrel covered with aluminium foil and 
left in vacuum conditions overnight to eliminate solvent residues. The obtained mem-
branes were cross-linked according to a previously described method22 using glutaralde-
hyde (Acros Organics, Geel, Belgium) vapour at room temperature for 24 h. After cross-
linking, the membranes were washed with 100 mM glycine (Sigma−Aldrich, St. Louis, 
USA) solution followed by a rinse with distilled water. Thereafter, the membranes were 
punched into disc shape with 15 mm or 8 mm in diameter for in vitro and in vivo analysis, 
respectively. Samples were freeze dried for 72 h, and subsequently sterilized by ethylene 
oxide (Synergy Health, Venlo, Netherlands) before further use. 
2.2. Membrane characterization 
The morphology of the fabricated GBR membrane was observed by a high-resolution 
field emission scanning electron microscope (SEM; JEOL-SM3010, Tokyo, Japan), operat-
ed at an acceleration voltage of 3.0 kV. The fiber diameters were measured from the 
SEM micrographs obtained at random locations (n≈100) using Image J software (National 
Institutes of Health, Bethesda, USA). 
Fourier transform infrared spectrometry (FTIR; Spectrum One, Perkin−Elmer, USA) was 
used to analyze the chemical structure of the membrane over a range of 650−4000 cm-1 
at a resolution of 4 cm-1. 
2.3. In vitro release experiment 
Recombinant human SDF-1α (R&D systems, Abingdon, UK) was labelled with 125I as de-
scribed previously23 for in vitro release experiments. Briefly, in a 500 μl eppendorf tube 
coated with 100 μg iodogen, 10 μl of 0.5 M phosphate buffer, pH 7.2 was added. SDF-1α  
(2 μg) and 10–15 MBq 125I (Perkin−Elmer, Boston, USA) was added and the total volume  
was adjusted to 100 µl with 0.05 M phosphate buffer.  The reaction mixture was incubat- 
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ed at room temperature for 10 min and after which 100 μl of saturated tyrosine solution 
in PBS was added. The labelling efficiency of the reaction was determined at 27% for SDF
-1α. To remove the non-incorporated 125I, the reaction mixture was eluted on a pre-
rinsed disposable NAP-5 column with 0.1% BSA in PBS (GE Healthcare, Diegem, Belgium). 
The specific activity of the 125I-labeled SDF-1α was 29 μCi/μg, and the radiochemical puri-
ty of the labelled protein was 98%, as determined by instant thin layer chromatography 
(ITLC). 
Three groups with different loading amounts of SDF-1α (n=3) were set up for the in vitro 
release experiment. In each group, a volume of 20 μl 125I-labeled/unlabelled mixture of 
SDF-1α solution containing 50, 100, or 200 ng was adsorbed onto disc-shaped PCL/
gelatin electrospun membranes (15 mm in diameter). Thereafter, the membranes (n=3) 
were placed separately in 10 ml glass vials and incubated in 3 ml sterile PBS at 37 °C on 
an orbital shaker at low rotational speed (60 rpm) for 35 days. At predetermined time 
intervals, the membranes were carefully transferred to new vials containing fresh PBS 
and the activity was measured in a shielded well-type gamma counter (Wizard, Pharma-
cia-LKB, Uppsala, Sweden). Standards were measured simultaneously to correct for radi-
oactive decay. The remaining activity in the PCL/gelatin membranes was expressed as 
percentage of the initial dose. 
2.4. Rat bone marrow stromal cells culture 
Rat bone marrow stromal cells (BMSCs) were isolated from 7-week-old male Wistar rats 
(Charles River; Approval No.: RU-DEC 2011-142) and 12-week-old green fluorescent pro-
tein (GFP)-transgenic Sprague−Dawley rats (Approval No.: RU-DEC 2010-028), respective-
ly, after the approval from Radboud University Nijmegen Animal Ethics Committee. Cell 
culture reagents including minimal essential medium (α-MEM), fetal bovine serum (FBS), 
gentamycin and fungizone were purchased from Gibco (Bleiswijk, Netherlands). 
Briefly, two femora of each rat were extracted and washed three times in α-MEM sup-
plemented with 0.5 mg/ml gentamycin and 3 μg/ml fungizone. Epiphyses were cut off 
and diaphyses were flushed out with 15ml proliferation medium, consisting of α-MEM 
supplemented with 10% FBS and 50 μg/ml gentamycin. The flush-out of bone marrow 
from different rats was pooled and cultured for 2 days in a humidified incubator (37 °C, 
5% CO2), after which the medium was refreshed to remove non-adherent cells. After 
primary culture for an additional 4 days, the cells were trypsinized and frozen in liquid 
nitrogen. Prior to the in vitro experiment, cells were thawed and expanded in 
proliferation medium up to passage 3-4 for further flowcytometry and migration 
analysis. 
2.5. Characterization of CXCR4 expression on rat BMSCs 
Prior to the cell migration assay, flowcytometry (both extracellular and intracellular 
staining) was performed to characterize the expression of CXCR4 in both wild type and  
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GFP-transgenic rat BMSCs (passage 3). Flowcytometry antibodies were all purchased 
from Abcam (Cambridge, UK). 
For extracellular staining, cells were incubated on ice with primary rabbit polyclonal anti-
body to CXCR4 (20 μg/ml, 30 min), followed by incubation with secondary donkey F(ab’)2 
polyclonal antibody to rabbit IgG conjugated with R-Phycoerythrin (10 μg/ml, 20 min). 
For intracellular staining, cells were incubated at 4°C for 45 min in Fixation/
Permeabilization buffer, which was prepared by four times dilution of Fixation/
Permeabilization concentrate (eBioscience, San Diego, USA) in Fixation/Permeabilization 
diluent (eBioscience, San Diego, USA). Cells were then stained with the aforementioned 
primary and secondary antibodies, which were diluted in Permeabilization buffer 
(eBioscience, San Diego, USA) using the same concentrations and time as described for 
extracellular staining. After staining, the cells were analysed using CyAn™ ADP 9 colour 
Analyser (Beckman Coulter, Inc., Miami, USA) with Summit Software 4.3.01.  
2.6. In vitro rat BMSCs recruitment 
A transwell migration model was used as previously described17 with slight modifications 
to examine rat BMSCs recruitment to the PCL/gelatin membrane with SDF-1α adsorp-
tion. In brief, wild type rat BMSCs (passage 4) were starved overnight in α-MEM supple-
mented with 0.2% bovine serum albumin (BSA; purity ≥ 98%; Sigma−Aldrich, St. Louis, 
USA) and 50 μg/ml gentamycin. Then, the cells were trypsinized and seeded onto 
ThinCertTM cell culture inserts (membrane pore 8μm, Greiner Bio-One) in a 24-well plate 
at cell density of 10,000 cells/insert. 
The SDF-1α dose used for in vitro cell recruitment assay was consistent with the one de-
scribed in section 2.3. In addition, membranes absorbed with 400 ng of SDF-1α were in-
cluded to examine the high dose effect of SDF-1α on BMSCs recruitment. The group of 
bare membranes was set up as a negative control. In brief, 5 groups of PCL/gelatin mem-
branes (15 mm in diameter; n=3) loaded with different amounts of SDF-1α (0-400 ng) 
were placed below the inserts, after which 200 μl and 600 μl of BMSCs proliferation me-
dium was added in the upper and lower chambers, respectively. After 24h culture in a 
humidified incubator (37 °C, 5% CO2), the inserts were removed and scraped on the up-
per side to remove adherent cells. Further, they were fixed in 10% formalin for 5 min, 
and crystal violet (0.05%) stained for 30 min to visualize the migrated cells. The inserts 
with stained cells were then photographed with Zeiss Imager Z1 together with AxioCam 
 MRc5 camera using AxioVision 4.6.3 software (Carl Zeiss Microimaging GmbH, Göttin-
gen, Germany). Quantification of migrated cells based on the obtained images was per-
formed by two independent examiners (WJ and MB) using Image J software (National 
Institutes of Health, Bethesda, USA). 
2.7. Animal experiment design 
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Eleven healthy 8-week old nude rats (Crl:NIH-Foxn1rnu), weighing 250 g in average, were 
used as experimental animals. The protocol was approved by the Animal Ethical Com-
mittee of the Radboud University Nijmegen Medical Center (Approval No.: RU-DEC 2011-
140) and national guidelines for the care and use of laboratory animals were observed. 
The animal experiment included two parts: (i) a short-term experiment used a single cra-
nial defect (8 mm in diameter) in the center of rat skull, aiming to trace the engraftment 
of BMSCs; and (ii) a long-term experiment used bilateral cranial defects (5 mm in diame-
ter), aiming to evaluate the biological performance of the obtained membranes. Sintered 
titanium fiber mesh (Bekaert N.v., Zwevegem, Belgium) was used in these studies as a 
filling material in the defects in order to avoid brain tissue dilation in cranial defect and 
to mimic clinical GBR strategy which usually involves filling of grafting materials in the 
defect. The fiber mesh, which has a volumetric porosity of 86%, density of 600 g/m2 and 
fiber diameter of 45 μm, showed excellent bone biocompatibility previously24. The titani-
um fiber mesh was punched into disc shape with the same diameter as the defect, and 
sterilized by autoclaving before implantation. The defect model and group information 
for the entire animal experiment are listed in Table 1. 
2.8. Surgical procedure 
Before surgery, the rats were anesthetized by isoflurane inhalation (Rhodia Organique 
Fine Limited, Avonmouth, Bristol, UK) via intubation. Then, the rats were immobilized on 
their abdomen and the skull was shaved and disinfected with chlorhexidine. A longitude- 
nal incision was made from the nasal bone to the occipital protuberance. To minimize  
 
Purpose Animal 
number 
Animal Model Groupsa Investigation 
period 
Analysis method 
bIn vivo 
cell track-
ing 
2 Cranial defect (8 mm 
in diameter) + intra-
venous injection of 
GFP-transgenic 
rBMSCs (2×106 cells) 
(1) SDF− 
(2) SDF+ 
 (n=1) 
2 weeks IVIS® Lumina 
Laser scanning confo-
cal microscopy 
c In vivo 
biological 
evaluation 
9 Bilateral cranial 
defect (5 mm in 
diameter) 
(1) SDF− 
(2) SDF+ 
(3) EMP 
 (n=6) 
8 weeks Micro CT 
Descriptive histology 
Histomorphometry 
Table 1. Animal experiment design 
a Groups in the animal experiment 
SDF−: defect filled with titanium fiber mesh and covered with bare electrospun membrane 
SDF+: defect filled with titanium fiber mesh and covered with SDF-1α loaded electrospun membrane 
EMP: empty defect (to provide biological reference) 
b Disc shape membranes (10 mm diameter) with retention volume of 50 μl were used. In SDF+ group, 50 μl of 
SDF-1α solution (100 μg/ml) was absorbed by the electrospun membrane; whereas in SDF- group, the same 
volume of PBS was absorbed by the membrane.  
c Disc shape membranes (8 mm in diameter) were used. In SDF+ group, 20 μl of SDF-1α solution (100 μg/ml) 
was absorbed by the electrospun membrane; whereas in SDF- group, the same volume of PBS was absorbed by 
the membrane 
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pain, lidocaine HCl 1% (B. Braun, Melsungen, Germany) was dripped onto the perioste-
um before incision and exposure of the parietal bone. 
2.8.1. In vivo cell tracking 
Two rats were used to trace the recruitment of BMSCs. For this purpose, a cranial defect 
with 8 mm in diameter was created by marking the defect outline with a dental trephine 
drill (outside diameter 8 mm, ACE dental implant system, Brockton MA, USA). After that, 
a full-thickness bone defect was created by removing cortical bone with an ultrasonic 
device (Piezosurgery, Mectron, Carasco, Italy) in the middle of the skull with caution for 
the underlying dura mater and sagittal sinus and using constant cooling with sterile sa-
line. Subsequently, the defect was filled with a disc-shaped titanium fiber mesh (8 mm in 
diameter) and then covered with an electrospun membrane with or without absorbing 
50 μl of SDF-1α solution (100 μg/ml) (SDF+ or SDF-). Finally, the skin and periosteal tis-
sues were closed over the implants with Vicryl® 5-0 sutures. To minimize post-operative 
discomfort, Rimadyl (Pfizer Animal Health B.V, Capelle aan den IJssel, Netherlands) was 
administered subcutaneously (5 mg/kg) directly after the operation and for 2 days after 
surgery. 
After 2 days of implantation, 2 ml PBS solution containing 2×106 GFP-transgenic rat 
BMSCs was injected into the tail vein of the rats. Thereafter, the recruitment of GFP-
transgenic rat BMSCs at the defect site was monitored using in vivo bioluminescence 
imaging (IVIS® Lumina, Caliper Life Sciences, USA). Fluorescent intensity measurements 
were performed over the region of the cranial defect every two days, and imaging data 
were analysed using Living Image® 3.0 software (Caliper Life Sciences, USA). After 2 
weeks, the rats were sacrificed using CO2 suffocation, and the samples with surrounding 
tissue were retrieved for histological analysis.  
2.8.2. In vivo biological evaluation 
Nine animals were randomized into 3 groups (Table 1) for a long term study to evaluate 
biological responses in a cranial defect upon implantation of a PCL/gelatin membrane 
with or without absorbing 20 μl of SDF-1α solution (100 μg/ml) (SDF+ or SDF-). Bilateral 
full-thickness bone defects (5 mm in diameter) were created by removing cortical bone 
with a dental trephine drill (outer diameter 5 mm, Hager & Meisinger GmbH, Neuss, Ger-
many). For the implantation groups SDF- and SDF+, the defect was filled with a disc- 
shaped titanium fiber mesh (5 mm in diameter), and thereafter covered with an electro-
spun membrane (SDF- or SDF+). The empty group (EMP), in which the defect was left 
uncovered, was set up as a biological reference. After that, the skin and periosteal tis-
sues were closed with Vicryl® 5-0 sutures, and the same post-surgery treatment as de 
scribed in section 2.8.1 was applied to the rats. After 8 weeks, the animals were sacri-
ficed using CO2 suffocation, and the implants with surrounding tissue were retrieved for  
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microcomputed tomography (micro-CT) imaging and histological analysis.  
2.9. Micro-CT imaging 
Three samples randomly selected from each group were used for micro-CT imaging to 
qualitatively visualize implant location and bone formation. The harvested cranial bone 
defects were imaged using a high resolution SkyScan-1072 micro-CT imaging system 
(SkyScan, Aartselaar, Belgium). For each sample, a total of 1023 micro-tomographic slices 
were gained using a slice increment of 20 μm in order to scan the whole defect (5 mm) 
and the surrounding bone. Then, using Nrecon V1.4 (SkyScan, Kontich, Belgium), a cone 
beam reconstruction was performed on the projected files. Finally, a 3D-reconstruction 
of the defect was obtained by using 3D creator software as previously described25. 
2.10. Histological preparations 
The retrieved implants with surrounding tissue were fixed in 10% formalin. dehydrated in 
a graded series of ethanol and embedded in methylmethacrylate. In the middle of the 
implants, perpendicular thin sections (10 μm) were prepared as previously described26 
using a microtome with a diamond blade (Leica Microsystems SP 1600, Nussloch, Germa-
ny). 
For the samples retrieved from the cell tracking experiment, three sections of each im-
plant were prepared and examined using laser scanning confocal microscopy (Olympus 
FV1000, Japan). The excitation wavelength for GFP was 488 nm, and images were cap-
tured with a 60×/1.35NA objective. For the samples retrieved from the biological evalua-
tion experiment, three sections of each implant were prepared and stained with meth-
ylene blue and basic fuchsin for histological and histomorphometrical evaluation. 
2.11. Histological and histomorphometrical evaluation 
All histological sections (n=3 per implant) were photographed with the Zeiss Imager Z1 
together with the AxioCam MRc5 camera using AxioVision 4.6.3 software (Carl Zeiss Mi-
croimaging GmbH, Göttingen, Germany). In each group, the probability of animals show-
ing bone formation was determined. Furthermore, histomorphometrical evaluation was 
performed to quantify bone formation. In brief, the sections were scored using computer
-based image analysis techniques (Leica® Qwin Pro-image analysis system, Wetzlar, Ger-
many), which recognize bone tissue from implanted titanium fiber mesh based on differ- 
ent RGB values from highly magnified digitalized images. Manual corrections were also 
applied to ensure the precise selection of newly formed bone tissue within defect area. 
The bone formation area (μm2) was determined as newly developed bone in two re-
gions: (i) inside the titanium fiber mesh, and (ii) outside the titanium fiber mesh. The 
amount of newly formed bone was defined as: 
 
 
Chapter 4 
 82 
Amount of bone formation=Total bone formation area (μm2)/cross-sectional distance 
(μm) (Figure 1). 
Three sections per specimen were measured and averaged. 
 
 
 
 
 
 
 
 
2.12. Statistical analysis 
Data was expressed as mean ± standard deviation. For in vitro cell migration measure-
ments, a one-way ANOVA with post Dunnett’s multiple comparison was applied. The 
statistical analysis was performed using Graphpad Instat software (Instat® 3.05, 
Graphpad Software Inc., La Jolla, USA). For histological and histomorphometrical evalua-
tion, statistical analysis was performed using SPSS 18.0 (SPSS, Chicago, USA). A Chi-
square test was applied to compare the bone formation probability between the groups. 
Furthermore, an independent t-test was performed to compare the amount of newly 
formed bone between groups SDF- and SDF+. 
3. Results 
3.1. Characterization of PCL/gelatin electrospun membrane 
The nanofibrous PCL/gelatin membranes were prepared by electrospinning, and their 
morphology was examined using SEM. SEM images (Figure 2a) showed a uniform fiber 
structure with average fiber diameters of 312±146 nm.  
FTIR spectra of prepared PCL/gelatin membrane are shown in Figure 2b. Infrared spectra 
for PCL related stretching modes were observed from the membrane, including 2940 cm-
1 (asymmetric CH2 stretching), 2869 cm
-1 (symmetric CH2 stretching), 1725 cm
-1 (carbonyl 
stretching), and 1237 cm-1 (asymmetric COC stretching). Characteristic bands of protein 
appeared at approximately 1652 cm-1 (amide I) and 1542 cm-1 (amide II), respectively. 
The amide I band at 1652 cm-1 was attributed to both a random coil and α-helix confor-
mation of gelatin 27. 
  
Figure 1. Schematic overview of histomorphometrical evaluation. The bone formation area (µm2) was 
determined as newly developed bone in two regions: (i) inside the titanium fiber mesh (blue area) and (ii) 
outside titanium fiber mesh (yellow area). The amount of newly formed bone was defined as:  
Amount of bone formation = Total bone formation area (µm2)/cross-sectional distance (µm) 
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3.2. In vitro SDF-1α release  
Figure 3 shows the cumulative protein release profiles of the electrospun membrane 
loaded with different amounts of SDF-1α. For all three groups, a similar release pattern 
was observed, which included a burst release within 4 h, followed by a sustained release 
up to 35 days.  
During burst release, 30.8±1.3 ng, 60.4±3.3 ng, and 114.7±2.9 ng SDF-1α was released 
 from membranes loaded with 50, 100, and 200 ng SDF-1α, respectively. The burst re-
lease percentage was similar (p>0.05) for all three groups with around 60% burst release 
(Table 2). From day 2 onwards, the membranes loaded with different amounts of SDF-1α 
exhibited similar sustained release profiles (approximately 0.35% release per day; 
p>0.05), which resulted in ~80% cumulative release after 35 days (Table 2). For each 
group, the cumulative release curve was successfully fitted by an allometric power 
growth equation y=ktn (Table 2).  
Figure 2. Characterization of prepared electrospun membrane. 
Figure 3. in vitro SDF-1α release profiles 
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Table 2. Cumulative release (%) of membrane loaded with different amount of SDF-1α (50−200ng) &  
allometric regression analysis (y=ktn) of cumulative release  
 
 
 
 
 
 
 
 
 
 
3.3. Expression of CXCR4 on rat BMSCs 
Flowcytometry was performed to detect the expression of SDF-1α receptor (CXCR4) on 
the rat BMSCs (passage 3) (Figure 4a&b). The results showed that CXCR4 could not be 
detected from extracellular staining (Figure 4a). In contrast, CXCR4 was highly detected 
from intracellular staining (Figure 4b). Similar CXCR4 expression patterns were observed 
for GFP-transgenic rat BMSCs (passage 3). 
3.4. In vitro rat BMSCs recruitment 
In vitro rat BMSCs recruitment was tested using a transwell system. Crystal violet staining 
showed that electrospun PCL/gelatin membranes with SDF-1α release were able to 
induce rat BMSCs migration across the transwell membrane (Figure 4c). Compared to the 
bare PCL/gelatin membranes, SDF-1α loaded membranes significantly enhanced rat 
BMSCs migration (p<0.05). Membranes absorbed with different amounts of SDF-1α (50, 
100, 200, & 400 ng, respectively) resulted in 5.64±1.29, 6.14±2.92, 6.97±1.00, and 
5.11±1.56 fold of migration, respectively, with no significant differences between differ-
ent amounts (p>0.05; Figure 4d).  
3.5. Animal experiment 
3.5.1. General observations 
From the total of 11 animals available for surgery, one animal died during anaesthesia. 
The remaining 10 animals recovered uneventfully from the surgical procedure and re-
mained in good health. No signs of wound complications were observed post-operatively  
and during the course of the experiment.  
At the end of experiment, 2 and 16 samples were retrieved from in vivo cell tracking and 
biological evaluation experiments, respectively (Table 3). Macroscopic signs of inflamma-
tion or adverse tissue responses were absent for all the retrieved samples. For the bio- 
logical evaluation experiment, two samples were lost (one from SDF- group and another 
from EMP group) due to animal death during anaesthesia. In addition, one sample from  
  50 ng 
(%) 
100 ng 
(%) 
200 ng 
(%) 
Burst release 
(within 4h) 
61.6 ± 2.5 60.4 ± 3.3 57.3 ± 1.5 
Total release 
(after 35 days) 
79.4 ± 0.4 78.6 ± 0.3 79.1 ± 0.5 
k 
n 
Adjusted R2 
64.27 
0.059 
0.98 
63.01 
0.062 
0.99 
62.59 
0.067 
0.98 
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Figure 4. CXCR4 expression on rat BMSCs & in vitro rat BMSCs migration upon to SDF-1α loaded membrane. 
The expression of SDF-1α receptor (CXCR4) on rat BMSCs was detected using flowcytometry. (a) A representa-
tive example of extracellular expression of CXCR4 in rat BMSCs by antibody staining (i) and isotype control (ii). 
No obvious cell population was observed in PE positive region (R2), indicating negative extracellular expression 
 of CXCR4. (b) A representative example of intracellular expression of CXCR4 in rat BMSCs by antibody staining 
(i) and isotype control (ii). Obvious cell population was observed in PE positive region (R2), indicating the  
SDF+ group was excluded from evaluation due to an inappropriate histological prepara-
tion (Table 3).  
Table 3. Summary of samples retrieved from animal experiment 
Purpose 
  
Groups 
  
Number of im-
planted samples 
Number of re-
trieved samples 
Number of samples 
for evaluation 
In vivo cell tracking SDF− 
 SDF+ 
1 
1 
1 
1 
1 
1 
In vivo biological 
evaluation 
SDF− 
 SDF+ 
EMP 
 5a 
6 
 5a 
5 
6 
5 
5 
  5b 
5 
a Both SDF- and EMP group lost one sample due to animal death caused by anaesthesia during surgery.  
b One sample from SDF+ group was excluded from evaluation due to the inappropriate histological 
preparation. 
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3.5.2. In vivo cell tracking  
In vivo tracking of GFP-BMSCs using luminescence appeared to be not possible, as no 
fluorescent signal was observed from in vivo bioluminescence imaging. As an alternative 
method, the infiltration of GFP-BMSCs within the cranial defect was assessed by laser 
scanning confocal microscopy 
using (non-stained) histological 
sections (Figure 5). Auto-
fluorescence of polymeric mem-
brane and newly formed blood 
vessel structures was observed 
in the cranial defect region. 
Compared to the bare mem-
brane, apparently more GFP-
signal was observed for SDF-1α 
loaded PCL/gelatin membrane 
throughout the whole thickness 
of defect the area. However, 
the exact contribution of GFP-
rat BMSCs to the GFP-signal 
could not be ascertained due to 
the relatively high autofluores-
cence of endogenous tissue.  
SDF-1α loaded PCL/gelatin membrane throughout the whole thickness of defect area. However, exact contribu-
tion of GFP-rat BMSCs to the GFP-signal could not be ascertained due to the relatively high autofluorescence of 
endogenous tissue. Scale bar = 30 µm. 
positive intracellular expression of CXCR4. (c) rat BMSCs migration across transwell membranes (pore 8 µm) 
was quantified after 24 h by removing cells from the seeded side and crystal violet staining on cells on the 
underside. (Representative image from the membrane loaded with 100 ng SDF-1α, scale bar = 100 µm). (d) 
Five different amount of SDF-1α (0−400 ng) was loaded on the electrospun membrane and tested in vitro 
chemotactic effect on rat BMSCs using transwell migration system. Compared to the bare membrane, the 
addition of SDF-1α significantly induced the rat BMSCs migration (p<0.05), and there was no dose-
dependent effect on rat BMSCs migration. 
Figure 5. Laser scanning confocal mi-
croscope images of the samples re-
trieved from the rats with GFP-
transgenic rat BMSCs injection. Auto-
fluorescence of polymeric membrane 
(indicated as “M”) and newly formed 
 blood vessel structures was observed 
in the cranial defect region. Compared 
to the bare membrane, apparently 
more GFP-signals were observed for  
Chapter 4 
 87 
3.5.3. Biological evaluation  
3.5.3.1. Micro-CT imaging 
The implant location and bone formation in the skull defects (n=3, randomly selected) 
was imaged with micro-CT. The micro-CT images (Figure 6) showed no bone formation 
for control group (empty defect, EMP) after 8 weeks of implantation. Due to scattering of 
the titanium fiber mesh, reliable quantification of bone formation within the cranial de-
fect area was not possible.  
 
3.5.3.2. Bone formation probability 
Regarding bone formation, animal variation was observed among animals from the same 
group regarding the bone formation (Table 4). Overall, 3 and 2 out of 5 animals from 
implantation groups SDF- & SDF+, respectively, showed bone ingrowth in the defect ar-
ea. In contrast, only 1 animal from control group (EMP) showed spontaneous bone for-
mation in the defect site. Chi-square analysis was performed to compare the bone for-
mation probability caused by animal variation among three groups. Statistical analysis 
showed that there was no statistical difference (p>0.05) among groups (Table 4).  
Table 4. Summary of animals showing bone formation after 8-week implantation 
Figure 6. Representative micro-CT images of the cranial defects after 8 weeks of implantation.  
Original defect area (5 mm in diameter) was indicated by dash red circle. After 8 weeks of implantation, no 
bone formation was observed in control group (EMP, empty defect). Due to scattering of the titanium fiber 
mesh, reliable quantification of bone formation within the cranial defect area from implantation group 
(SDF− and SDF+) was not possible. 
Group Probability of animals showing bone formation a 
SDF-    3/5 
SDF+    2/5 
EMP     1/5 
a Chi-square analysis indicated no statistical differences (p>0.05) among 3 groups regarding the probability 
of animals showing bone formation. 
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3.5.3.3. Descriptive histology 
Figure 7 presents an overview of histological sections of different groups after 8-week 
implantation. In the control group (EMP), original defect edges were observed, and the 
existing gap was mainly occupied by soft tissues. Furthermore, dura mater was extruding 
from defect area and adherent to the soft tissue originating from skin side. Alternately, in 
both implantation groups (SDF- & SDF+), titanium fiber mesh remained inside the defect 
and covered with PCL/gelatin membrane. Mild fibrous encapsulation and fibroblast infil-
tration was observed surrounding the implanted membrane in both implantation groups 
(SDF- & SDF+) (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the specimens showing bone formation, bone ingrowth within the porous titanium 
fiber mesh was observed in both SDF- and SDF+ group, accompanied by newly formed 
vascular structures (Figure 8). In particular, specimens from SDF+ group also showed new 
bone formation outside the titanium fiber mesh in the area beneath the SDF-1α loaded 
membrane, with intensive cell assembling between the newly formed bone fragments 
(Figure 8).  
Figure 7. Representative histological 
images (general view) of cranial de-
fects after 8 weeks of implantation.  
Methylene blue and basic fuchsin 
staining on the sections, in which bone 
appears red while cells appear blue 
and the titanium fibers appear black. 
Scale bar = 500 µm 
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3.5.3.4. Histomorphometrical evaluation 
Figure 9 shows the results of histomorpho-
metrical evaluation between two implanta-
tion groups. The total amount of bone for-
mation in SDF- and SDF+ group was 58±22 
μm2/μm and 321±108 μm2/μm, respectively 
(p=0.02). For SDF- group, 93±7% of total 
amount of bone formation was formed in-
side the titanium fiber mesh, with approxi-
mate 7% of new bone formed outside the 
titanium mesh. In contrast, 71±1% of new 
bone formation amount in SDF+ group was 
formed inside the titanium fiber mesh, 
whereas 29±1% of the newly formed bone 
was observed outside the titanium fiber 
mesh. 
Figure 8. Magnified histological sections of three 
groups. Both SDF- and SDF+ group showed bone for-
mation inside titanium fiber mesh, in accompany with 
newly formed vascular structures (indicated by ar-
rows). In particular, SDF+ group showed bone for-
mation closely beneath the implanted membrane 
(indicated as “M”), with intensive cell infiltrations 
between the newly formed bone fragments. In con-
trast, limited bone formation was observed from 
control group (EMP). Scale bar = 100 μm. 
Figure 9. Results of histo-
morphometrical evalua-
tion. The total amount of 
bone formation in SDF- and 
SDF+ group were 
57.83±21.99 μm2/μm and 
321.74±108.35μm2/μm, 
respectively, which was 
significantly different be-
tween groups (p=0.02).  
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4. Discussion 
The aim of current study was to generate electrospun membranes with SDF-1α release 
as bioactive GBR membranes and to evaluate the effects on BMSCs recruitment and 
bone regeneration. We hypothesized that an electrospun membrane loaded with SDF-1α 
would induce BMSCs recruitment, and hence enhance bone regeneration in the defect 
site. For this purpose, different amounts of SDF-1α were loaded on PCL/gelatin electro-
spun membranes via physical adsorption and the obtained membranes were used in an 
in vitro SDF-1α release experiment, BMSCs recruitment assay, and subsequently implant- 
ed in rat cranial defects. Our main findings showed that PCL/gelatin electrospun mem-
branes acted as an effective SDF-1α carrier, providing a diffusion-controlled SDF-1α re-
lease profile. Furthermore, the SDF-1α loaded membranes significantly induced in vitro 
BMSCs recruitment, although no dose-dependent effect of SDF-1α was observed on 
BMSCs recruitment. Despite animal individual variation, SDF-1α loaded membranes sig-
nificantly increased bone formation in rat cranial defects after 8-week implantation. Ani-
mals implanted with SDF-1α loaded membranes showed 6 fold higher amount of total 
bone formation compared to the ones implanted with bare membranes, albeit the con-
tribution of in vivo BMSCs recruitment to the bone formation could not be ascertained. 
Physical adsorption was found as an efficient approach to functionalize PCL/gelatin mem-
brane with SDF-1α release. The membrane loaded with different amounts of SDF-1α 
showed a universal release profile, including an approximately 60% release of loaded 
protein within 4 h, followed by sustained release up to 35 days. Such a release profile is 
predominantly controlled by a diffusion mechanism, as evidenced by the release compo-
nent (n) close to 0.5 calculated based on Ritger and Peppas equation (y = ktn), which indi-
cates a diffusion controlled release from a thin film system28. A large initial burst release 
(~60%) was observed in the current study, which was similar to a previous report, where 
SDF-1α was loaded in a hydrogel29. A large burst release is often regarded as a negative 
consequence for certain long term controlled release devices, as it might shorten the 
release profile of loaded biomolecule, which requires more frequent dosing30. However, 
in our case for SDF-1α delivery, we assume the high initial burst release is favorable for 
clinical setting up, because it is likely to enable local SDF-1α up to effective threshold 
within a short time period, hence triggering stem/progenitor cell recruitment as well as 
orchestrating subsequent tissue regeneration processes. 
The SDF-1α loaded PCL/gelatin electrospun membrane showed a strong cell recruiting 
capacity in vitro, which is evidenced by significantly enhanced rat BMSCs migration in 
response to the SDF-1α loaded PCL/gelatin membrane. This can be attributed to the re-
leased gradients of exogenous SDF-1α leading to BMSCs mobilization16, 17. Controversial 
results existed in previous research regarding the SDF-1α threshold to induce BMSCs 
mobilization. Otsuru et al31 previously reported that 1000ng/ml SDF-1α supplemented in  
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the medium induced maximum migration of mouse bone marrow-derived osteoblast 
progenitor cells. In contrast, Schantz et al18 reported that human MSCs migrated toward 
an SDF-1 stimulus with maximal chemotaxis at a concentration of 100 ng/ml. In the cur-
rent study, there was no significant difference in BMSCs migration when SDF-1α loading 
amount exceeded 50 ng in the membrane. Based on our protein release profile 
(approximate 70% release within 24 h), we assume that threshold SDF-1α concentration 
to induce maximum rat BMSCs chemotaxis is ~35 ng/ml. Such findings indicate the po-
tential usage of SDF-1α loaded PCL/gelatin membrane to achieve a more cost-effective  
stem/progenitor cell recruiting capacity, which might be beneficial for further clinical 
application.  
The molecular mechanism regulating BMSCs migrating towards SDF-1α stimuli has been 
extensively investigated. It is generally accepted that CXCR4, a chemokine CXC-motif 
receptor, is the functional receptor corresponding to SDF-1α in regulating stem/
progenitor cell migration12, 14, 15, 32. When the cells were treated with anti-CXCR4 anti-
body, inhibited migration of marrow stromal cells was shown in response to exogenous 
SDF-1α16, 18. However, controversial findings exist regarding the CXCR4 expression on the 
progenitor cells isolated from bone marrow. Honczarenko et al14 previously reported 
that 45% of human BMSCs showed surface expression of CXCR4. In contrast, our results 
demonstrated CXCR4 expression in BMSCs was predominantly intracellular, which cor-
roborates several other reports16, 18, 33. It seems that the intracellular CXCR4 can be func-
tionally expressed on the cell membrane to mediate SDF-1α dependent cell migration34. 
However, future studies are needed to clarify the mechanism responsible for such dy-
namic CXCR4 expression in regulating progenitor cells mobility for a comprehensive un-
derstanding the role of SDF-1α/CXCR4 axis in stem cell/progenitor cell homing strategy. 
A rat cranial defect was used as a defect model to mimic the clinical situation for GBR 
application because it provides a suitable non-load bearing bone healing model with rel-
ative biological resemblance to the atrophic mandibular bone in humans35. In two im-
plantation groups (SDF- and SDF+), a titanium fiber mesh was placed to avoid the dilation 
of brain tissue beneath the defect in the defect36, 37. In addition, the non-degradable tita-
nium fiber mesh also provided a defined defect area for further quantification of bone 
formation. In current study, bilateral cranial defects with 5 mm in diameter were created 
in nude rats. After 8 weeks, limited spontaneous healing was observed from animals with 
empty defects (n=5). Such findings were different from previous report, which conven-
tionally claims that a rat cranial defect with diameter less than 8mm shows spontaneous 
healing capacity through 8-week investigation period38.  
PCL/gelatin membrane loaded with 2 mg of SDF-1α enhanced bone formation in rat cra-
nial defects (5 mm in diameter) after 8-week implantation, which is evidenced by the 
histological and histomorphometrical results. Animals implanted with bare membranes  
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showed majority of bone formation and vascularization structures inside the titanium 
fiber mesh, and bare new bone formation was observed outside the titanium fiber mesh. 
In contrast, animals implanted with SDF-1α loaded membranes showed approximate  
30% of newly formed bone outside the titanium fiber mesh and closely beneath the 
membrane. Furthermore, intensive cell infiltrations were observed within the new bone 
fragments in such area in accompany with vascularization structures nearby. Such obser-
vations indicate that membranes with SDF-1α delivery played important roles in new 
bone formation. There are two plausible mechanisms contributing to the enhanced new 
bone formation in response to local SDF-1α stimuli. First, the bone marrow-derived oste- 
oblast progenitor cells existed in the circulating blood31, 39, 40, might be recruited to the 
defect site in response to local release of SDF-1α via aforementioned SDF-1α/CXCR4 axis. 
Those recruited cells contribute to the bone healing process by not only exerting their 
osteogenic capacity in the defect site, but also secreting a number of cytokines and 
growth factors to promote tissue regeneration41. Second, the local release of SDF-1α 
might also generate proangiogenic environment in the defect site by mobilizing other 
progenitor cells resident in bone marrow, such as hematopoietic stem cell (HSC) and 
endothelial progenitor cell (EPC), to the defect site through SDF-1α/CXCR4 axis17, 42, 43. 
Those cells could enhance angiogenesis in the defect area, hence indirectly enhancing 
bone formation. Although it is still unclear which mechanism plays the dominant role in 
bone regeneration processes, our results indicate a great potential of locally delivered 
SDF-1α from PCL/gelatin membrane to achieve cell recruitment strategy by using SDF-1α 
loaded membrane to promote bone formation in GBR application.  
Although a few recent studies reported the in vivo BMSCs recruitment by using subcuta-
neous implantation model42, 44, no available studies investigated the in vivo BMSCs re-
cruitment in bony defects as well as the contribution of BMSCs recruitment to the bone 
regeneration. Therefore, in the current study, we also set up an experiment aiming to 
trace the in vivo cell mobilization by intravenous injection of GFP-transgenic rat BMSCs 
into experimental animals. Such method was previously reported as an effective ap-
proach to trace BMSCs migration in rat brain tissue45. However, due to the strong auto-
fluorescence of host tissues, we were unable to determine GFP-fluorescent signals from 
live animals by using bioluminescence imaging or from histological sections by using fluo-
rescent microscopy. Such observations suggest that the GFP-fluorescent signal might not 
be an optimal markers for in vivo cell tracing in bony tissue due to its short wavelength 
as well as close fluorescent spectrum with the natural tissue46. It is necessary to conduct 
further experiments using cells with more sensitive labelling marker, such as luciferase47, 
to elucidate in vivo BMSCs mobilization and corresponding biological function to bone 
regeneration.  
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5. Conclusions 
The results of current study show that the PCL/gelatin electrospun membranes with SDF-
1α adsorption provide a diffusion-controlled SDF-1α release profile. The local release of 
SDF-1α significantly induced in vitro rat BMSCs recruitment, although no dose-
dependent of SDF-1α was observed. Regarding bone formation, SDF-1α loaded mem-
branes significantly increased bone formation in rat cranial defects after 8-week implan-
tation, as evidenced by a 6-fold increase in the amount of bone formation compared to 
the bare membranes. However, the current study could not ascertain the contribution of 
in vivo BMSCs recruitment to the bone formation in cranial defects due to the strong 
auto-fluorescence caused by host tissues.  
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1. Introduction 
The structural and functional properties of the natural extracellular matrix (ECM) are 
crucial for the proliferation, differentiation and migration of cells. As a consequence, 
there is an increasing tendency to design scaffold materials, as applied in tissue regener-
ation approaches, according to the characteristics of ECM. Natural ECM is composed of 
nano-scaled collagen fibers in which biomolecules (e.g. cytokines and growth factors) are 
incorporated. As early as the 1960s, it was claimed that the nanoscaled architecture of 
ECM influences the adhesion and orientation of cells1, while the release of biomolecules 
from the ECM regulates cellular proliferation and differentiation2. In view of this, it 
seems logical  to assume that scaffolds, as used for tissue regeneration, should provide 
more than only physical support for cells. An appropriate architecture has to be com-
bined with the release of biomolecules in the design process of scaffolds in order to 
modulate an optimal cellular behavior. Tissue engineering scaffolds have been prepared 
using a multitude of different techniques, such as gas foaming, emulsion freeze drying 
and rapid prototyping3. Recently, a new technique named electrospinning has attracted a 
lot of attention due to its relative simplicity regarding the generation of  fibrous scaffolds 
with nanoscale dimensions. Electrospinning utilizes electrostatic forces to spin polymer 
solutions or melts into whipped jets, revealing continuous fibers with diameters from a 
few nanometers to micrometers after solvent evaporation in the spinning process4, 5. In 
addition to the nanoscale properties, electrospun scaffolds have been considered as an 
effective delivery system due to the stereological porous structure and high specific sur-
face area6-8. 
Enhancement of the biological functionality of electrospun scaffolds by incorporating 
biomolecules during the electrospinning process can be generally achieved by two differ-
ent approaches: blend electrospinning and coaxial electrospinning. Blend electrospinning 
involves mixing of the proteinaceous biomolecules with the polymer solution. Some re-
searchers also named this method as “emulsion electrospinning”9 because the aqueous 
protein solution was first emulsified by ultra-sonication, then the protein emulsion was 
mixed with polymer solution for electrospinning. Considering its same principle, we as-
sume that it still belongs to blend electrospinning approach.  Different from blend elec-
trospinning, in the coaxial electrospinning, two solutions (e.g. polymer solution and bio-
logical solution) are coaxially and simultaneously electrospun through different feeding 
capillary channels in one nozzle to generate composite nano-fibers with core-shell struc-
tures. A previous study indicated that the aqueous biological solution is unspinable due 
to its low viscosity10. Therefore, in both approaches, hydrophilic polymers (e.g. poly
(ethylene glycol), poly(ethylene oxide),  poly(ethylene imine), and dextran) are usually 
added in the aqueous biological solution to improve its fiber-forming property6, 8, 11-15. 
The addition of these hydrophilic polymers can also be helpful to modulate the release  
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profiles of the biomolecules7, 8, 11, as their addition enhances the water uptake of the 
electrospun scaffolds11.  
Compared to coaxial electrospinning, blend electrospinning is assumed to be relatively 
easy to perform, but the biomolecules may lose their bioactivity due to conformational 
changes in the organic solution environment. As coaxial electrospinning utilizes two sep-
arate channels for different solutions (i.e. organic polymer solution and aqueous biologi-
cal solution), it is hypothesized to be beneficial for maintaining the functional activity of 
the biomolecules. On the other hand, it may be not easy to set the parameters for stable 
coaxial electrospinning in order to form uniform fibrous structure due to the difference 
in conductivity and viscosity of the two solutions. Up to now, considerable efforts have 
been conducted on the exploration of the methodology of preparing protein loaded elec-
trospun scaffolds using these two techniques. Although previous studies provided differ-
ent protein release profiles from blend6, 9, 11, 16 and coaxial fibers7, 8, 12, little attention has 
been paid to compare these two techniques to determine which method provides a 
more controllable release system for biomolecules from the electrospun scaffolds.  
Furthermore, there is limited information about the effect of electrospinning conditions 
on activity of the biomolecules. Based on our literature survey, only a few recent studies 
investigated the stability of lysozyme loaded in blend electrospun scaffolds9, 16.  
However, compared to other therapeutic proteins, lysozyme is a small molecular protein 
(14 kDa) with a relative simple structure17. It is still necessary to further investigate the 
effect of different electrospinning process on those functional protein with complicated 
structure. 
In view of the aforementioned, the aim of the present study was to generate polycapro-
lactone-based scaffolds with incorporation of biomolecules via either blend or coaxial 
electrospinning techniques. These types of electrospinning techniques were compared in 
terms of the processing set up, scaffold characterization as well as the release kinetics 
and biological activity of the loaded protein. Bovine serum albumin (BSA) was used as a 
model protein to determine the release profiles, and alkaline phosphatase (ALP) was 
used to determine the activity of the biomolecule after electrospinning.  
2. Materials and Methods 
2.1. Materials 
Granular poly(ε-caprolactone) (PCL; Mn 80kDa), poly(ethylenee glycol) (PEG; Mn 35kDa), 
bovine albumin serum (BSA; purity ≥98%), alkaline phosphates (ALP; from bovine intesti-
nal mucosa; P7640, ≥10 DEA units/mg solid, specific activity: 42500U/mg), fluorescein 
isothiocyanate-conjugated bovine serum albumin (fitcBSA, Mw 67kDa), Rhodamine B 
(purity ≥80%) and formic acid solution (50% w/v) were purchased from Sigma−Aldrich, 
Inc. (St Louise, MO, USA). Organic solvents 2,2,2-trifluoroethanol (TFE) (purity ≥99.8%) 
and acetonitril (purity ≥99.0% ) were obtained from Acros (Geel, Belgium) and Lab-scan  
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(Meppel, The Netherlands), respectively.  
2.2. Electrospinning processing parameters 
Four different types of scaffolds were prepared by either blend or coaxial electrospin-
ning, of which the processing parameters and analytical methods are presented in Table 
1. The coaxial electrospinning was conducted using a compound nozzle, and the solution 
for fiber core and shell is delivered to the co-axial inner and outer needle, respectively. 
The exit orifice diameters of the inner and outer capillaries are 0.5 and 0.8 mm, respec-
tively. Electrospun fibers were collected on a grounded rotating plate covered by alumin-
ium foil, unless it has been specified otherwise. Subsequently, they were freeze dried for 
3 days before further characterization. 
2.3. Morphological characterization of electrospun scaffolds 
2.3.1. Scanning Electron Microscopy (SEM) 
Electrospun nanofibrous scaffolds, mounted on metal stubs using conductive double-
sided tape, were sputter-coated with gold using a JEOL JFC-1200 equipment. Scaffold 
morphology was examined using scanning electron microscopy (JEOL JSM-6310) at an 
accelerating voltage of 10 kV. Fiber diameters of the scaffolds were analysed with image 
visualization software (ImageJ 1.42q; Wayne Rasband, National Institutes of Health, USA 
(http://rsb.info.nih.gov/ij)). Approximate 130~150 counts for each scaffold were used to 
calculate the fiber diameter. 
2.3.2. Transmission Electron Microscopy (TEM) 
The fiber structure of the blend and coaxial scaffolds with BSA incorporated was exam-
ined using a JEOL 1010 Transmission Electron microscope, equipped with a Kodak mega-
plus 4 CCD camera, operated at 60 kV. The samples for TEM were prepared by direct 
deposition of the electrospun fibers onto copper grids.  
2.3.3. Laser Scanning Confocal Microscopy (LSCM) 
To visualize the presences and distributions of the protein in the electrospun scaffolds, 
samples for confocal microscope were prepared using Rhodamin B (50 μg/ml) and 
fitcBSA to stain the polymer and protein, respectively. A thin layer of electrospun fibers 
were collected on glass slides, and then observed by laser scanning confocal microscopy 
(Olympus FV1000, Japan). The excitation wavelengths for Rhodamin B and fitc BSA were 
559 nm and 488 nm, respectively, and multi-track images were captured with a 
60×/1.35NA objective.  
2.4. Determination of protein loading efficiency  
The total protein content was determined according to the method of Sah18 with modify- 
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cations. Briefly, freeze dried scaffolds (n=3) were incubated in 2 ml dimethylsulfoxide 
(DMSO) for 1 hour, then 4 ml 0.2 M-NaOH solution containing 0.5% SDS was added for 
another1-h incubation. The protein concentration in this solution was measured by a 
Micro BCATM assay (Pierce, Rockford, USA). Results are presented as “loading efficiency” 
values, which indicate the percentage of protein loaded in the scaffolds with respect to 
the total amount of protein used in the process.  
2.5. Release study in vitro 
The electrospun scaffolds with incorporated BSA (b-BSA/PEG, c-BSA/PEG and c-BSA) 
(Table 1) were cut into small squares (2cm×2cm) before protein release in vitro. The re-
lease study was performed in MilliQ water and samples were incubated in a shaking wa-
ter bath (37°C; 70rpm). Initially, 1.5 ml of MilliQ water was added to immerse the fiber 
meshes, A sample volume of 200 μl was taken at t = 0.5, 1.0, 2.0, 4.0 and 24 h. There-
after, the release medium was refilled to 1.5 ml and a sample volume of 500 μl was tak-
en at t = 2,3,7 days, and similarly every week until 42 days, with replenishment of the 
release medium to 1.5ml each time when a sample was taken out. 
For each group, the assay samples were taken in triplicate (n=3) at each time interval. 
The BSA concentration in the collecting supernatant was analysed by high performance 
liquid chromatography (HPLC) using a reversed-phase (RP)-HPLC column (Atlantis®, Wa-
ters corp., Milford, MA, USA) connected to a L2130 HPLC pump and a L-2400 UV detector 
set at 280 nm (Hitachi corp., Tokyo, Japan). Before each analysis, samples were filtered 
using Acrodisk® filters (Waters corp., Milford, MA, USA). A 40/60 mixture of acetonitril/
water containing 0.1% (w/v) formic acid was used as mobile phase with a flowing rate of 
0.4 ml/min. The results for the release test are presented as cumulative release as a 
function of time:  
Cumulative amount of release (%)=100×Mt/M∞ 
where Mt is the  amount of BSA released at time t, and M∞ is the total amount of BSA 
loaded in the membranes corrected using the measured protein loading efficiency. 
At the end of release study, the release kinetics from the three groups were calculated to 
regression analysis according to the Ritger and Peppas equation19: Mt/M∞ =kt
n 
in which k is a constant related to the structure and geometric characteristics of the sys-
tem, and n is the release exponent indicating the mechanism of the protein release20.  
Furthermore, the morphology of the post-release samples was assessed on a high-
resolution field emission scanning electron microscope (FESEM, JEOL, SM3010, Tokyo, 
Japan), operated at an acceleration voltage of 3.0 kV.  
2.6. Biological activity of the incorporated protein in electrospun scaffolds 
2.6.1. Sample preparation 
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To evaluate the effect of the electrospinning process on protein activity, ALP was added 
as the protein component (Table 1). Because the conventional chloroform extraction7, 9 
to obtain the protein from the electrospun scaffolds was shown to severely decrease the 
protein activity (data not shown), the samples for protein functional assay were pre-
pared without PCL polymer in the electrospinning solution under the same electrospin-
ning parameters (Table 1). The collected droplets, not fibers (n=5) were dissolved in  
MilliQ water and evaluated for biological functionality using an ALP activity assay and for 
secondary structure analysis using circular dichroism (CD) spectroscopy. Freshly dis-
solved ALP served as a control. 
2.6.2. ALP activity assay 
ALP activity measurements were performed according to a previously described 
method21. In brief, 20 μl of 0.5 M 2-amino-2-methyl-1-propanol (AMP) buffer (Sigma) 
was added to 80 μl of the samples or standards. Then, 100 μl of substrate solution pre-
pared from p-(nitrophenyl phosphate) was added and the mixtures were incubated at 37 
°C for 1 h. ALP activity was measured at 405 nm using an ELISA micro-plate reader (Bio-
Tek Instruments Inc., Winooski, VT, USA). 
2.6.3. Circular Dichroism (CD) analysis 
CD spectra were recorded in the range of 190 to 250 nm at a scan of 2 seconds per 0.5 
nm with a Jasco J−810 spectropolarimeter (Oklahoma, USA). A quartz cell of 0.1 cm thick-
ness was used. Values of the CD spectra were expressed as mean residue ellipticities (in 
deg. cm2 dmol-1). Results were further conducted a non-linear regression analysis to illus-
trate the constitution of secondary structure using the Gauss–Newton algorithm  
method.  
2.7. Statistical analysis 
Data are represented as mean ± standard deviation. Statistical analysis were conducted 
using one way ANOVA with a post-hoc Tukey test calculated by Graphpad Instat software 
(Instat® 3.05, Graphpad Software Inc., San Diego, CA, USA). Statistical significance was set 
at p < 0.05. 
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3. Results 
3.1. Characterization of electrospun scaffolds 
During scaffold preparation, it was found that b-BSA solution could not be electrospun 
into fibers because a stable processing condition could not be achieved. For the rest of 
the groups, SEM images showed irregular fiber morphology for the blend electrospun 
scaffold (b-BSA/PEG) with obvious beaded structure, whereas the coaxially electrospun 
scaffolds (c-BSA/PEG, c-BSA and c-PEG) revealed a relatively uniform fiber morphology 
(Figure 1). The average fiber diameter was significantly different for each group (p<0.05), 
i.e. 460, 420, 340 and 660 nm for b-BSA/PEG, c-BSA/PEG, c-BSA and c-PEG, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. SEM images of virgin fibrous scaffolds prepared by blend or coaxial electrospinning 
techniques and their fiber diameter distributions. (a) blend scaffold b-BSA/PEG; (b) coaxial 
scaffold c-BSA/PEG; (c) coaxial scaffold c-BSA; (d) coaxial scaffold c-PEG. Arrow indicates the 
beads-formation in the blend electrospinning process. Fiber diameters in the different scaffolds 
are significantly different at p<0.05 level (one way ANOVA, Tukey’s test). 
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TEM demonstrated that the coaxially electrospun scaffolds exhibited an obvious core-
shell structure (Figure 2), indicated by the difference in electron density between the 
inner core and outer shell of the fibers. This different electron density was not observed 
for blend electrospun fibers. 
 
LSCM was used to visualize protein distribution within the electrospun fibers prepared by 
the two techniques. The red stain can be attributed to Rhodamin B, as present in the 
polymer shell solution, whereas the green stain was from the FITC-label linked to BSA in 
the core solution. The coaxially electrospun fibers c-fitcBSA/PEG exhibited a relatively 
homogenous protein distribution (Figure 3a). In contrast, the blend sample b-fitcBSA/
PEG showed a bead-like appearance, in which the beads contained stronger green 
(fitcBSA) signal than the fiber strings (Figure 3b).  
Figure 2. TEM image of 
coaxial fiber c-BSA/PEG. 
Core-shell structure can 
be observed from coaxial 
scaffold c-BSA/PEG. 
Arrows indicate the core 
and shell parts within the 
fiber. Scale bar = 200 nm 
Figure 3. Laser scanning confocal microscopy images of blend and coaxial electrospun scaffolds. Laser 
scanning confocal microscopy images visualize protein distribution in blend and coaxial electrospun  
scaffolds. (a) coaxial scaffold c-BSA/PEG; (b) blend scaffold b-BSA/PEG. The panels in each image are: 
upper left: fitc (green); upper right: rhodamin B (red); bottom left: natural light; bottom right: the mer-
ger of fitc and rhodamin B.  
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3.2. Protein loading efficiency and in vitro release 
The protein loading efficiency could only be measured for the coaxial scaffold c-BSA, due 
to the interference of PEG with the micro-BCA assay, and the average loading efficiency 
was 92.1±1.7%. Considering the similarities in protein/polymer ratios, 92.1% was used as 
the protein loading efficiency to calculate the loaded protein for all types of scaffolds.  
Figure 4 shows the cumulative protein release curves for the protein incorporated 
scaffolds (b-BSA/PEG, c-BSA/PEG and c-BSA). For all three groups, a burst release was 
observed within 4 hours, which was 16.20±1.17%, 15.12±1.90% and 13.39±1.46% for b-
BSA/PEG, c-BSA/PEG and c-BSA scaffolds, respectively, and these values were insignifi-
cantly different (p>0.05) from each other. From day 10 on-award, the three types of 
scaffolds exhibited a similar sustained release profiles, proximal 0.7% of cumulative re-
lease per day till the end of the release study. After 5 weeks, the three types of scaffolds 
showed a total cumulative release ranging from ~45% to ~70%. For each of these 
scaffolds, the cumulative release curve was successfully fitted by an allometric power 
growth equation y=ktn (Table 2). 
 
Figure 4. Protein release profiles from electrospun scaffolds. Protein release profiles of 
blend and coaxial electrospun scaffolds loaded with 0.2% BSA. 
  b-BSA/PEG c- BSA/PEG c-BSA 
k 20.2 15.1 14.0 
n 0.37 0.43 0.37 
Adj.R-Square 0.99 0.97 0.98 
Table 2 Allometric regression analysis (y=ktn) of protein release for each protein loaded scaffold  
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The post-release SEM images (Figure 5) illustrate morphological changes of electrospun 
fibers after the 35-day release study. The fibers in the blend electrospun scaffolds b-BSA/
PEG showed rough and eroded-like fiber surfaces with very obvious pits and cavities pre-
sented, whereas the fibers in the coaxial scaffolds c-BSA/PEG and c-BSA became com-
pressed and collapsed compared to their previous smoothly cylindrical shape. 
 
Figure 5. FESEM images of electrospun scaffolds with BSA incorporation before and after release 
study. (a),(b)&(c) are virgin scaffolds; (d),(e)&(f) are scaffolds after 35 days in vitro release. (a)&(d) 
blend scaffolds b-BSA/PEG; (b)&(e)coaxial scaffolds c-BSA/PEG; (c)&(f) coaxial scaffolds c-BSA. Arrows 
indicate cavity-like damaged fiber surface after 35-day release in blend scaffold b-BSA/PEG. 
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3.3. Protein activity and secondary structure  
Compared to freshly dissolved one, the ALP samples after electrospinning had a signifi-
cant decrease in enzyme activity (p<0.001) (Figure 6). Among them, the ALP through co-
axial electrospinning with PEG loaded (c-ALP/PEG) maintained 76.2±8.4% of enzyme ac-
tivity, which was significantly higher (p<0.05) than b-ALP/PEG (49.3±4.5%) and c-ALP 
(13.4±1.7%).  
 
The far-ultraviolet circular dichroism (CD) spectrum (Figure 7) illustrates the conforma-
tional change of ALP after electrospinning process. Compared to freshly dissolved ALP, 
noticeable changes in molar CD values were observed at 190~200 nm and 208~222 nm 
after electrospinning process. The secondary structure analysis further quantified the 
conformational change of the electrospun ALP (Table 3). After electrospinning process, 
protein b-ALP/PEG and c-ALP/PEG revealed a significant decrease of α-helix and increase 
of β-sheet, as well as a 
slight decrease of random 
coil structure, whereas c-
ALP showed a noticeable 
increase (4 fold) of random 
coil structure.  
 
 
Figure 6. Protein activity preserva-
tion after the electrospinning 
process. ALP was used as model 
protein to determine the protein 
activity preservation.  Enzyme 
activity was determined after 
electrospinning. Data are related 
to the activity of freshly dissolved 
ALP solution. *statistically signifi-
cant difference (p<0.05) com-
pared to freshly dissolved ALP. 
Figure 7. Protein conformational 
change after electrospinning. Far 
ultraviolet circular dichroism spec-
trum of the freshly dissolved and 
electrospun ALP. The protein con-
centration was 50µg/ml in a 0.1 cm 
path-length cell. 
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4. Discussion 
Electrospinning has evolved as a powerful method to generate scaffolds which consist of 
(nano)fibrous networks with morphological similarities to the native extracellular matrix 
(ECM). In order to further mimic ECM composition, the present study focused on the 
incorporation of proteinaceous biomolecules into the electrospun fibers by using a blend 
and coaxial electrospinning approach. The obtained scaffolds were evaluated for their (i) 
morphology, (ii) biomolecular loading, distribution and release, and (iii) biological activity 
of the loaded biomolecules. The main findings were that both electrospinning techniques 
can be used for the preparation of nano-scaled electrospun scaffolds with incorporated 
biomolecules, and coaxial electrospinning was superior to the blend electrospinning as it 
provided uniform scaffold morphology, sustained release profiles as well as high conver-
sation of protein activity. Morphologically, coaxial electrospinning generated a uniform 
fiber structure with homogeneous protein distribution throughout the fibers in a core/
shell fashion, whereas blend electrospinning resulted in a bead-like fibrous structure 
with heterogeneous protein distribution. The in vitro release experiment showed an in-
stantaneous burst release for all electrospun scaffolds, after which a more sustained re-
lease profile was observed with a total cumulative release ranging from ~45% to ~70% 
after five weeks. Although both electrospinning techniques depressed the biological ac-
tivity of the loaded protein, the addition of PEG demonstrated to be able to preserve 
protein activity in coaxial electrospinning for up to 75%.  
In our study, coaxial electrospinning demonstrated a superior feasibility compared to 
blend electrospinning for the incorporation of protein within the scaffolds. As aqueous 
protein solutions are reported to be un-electrospinnable due to their high fluidity22, PEG 
is usually added to the aqueous protein solutions to improve its viscosity and to stabilize 
the processing parameters7, 8, 12. Our attempts for blend electrospinning confirmed that it 
is difficult to achieve stable electrospinning when the aqueous protein solution without 
PEG is mixed with the polymer solution. However, we were able to successfully set the 
parameters for coaxial electrospinning using an aqueous protein solution without PEG as 
supporting polymer. The optimal coaxial electrospinning process might be partially ex-
plained by the good electrospinability of the shell polymer solution (12% PCL/TFE), which  
  α-helix (%) β-sheet (%) random coil (%) 
Fresh ALP 42.2 53.1 4.7 
b-ALP/PEG 20.2 78.0 1.8 
c-ALP/PEG 28.2 70.5 1.3 
c-ALP 55.6 28.4 16.0 
Table 3 Secondary structure analysis of the freshly dissolved and electrospun ALP 
The analysis was conducted based on the CD spectrum using the Gauss–Newton algorithm method 
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was assumed to play an major role in the coaxial electrospinning process7. Furthermore, 
it was favored by the selection of optimal feeding rate ratios between core and shell so-
lutions. It has been reported that at flow rate ratio (core: shell) between 1:3 and 1:6 al-
lows the formation of stable core/shell Taylor cones and yield consistent electrospun 
core-shell fibers23. TEM confirmed the successful achievement of core-shell structure 
fibers by using coaxial electrospinning. Previously, Saraf et al.24 also showed the core/
shell structure using LSCM. However, the two structure components of our coaxial fibers 
could not be separately detected in the LSCM images due to the thin fiber diameter as 
well as the limited resolution of confocal microscopy. 
Scaffold characterization demonstrated that blend and coaxial electrospinning tech-
niques resulted in different fiber morphology. Consistent with a previous report, SEM 
showed that the coaxial electrospun scaffolds exhibited a relatively uniform fibrous 
structure7, whereas blend electrospun scaffolds presented a bead-like structure14, 25. An 
explanation for this morphological difference is that the mixture of aqueous protein and 
organic polymer components in the blend system behaves as an emulsion. Consequently, 
during electrospinning, the dispersed aqueous phase tends to accumulate centrally in 
the polymer jets, thereby forming beads in the fibers25.  
Due to its moderate molecular weight (60kDa) and relatively low cost, BSA was used as a 
model protein loaded in the scaffolds for the release study, and the loading efficiency for 
coaxial scaffold c-BSA was 92.1%. This value can be representative for the other protein 
loaded scaffolds because the protein loading during electrospinning is related to the pro-
cess set up, i.e. the feeding rate and collecting method26. In addition, it is logical to as-
sume similar loading efficiency among the three types of BSA-loaded scaffolds prepared 
in this study, as standardized processing parameters we used for all of them. 
The release experiment revealed different protein release profiles from the three types 
of BSA loaded electrospun scaffolds incorporated BSA. A similar burst release occurred 
within 4 hours for the three types of BSA loaded electrospun scaffolds. This burst effect 
may be related to the migration of BSA during drying and storage steps, which made 
certain amount of BSA molecules locating near the fiber surface27, and its high solubility 
and partition coefficients can lead to a rapid release through short diffusion pathways 
due to thermodynamic imbalances28. After burst release stage, compared to the blend 
scaffolds (b-BSA/PEG), coaxial electrospun scaffold (c-BSA/PEG and c-BSA) showed a 
more sustained protein release profile, and PEG accelerated protein release from coaxial 
electrospun scaffolds. The different release profiles can be related to the different fiber 
structure and protein distribution within scaffolds. The heterogeneously distributed pro-
tein in the blend fibers dispersed randomly upon activation in the release medium20. The 
cavity-like fiber structure in the post-release blend scaffold suggests the dissolution of 
protein or protein/PEG mixture on the fibers, which corroborates with a previous re- 
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port7. In contrast, the core-shell-structured coaxial fibers provide a protein reservoir sys-
tem, with a barrier membrane that controls the protein diffusion rate20. Our results 
showed that the addition of PEG in the core part of coaxial fibers can accelerate the pro-
tein diffusion. It has been shown that in high mass polymer crowded solution (i.e. PEG, 
dextran, etc), molecules diffused much faster than expected, in spite of the increased 
viscosity of the solution29, 30. This phenomenon was attributed to the fact that diffusing 
molecules were affected by the “microviscosity” of the local environment rather than the 
“macroviscosity” of the solution as a whole. And high mass polymers behave as a porous 
medium, in which proteins can associate relatively freely29. 
Empirical mathematical models might only be realistic in certain, extreme cases, but they 
give an indication for the underlying drug release mechanism under very specific condi-
tions and thus can be useful for a comparison of different drug release profiles20. In our 
case, due to the slow biodegradability and good biomolecular permeability of PCL, diffu-
sion was the predominant release mechanism, which can be calculated by the Ritger & 
Peppas equation (y=ktn)31, 32. In this equation, k is a constant related to the structure and 
geometric characteristics of the release system, while n is the release exponent indi-
cating the release mechanism. In the ideal case, the release is totally controlled by diffu-
sion when n=0.4519, and a zero-order kinetics (n=0) can be correspond to a surface erod-
ing polymer matrices33. Release exponents that are in between these extreme values 
indicate so-called “anomalous” transport, thus, an overlapping of different types of phe-
nomena20. The coaxial scaffold c-BSA/PEG showed a release exponent (n) close to 0.45, 
suggesting that the protein release kinetics better followed the mechanism of diffusion. 
On the contrary, the blend electrospun scaffold showed a lower release exponent 
(n=0.37), indicating that the release process was relatively irregular protein transporta-
tion.  
Further, we compared the influence of different electrospinning process on the protein 
activity by using ALP as a model protein. ALP exists as a dimer of identical subunits each 
containing 429 amino acids34, which relatively closely resembles the complexity of other 
therapeutic proteins. So far, there has been rare report on the activity and conforma-
tional change of ALP after blend or coaxial electrospinning process. The results indicated 
that both electrospinning techniques depressed the biological activity of the incorpo-
rated ALP, suggesting that high voltage and contact with organic solvents are harmful to 
the loaded biomolecules. Although the coaxial electrospinning greatly minimizes the 
interaction of protein with organic solvents before electrospinning, the measured low 
activity of c-ALP provided the evidence that this method alone is not enough to preserve 
protein activity as assumed before. However, the addition of PEG in coaxial electrospin-
ning was shown to be beneficial for protein activity preservation, most likely because 
PEG is proposed to eliminate protein adsorption to the organic polymer phase during  
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electrospinning35-37. Due to the limitation of the protein extraction method, PCL was not 
added to the sample preparation for the protein activity test.  As PCL was very stable in 
ambient conditions38, it is unlikely to affect the activity of the loaded protein.  
5. Conclusion  
In this study, protein-loaded nano-scaled electrospun scaffolds with protein were pre-
pared using blend and coaxial electrospinning techniques. Morphologically, the coaxial 
scaffolds showed uniform fiber morphology with core-shell structure, whereas the blend 
scaffolds exhibited a bead-like fiber structure. Protein distribution was homogeneous in 
the coaxial fibers, but heterogeneous in blend fibers. The different fiber structure and 
protein distribution affected protein release from the two types of scaffolds. The coaxial 
scaffolds revealed more sustained release profiles than the comparable blend scaffold, 
while the addition of PEG favored protein release. Both electrospinning techniques de-
creased the biological activity of the incorporated protein. However, the coaxial electro-
spinning method, where PEG was used as an additive, provided a superior conservation 
of protein activity preservation up to approximately 75%. Consequently, coaxial electro-
spinning represents a promising method for protein incorporation with minimal or no 
effects on fiber morphology and preservation of biological activity of the loaded protein 
in the scaffolds.  
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1. Introduction 
Suitable scaffolds for tissue engineering (TE) applications are structures based on biode-
gradable and biocompatible materials, which can support cell attachment and prolifera-
tion, deliver biochemical factors (i.e. growth factors), and enable diffusion of vital cell 
nutrients/metabolic products into/out of the scaffold, respectively1. In fact, the success 
of TE approaches depends on the integration of all these factors in an implantable de-
vice. Therefore, development of biocompatible scaffolds, which are capable to deliver 
active biomolecules (e.g. growth factors) at the desired site with a sufficient local dose 
for a specific time frame and that support cell adhesion and preserve cell function is of 
great importance2. There are two methods of incorporating biomolecules in polymeric 
matrices: (1) chemical bonding of the biomolecules of interest to the polymer matrix and 
(2) physical encapsulation of the biomolecules inside the polymer matrix3, 4. One of the 
methods that can be used for the physical incorporation of biomolecules to obtain bioac-
tive scaffolds is electrospinning5, which is a versatile and simple method to produce ul-
trafine fibrous structures from polymer solutions mimicking the fibrous structure of the 
extracellular matrix (ECM)6, 7.  The diameters of the fibers obtained using this technique 
range from several nanometers to a few microns8. Several researchers have developed 
electrospun nanofibers based on both natural polymers such as chitosan9, alginate10, 
gelatin11, and synthetic polymers including poly(ε-caprolactone) (PCL)12, poly(lactic-co-
glycolic acid)13-17, and poly(L-lactide-co-caprolactone)18-21.  
Coaxial electrospinning is an advanced technique comprising of two concentric needles 
rendering the possibility to make fiber mesh scaffolds with core/sheath morphology pre-
pared from an immiscible organic polymer solution and an aqueous biomolecule solu-
tion22. As a result, the obtained scaffolds are loaded with biomolecules that after release 
promote cell adhesion and growth. The most frequently used polymer for coaxial elec-
trospinning is PCL23-27 due to its ease of processing into fibers. However, PCL is a slowly 
degrading polyester that is eliminated from the body only after 2 to 4 years28, is intrinsi-
cally hydrophobic and lacks functional groups to promote cell adhesion29, 30. 
We have recently developed a novel polyester, poly(hydroxymethylglycolide-co-ε-
caprolactone) (pHMGCL)31, which is based on PCL and features a tunable degradation 
rate32 and has hydroxyl groups for further biofunctionalization33. Previously, we have 
shown that the scaffolds made of this polymer exhibit superior human mesenchymal 
stem cells adhesion, proliferation, and differentiation properties as compared to PCL 
matrices, both in 2D34 and 3D35 forms. In the present study, we aimed to improve the 
properties of coaxially electrospun PCL scaffolds with respect to hydrophilicity, degrada-
tion rate, biomolecule release rate, and cell adhesion/proliferation by incorporating 
pHMGCL into these structures. Therefore, we prepared scaffolds using pHMGCL/PCL so-
lutions to prepare the fiber shell. An aqueous solution of bovine serum albumin (BSA), as  
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a model protein and protein stabilizer, as well as vascular endothelial growth factor 
(VEGF), as a potent angiogenic factor36 were selected as representative biomolecules and 
formed the core of the fibers. The release of protein from different scaffolds was investi-
gated and to demonstrate that the bioactivity of released VEGF was preserved, the effect 
of released VEGF on attachment and proliferation of endothelial cells seeded on these 
scaffolds was demonstrated.  
2. Materials and Methods 
2.1. Materials 
All chemicals used in this study were purchased from Sigma-Aldrich and used as re-
ceived, unless stated otherwise. All solvents were purchased from Biosolve 
(Valkenswaard, The Netherlands). Toluene was distilled from P2O5 and stored over 3 Å 
molecular sieves under argon. Tetrahydrofuran (THF) was distilled from sodium/
benzophenone. 3S-Benzyloxymethyl-1,4-dioxane-2,5-dione (benzyl-protected hy-
droxymethyl glycolide, BMG) was synthesized as described by Leemhuis et al.37, 38. ε-
Caprolactone (CL) and silica gel (0.035-0.070 mm, 60 Å) were obtained from Acros (Geel, 
Belgium), and benzyl alcohol (BnOH) was provided by Merck (Darmstadt, Germany), Pd/C 
(palladium, 10 wt % (dry basis) on activated carbon, wet (50% water w/w), Degussa type 
E101 NE/W) were obtained from Aldrich (Zwijndrecht, The Netherlands). Recombinant 
human VEGF 165 was purchased from R&D Systems (Netherlands). 
For cell culture study, human umbilical vein endothelial cells (HUVECs) were purchased 
from BD (Franklin Lakes, USA). The endothelial medium (EM, containing basal medium 
200, low serum growth supplements (LSGS) kit containing 2% fetal bovine serum (FBS), 
10 ng/ml epidermal growth factor, 3 ng/ml basic fibroblast growth factor (bFGF), 10 mg/
ml heparin, 0.2 mg/ml bovine serum albumin (BSA), 1 mg/ml hydrocortisone, and 0.2% 
gentamicin/amphotericin B) was purchased from Cascade Biologics (Oregon, USA) and 
assay medium (AM, containing minimal essential medium (α-MEM), 10% FBS, 50 μg/ml 
gentamycin) was purchased from Gibco-BRL. 
2.2. Synthesis of PCL 
PCL was synthesized via ring opening polymerization of ε-caprolactone (CL) using BnOH 
and SnOct2 as initiator and catalyst, respectively, according to a previously described 
method34. The molar ratio of CL/BnOH was 1000/1 in the feed. The obtained PCL was 
characterized by 1H NMR, GPC and DSC. 
2.3. Synthesis of Poly(hydroxymethylglycolide-co-ε-caprolactone), (pHMGCL) 
A random copolymer of benzyl protected hydroxymethylglycolide (BMG) and ε-
caprolactone (p(BMGCL)) was synthesized, using monomer-to-initiator molar ratio of  
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300/1, by ring opening polymerization method as described before35. Briefly, ε-CL (2.29 
ml, 0.02 mol), BMG (1.6 g, 0.007 mol), BnOH (9.94 mg, 0.09 mmol), and SnOct2 (18.61 
mg, 0.04 mmol) were loaded into a dry schlenk tube, equipped with a magnetic stirrer, 
under a dry nitrogen atmosphere. Following 2 hours of evacuation, the tube was subse-
quently closed and immersed in an oil bath pre-heated at 130 °C. The polymerization was 
performed overnight and the formed polymer was precipitated in methanol, filtrated, 
and dried in vacuum overnight. The protective benzyl groups of pBMGCL were removed 
in a hydrogenation reaction using Pd/C catalyst essentially as described by Leemhuis et 
al.37. In short, pBMGCL (4.0 g, 8.5 mmol) was dissolved in dry THF (400 ml) and subse-
quently the Pd/C catalyst (3.0 g, 7.4 mmol) was added. The flask was filled with hydrogen 
in three consecutive steps of evacuation, refilling with H2 and the reaction was done at 
room temperature under an H2 pressure overnight. The catalyst was removed afterwards 
using a glass filter and THF by evaporation. pBMGCL and pHMGCL were characterized by 
1H NMR, DSC and GPC.  
2.4. Fabrication of Coaxial Electrospun Scaffolds 
Different types of scaffolds were prepared by coaxial electrospinning. The processing 
parameters used to obtain these scaffold are presented in Table 1. In general, coaxial 
electrospinning was performed using a nozzle, which delivered the core and shell solu-
tions to the inner and outer needles, respectively, as previously described39. The diame-
ters of the inner and outer needles were 0.5 and 0.8 mm, respectively. The electrospun 
fibers were collected on a stationary plate covered with an aluminum foil and the 
scaffolds were freeze-dried for three days before further characterization. 
2.5. Scanning Electron Microscopy (SEM) 
The morphology of the prepared fibrous scaffolds was studied by SEM. Scaffolds were 
mounted on metal stubs using conductive double-sided tapes and subsequently sputter-
coated with platinum. The morphology of the fibers was examined by SEM (JEOL JSM-
3010) at an accelerating voltage of 3.0kV. Fiber diameters were measured by ImageJ 
software and more than 100 counts were used for each scaffold.  
2.6. Transmission Electron Microscopy (TEM) 
The core-shell structure of fibers was examined using a JEOL 1010 transmission electron 
microscope equipped with a Kodak megaplus 4 CCD camera, operated at 60 kV. The sam-
ples for TEM were prepared by direct deposition of the electrospun fibers onto copper 
grids. 
2.7. Fluorescence Microscopy (FM) 
In order to visualize the presence and distribution of BSA inside the coaxial fibers, sam- 
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ples for fluorescent microscopy were prepared using FITC-labeled protein, which was 
dissolved in the core solution (Table1, Groups 5-7). A thin layer of electrospun fibers was 
collected on a glass slide and observed using an automated fluorescence microscope 
(Axio Imager Microscope Z1; Carl Zeiss Micro imaging GmbH, Gottingen, Germany). The 
excitation and emission wavelengths for FITC-BSA were 488 and 525 nm, respectively, 
and images were captured with a 40X/ 0.75 objective. 
2.8. Nuclear Magnetic Resonance (NMR) 
NMR measurements of the polymers were performed using a Gemini 300 MHz spec-
trometer (Varian Associates Inc., NMR Instruments, Palo Alto, CA). Chemical shifts were 
recorded in ppm with reference to the solvent peak (δ= 7.26 ppm for CDCl3 in 
1H NMR). 
2.9. Differential Scanning Calorimetry (DSC) 
The thermal properties of polymers and scaffolds were evaluated by differential scanning 
calorimetry (DSC). For the polymers, scans were taken from -80 °C to 100 °C with a 
heating rate of 10 °C/min and a cooling rate of 0.5 °C/min under a nitrogen flow of 50 
ml/min. The glass transition temperature (Tg) was recorded as the midpoint of heat ca- 
Sample 
code 
Solutions 
Voltage 
(kV) 
Analysis 
Group 1 
20% PCL/TFE + 
0.2% BSA/MilliQ 
10 
Characterization (SEM, DSC, load-
ing efficiency) 
& protein release 
Group 2 
20% PCL/pHMGCL(1:1)/TFE + 0.2% 
BSA/MilliQ 
11 
Characterization (SEM, DSC, load-
ing efficiency) 
& protein release 
Group 3 
20% PCL/pHMGCL(1:2)/TFE + 0.2% 
BSA/MilliQ 
13 
Characterization (SEM, DSC, load-
ing efficiency), 
protein release, endothelial cell 
proliferation 
Group 4 
20% PCL/pHMGCL(1:2)/TFE + 0.2% 
BSA + 5 µg VEGF /MilliQ 
12 Endothelial cell proliferation 
Group 5 
20% PCL/TFE + 
0.2% FITC-BSA/MilliQ 
10 FM 
Group 6 
20% PCL/pHMGCL(1:1)/TFE + 0.2% 
FITC-BSA/MilliQ 
11 FM 
Group 7 
20% PCL/pHMGCL(1:2)/TFE + 0.2% 
FITC-BSA/MilliQ 
13 FM 
Table 1. Experimental groups of coaxial electrospun scaffolds used in this study. 
The flow rate of core and shell solutions was 1.8 and 0.6 mL hr-1, respectively, and the collection 
distance (18 cm) was constant for all the groups. 
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pacity change in the second heating run. Melting temperature (Tm) and heat of fusion 
(ΔHf) were determined from the onset of endothermic peak position and integration of 
endothermic area in the second heating run, respectively. For scaffolds, the samples 
were equilibrated at -90 °C and then heated to 100 °C with a heating rate of 10 °C/min. 
The thermal transitions of the scaffolds were reported for the first and second heating 
runs. 
2.10. Gel Permeation Chromatography (GPC) 
The molecular weights of the polymers were measured by means of GPC using a 2695 
Waters Aliance system and a Waters 2414 refractive index detector. Two PL-gel 5 μm 
mixed-D columns fitted with a guard column (Polymer Labs, Mw range 0.2- 400 KDa) 
were used. The columns were calibrated with polystyrene standards of known molecular 
weights using AR grade THF, eluting at 1 ml/min flow rate at 30 °C. The concentration of 
the polymers was approximately 5 mg/ml and the injection volume was 50 μl. 
2.11. Water Contact Angle Measurements (CA) 
The wettability of polymer films was evaluated by measuring advancing and receding 
water contact angles using sessile drop technique (Data Physics, OSC50). Uniform poly-
meric films were prepared by means of spin coating method (Specialty Coating Systems, 
Inc., model P6708D) using polymer solutions in chloroform (0.2 g/ml) and spin coated for 
120 s at a speed of 1800-2000 rpm on round glass cover slips (Fisher Scientific, The Neth-
erlands). Subsequently, the films were put in a vacuum oven at room temperature for 48 
h to evaporate the solvent. 
For advancing contact angle (Adv-CA), a water droplet (10 μl) was placed onto the sur-
face of a polymeric film and the contact angle between water and surface was measured 
immediately by taking pictures of the droplet using an optical microscope and averaging 
the right and left angles using surface contact angle software (SCA20, Data Physics). For 
the receding contact angle (Rec-CA), the water droplet was withdrawn slowly and the 
contact angle was measured after different time points. The reported values are mean 
values of at least four measurements. 
2.12. Protein Loading Efficiency (LE) 
The protein loading efficiency of the scaffolds was determined according to the method 
described by Ji et al.40 To get accurate weight of scaffolds, scaffolds were freeze-dried 
prior to assessing to eliminate the moisture and solvent remnant which will interfere 
with the scaffold weight. Briefly, round pieces (diameter of 1 cm, weighing approximate-
ly 20 mg) of freeze-dried scaffolds (n=3) were incubated in 2 ml of dimethylsulfoxide for 
1h to dissolve the polymer. Subsequently, 4 ml of 0.2 M NaOH aqueous solution contain-
ing 0.5% sodium dodecyl sulfate was added and the obtained solution was incubated for  
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1 hour at room temperature. Next, the protein concentration in this solution was meas-
ured by Micro-BCA™ assay (Pierce, Rockford, IL). Results are presented as the “loading 
efficiency” of scaffolds, which is defined as the percentage of protein loaded in the 
scaffolds with respect to the total amount of protein used in the process. 
2.13. In-vitro Release Study 
The release of BSA from the different fibrous scaffolds was investigated as described by Ji 
et al.41. In short, round BSA-loaded scaffolds punched out of the electrospun mat 
(diameter of 1cm, thickness of approximately 2 mm, weighing approximately 20 mg) 
were introduced in MilliQ water (1.5 mL) at 37 °C. Initially, 1.5 ml of MilliQ water was 
added to immerse the fiber meshes, and a sample volume of 200 µl was taken at t = 0.5, 
1.0, 2.0, 4.0 and 24 h. Thereafter, the release medium was refilled to 1.5 ml and a sample 
volume of 500 µl was taken at different time intervals up to 35 days, with replenishment 
of the release medium to 1.5 ml each time a sample was taken out. Release experiments 
were performed in triplicate under a dynamic situation (100rpm). The BSA concentration 
in the samples was determined by high performance liquid chromatography (HPLC) using 
a HPLC column (Hypersil Gold, Thermo Scientific, USA) connected to a L2130 HPLC pump 
and a L-2400 UV detector set at 280 nm (Hitachi Corp., Tokyo, Japan). A 40/60 mixture of 
acetonitrile/water containing 0.1% (w/v) formic acid was used as the mobile phase with 
a flow rate of 0.4 ml min-1. The results are presented as cumulative release as a function 
of time according to the following equation:   
                                         Cumulative release (%) =    
where Mt is the amount of protein released at time t and M is the amount of protein 
loaded in the scaffold. BSA standards (1.8 - 180 µg/ml) were used for calibration. 
2.14. VEGF Bioactivity Assay 
An in vitro cell-based assay was used to investigate the biological activity of VEGF re-
leased from the scaffolds. A scaffold based on PCL/pHMGCL 1:2 (Group 4, Table 2) with 
VEGF loading was selected for this assay because of its attractive BSA release properties. 
Scaffolds with or without VEGF incorporation were punched into circular shape (15 mm 
in diameter) for cell culture substrates. They were freeze dried for 2 days, followed by 
ethylene oxide sterilization (Synergy Health, Ede, The Netherlands) before cell culture 
experiment. The total amount of VEGF in the single substrate of S-VEGF was calculated 
according to the weight ratio of VEGF in the entire scaffolds. The average total amount of 
VEGF in each S+VEGF substrate was (1.6±0.4) μg.  
HUVECs were expanded in endothelial medium (EM) at 37 °C in a humid atmosphere 
with 5% CO2 according to the guidelines provided by BD. The medium was changed twice  



M
M t100
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a week, and cells from passage 8 were used. Afterwards, cells were seeded at a density 
of 40×103 cells/cm2, and cultured in assay medium (AM) to exclude potential effects of 
factors supplemented in EM. Five groups were set up in cell culture experiment:  
1. (S): Naïve scaffolds in AM  
2. (S+VEGF): Scaffolds loaded  with VEGF in AM  
3. (S+TVEGF) Naïve scaffolds in AM supplemented with total amount of VEGF (1.6 
μg) 
4. (S+SVEGF) Naïve scaffolds in AM supplemented with 12.5 ng/ml VEGF (after 
each medium refreshment) 
5. (TCP+SVEGF): Tissue culture plates in AM supplemented with 12.5 ng/ml VEGF 
(after each medium refreshment) 
Prior to the cell seeding, all the scaffolds were placed in 24-well plates and incubated 
assay medium for 1 hour at 37 °C to increase cell attachment. The medium was refreshed 
at 1 day after cell seeding, and thereafter 2 times per week. For S+TVEGF group, no VEGF 
was further supplemented after refreshing medium at day 1. For S+SVEGF and TCP+SVEGF 
group, an amount of VEGF (12.5 ng/ml) was supplemented every time after medium re-
freshment. 
HUVECs growth, as measured by total cellular DNA content, was assessed by Quant-iTTM 
Picogreen® dsDNA assay kit (Molecular Probes, Eugene, USA) according to the instruc-
tions of the manufacturer. At selected time points (1, 4, and 7 days post-seeding), sam-
ples (n=3) were prepared by washing the cell layers twice with PBS and adding 1ml of 
MilliQ to each well, after which repetitive freezing (-80 °C) and thawing (room tempera-
ture) cycles were performed followed by 10 minutes of sonication. 
For the standard curve, serial dilutions of dsDNA stock were prepared (concentrations 
ranging from 0–2000 ng/ml). Next, 100 µL of either sample or dsDNA was added to the 
wells, followed by 100 µL of working solution. After 2-5 minutes of incubation in the 
dark, DNA was measured on a fluorescence cuvette reader (microplate fluorescence 
reader, Bio-Tek, Winooski, USA) with a 485 nm excitation filter and a 530 nm emission 
filter. Data were normalized to S+SVEGF group and expressed as fold of DNA content. 
The morphology of HUVECs cultured on the scaffolds was also examined. Two samples of 
each group at each time point were seeded with HUVECs at a density of 40×103 cells/cm2 
and incubated in AM for 4 and 7 days.  
After these culture periods, cell layers were rinsed twice with PBS, fixed with 2% glutaral-
dehyde in cacodylate buffer [Na(CH3)2AsO2.3H2O] for 5 min and dehydrated in a graded 
series of ethanol. Finally, cell layers were dried using tetramethylsilane (TMS), sputter 
coated with gold/platinum composite, and the cells were examined morphologically us-
ing a scanning electron microscope (JEOL, SEM 6340F).  
In addition, cytoskeletal structure of HUVEC was observed using confocal laser scan mi- 
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croscopy (CLSM, Olympus FV1000) for samples cultured for 4 days. Fixation of the cell-
scaffold samples was carried out for 20 minutes in freshly prepared 2% (v/v) paraformal-
dehyde. Then the samples were washed in PBS for three times, permeabilized in PBS 
containing a 10% (v/v) FBS plus 0.5% (v/v) Triton-X 100 (Sigma Aldrich, St. Louis, MO, 
USA) for 20 minutes, and incubated in PBS containing a 10% (v/v) FBS for 30 minutes. 
Thereafter, samples were stained with Alexa-fluor 568 conjugated phalloidin for filamen-
tous actin fluorescence (1:200) and DAPI staining for nuclei UV-visualization (1:2000) for 
1.5 hours. Antibodies were purchased from Invitrogen (Molecular probes®, Carlsbad, CA, 
USA). Subsequently, specimens were thoroughly washed with PBS, and rinsed with de-
ionised water for 2 minutes, then mounted in VECTASHIELD® Mounting Medium (Vector 
Laboratories, Inc., Burlingame, CA, USA) on glass slides. Finally specimens were examined 
using Olympus FV1000 confocal laser scanning microscope (Olympus, Tokyo, Japan) and 
multi- track images were captured with a 60×/1.35NA objective. 
2.15. Statistical Analysis 
Statistical analysis of the data was done using a one-way analysis of variance (ANOVA) 
with a post hoc Bonferroni multiple comparison test41 for cell growth at individual time 
points using GraphPad Instat software (version 3.05; San Diego, CA). A p-value<0.05 was 
considered statistically significant. 
 3. Results and Discussion  
3.1. Polymer Synthesis and Characterization 
PCL and pHMGCL were synthesized via ring opening polymerization (ROP) at 130 °C for 
16 hours using BnOH and SnOct2 as initiator and catalyst, respectively, as described be-
fore34, 35. The BMG/CL monomer molar ratio in the feed was 25/75 and the obtained 
pBMGCL was subsequently deprotected by removal of the benzyl groups to yield 
pHMGCL. 1H NMR analysis showed that the HMG/CL monomer molar ratio in the poly-
mer was very close to that of the feed (Table 2). DSC analysis showed that the melting 
temperature of PCL and pHMGCL was 54 and 37 °C, respectively. The crystallinity of 
pHMGCL was substantially lower than PCL as indicated by the heat of fusion (ΔH) which 
was 65 and 31 J/g for PCL and pHMGCL, respectively. GPC analysis showed that the mo-
lecular weights (Mn) of PCL and pHMGCL were 71.1 and 17.3 kDa, respectively. The poly-
dispersities were around 2 and in agreement with values generally obtained for polymers 
synthesized using ROP42. 
3.2. Scaffolds Preparation and Characterization 
BSA-loaded PCL scaffolds were prepared by coaxially electrospinning a PCL solution in 
TFE (20 w/v %) and a BSA solution in MilliQ water (0.2 w/v %), as shell and core solutions,  
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respectively (Group 1, Table 1). Scaffolds with a uniform fibrous structure and with a 
fiber diameter of 0.7 ± 0.1 µm were formed (Figure 1A). However, preparation of 
scaffolds of acceptable quality composed of only pHMGCL as shell forming polymer was 
not possible likely due to the low molecular weight of this polymer as compared to PCL 
(Mw of 35 versus 128 kDa) and hence low viscosity of the 20 w/v% polymer solution. The 
viscosity of pHMGCL solution was raised by increasing the concentration from 20 w/v % 
up to 40 w/v %. However, the resulting solution was sticky and not electrospinnable due 
to blockage of the nozzle. An attempt to increase the molecular weight of pHMGCL by 
increasing M/I ratio did not yield significantly longer polymer chains likely because of 
traces of impurities present in the synthesized monomer.34 
To increase the hydrophilicity of the scaffolds, pHMGCL was blended with PCL in differ-
ent weight ratios (Group 2 and 3 scaffolds, Table 1). SEM analysis of these scaffolds 
showed absence of beads and a uniform structure (Figure 1, B and C) composed of fibers 
with the same diameters as the fibers of the PCL scaffold. In our approach, using solu-
tions of pHMGCL and PCL resulted in good electrospinning conditions (e.g. stable Taylor 
cone and continuous jet ejecting during process). According to other reports24, 43 the for-
mation of uniform fibers is affected by the feed rate ratio between the core and the shell 
solutions. A flow rate ratio (core: shell) between 1:3 and 1:6 allows the formation of sta-
ble core/shell Taylor cones that subsequently after evaporation of the solvents yields 
uniform core/shell fibers. Therefore, an inner/outer solution flow rate of 1:3 was chosen. 
TEM analysis showed that the obtained coaxially electrospun scaffolds were composed 
of core-sheath structure (Figure 2), indicated by the difference in electron density be-
tween the inner core and outer shell of the fibers. The sharp boundaries between core 
and shell layers can be observed clearly in Figure 2 and is attributed to the immiscibility 
of core/ shell solutions. 
The successful loading of FITC-BSA inside the nanofibers was shown by means of fluores-
cence microscopy (FM) and Figure 2 demonstrates a uniform distribution of protein 
(indicated by green stain) in the fibers. The fibrous bead-free morphology observed in 
these images is also consistent with SEM images shown in Figure 3. 
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Figure 1. Left: Scanning electron microscopy images of fibrous scaffolds (A) PCL, (B) PCL/pHMGCL 1:1, 
and (C) PCL/pHMGCL 1:2 (scale bar is 5 µm). Right: Fiber size distribution of electrospun coaxial 
scaffolds obtained using ImageJ software and considering more than 100 counts per scaffold. 
Figure 2. TEM image of PCL coax-
ial fibers. Core and shell part 
were indicated by asterisk and 
arrows, respectively. (scale bar is 
500 nm). 
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Contact angle (CA) measurements on spun-coated films of the same composition as the 
electrospun scaffolds were performed to study the blend composition-dependent sur-
face hydrophilicity. Figure 4 shows that the advancing contact angle (Adv-CA) for a PCL 
film was 77.7 ± 4.5°. For the PCL/pHMGCL blends of 1:1 and 1:2 weight ratios, the Adv-
CA’s were 76.8 ± 3.4° and 75.8 ± 1.4° (Figure 4A), respectively. The receding CA’s (Rec-
CA) were measured in time and Figure 3 shows that they slightly decreased for PCL films 
from 74.7 ± 4.1° to 68.7 ± 6.5° within 20 minutes. Interestingly, for films prepared of PCL/
pHMGCL 1:1 blend, the Rec-CA decreased from 70.4 ± 2.1° to 55.1 ± 3.3° within 10 
minutes whereas for films of PCL/pHMGCL 1:2 blend, the Rec-CA decreased even more 
from 68.4 ± 1.9° to 47.7 ± 1.2° in 10 minutes. It was not possible to measure the Rec-CA 
further due to an almost full spreading of the water droplets on the surface (Figure 4B). 
The considerable decrease in Rec-CA in time can be attributed to the reorientation of the 
polar hydroxyl groups of pHMGCL on the surface of the polymeric film upon exposure to 
water. This is in agreement with our previous findings34 where we showed that receding 
contact angles on polymeric films of pHMGCL decrease substantially with increasing the 
percentage of hydrophilic units in this copolymer and also decrease in time. However, 
the full water-spreading as we observed for the blends was not observed on the film 
containing only pHMGCL with maximum 10 molar% of HMG units34.  
Figure 3. Fluorescent microscopy images of FITC-BSA loaded in coaxial fibrous scaffolds (A) PCL,  
(B) PCL/pHMGCL 1:1, and (C) PCL/pHMGCL 1:2. Scale bar is 20 µm. 
Figure 4. : (A) Advancing contact angle and (B) receding contact angle after 20 minutes water exposure 
on film of PCL/pHMGCL 1:2.  (to be continued) 
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The thermal properties of the scaffolds were analyzed using DSC. As shown in Table 3, a 
single melting peak was observed for scaffolds with PCL/pHMGCL blends as the shell 
(Table 1, Groups 2 and 3). The heat of fusion of these scaffolds (in the first heating run) 
decreased from 73 to 54 J/g with increasing pHMGCL content in the blend from 0 % 
pHMGCL in PCL scaffolds to 67 % in PCL/pHMGCL 1:2 scaffolds. However, ΔH values 
measured at the second heating run were slightly lower than those obtained in the first 
heating cycles most probably due to the thermal history of the samples. Further, ΔH val-
ues (second heating run) were in good agreement with the calculated ΔH values (Table 
3). The glass transition temperatures (Tg) of the scaffolds were -58.6 °C, -55.2 °C, and -
47.4 °C for PCL, PCL/pHMGCL 1:1, and PCL/pHMGCL 1:2, respectively. Table 3 shows that 
the experimental Tg’s are in good agreement with those calculated by the Fox equation
44: 
 
 
in which W1 and W2 are the weight fractions and Tg,1 and Tg,2 are the glass transition tem-
peratures of the components in a blend. Based on these results, it can be concluded that 
electrospun scaffolds of pHMGCL and PCL consist of a miscible blend of the two poly-
mers. 
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3.3. BSA Loading Efficiency and in-vitro Release 
BSA was chosen as a model protein for VEGF in this study due to similarities in their mo-
lecular weight (Mw, BSA= 67 kDa, Mw,VEGF=45 kDa)
45-47 and hydrodynamic radius (Rh,BSA=3.5 
nm48, Rh,VEGF= 3 nm
49). The measured protein loading was 93.1±1.2%, 93.3±0.5%, and 
93.1±1.5 % for PCL, PCL/pHMGCL 1:1, and PCL/pHMGCL 1:2, respectively. The BSA re-
lease profiles of the different scaffolds are shown in Figure 5.  
This figure shows that three stages can be distinguished in the release profiles; up to 4 
hours an initial release (‘burst’ phase) followed by a gradual sustained release up to 10 
days (phase 1) and a slow release up to 35 days (phase 2) (Table 4). The protein release 
from PCL scaffolds was predominantly controlled by a diffusion mechanism correspond-
ing to our previous studies50, whereas the protein release from PCL/pHMGCL 1:1, and  
Figure 5. BSA release profiles of coaxial electrospun scaffolds (Group 1, 2 and 3) loaded with 0.2% BSA (n=3). 
Results are shown as mean ± SD. The cumulative release is reported based on the amount of protein loaded 
in each scaffold. The insert shows the burst release of BSA up to 4 hours.  
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PCL/pHMGCL 1:2 scaffolds were controlled by both diffusion and degradation mecha-
nisms. The burst release was 21.0±1.2%, 34.9±1.3%, and 27.2±0.8% for PCL, PCL/
pHMGCL 1:1, and PCL/pHMGCL 1:2 scaffolds, respectively. This burst release of protein is 
most likely due to either the presence of some non-uniformities (such as cracks, open 
ends, etc.) in the fibers structure and/or partial mixing of core and shell solutions during 
electrospinning, which might lead to presence of protein on the surface of fibers instead 
of in the core. In current study, the largest burst release was observed for the PCL/
pHMGCL 1:1 group, which might be related to the exposure of protein on the fiber sur-
face as a result of the electrospinning processing for this polymer combination. After this 
burst release, the protein was released in a sustained manner reaching 40.2±1.8%, 
61.7±2.1%, and 70.1±6.8% for PCL, PCL/pHMGCL 1:1, and PCL/pHMGCL 1:2 scaffolds 
after 10 days. After this phase, a very small amount of BSA was released in the next 
phase for all scaffolds up to 35 days and reached 46.8±2.1, 70.1±2.3, and 77.5±5.1 for 
PCL, PCL/pHMGCL 1:1, and PCL/pHMGCL 1:2 scaffolds, respectively.  
 
It has been reported that several parameters among which shell thickness, surface area, 
defects, permeability, and solubility of the drug in the polymer shell control the rate of 
drug release from coaxial fibrous scaffolds51. For the coaxial fibers of the present study, it 
is most likely that the protein release is due to diffusion across nanopores in the poly-
meric shell, degradation of polymeric shell, and/ or a combination of these factors52. 
Degradation does not likely play a role in the mechanism of BSA release from PCL 
scaffolds because this polymer undergoes a very slow hydrolytic degradation, which 
takes more than 2 years32, 53, 54. However, in our previous degradation study of pHMGCL 
with 10% HMG content32, we showed that this polymer degrades much faster than PCL 
and undergoes more than 10% weight loss within 35 days while the Mn drops from 30 
kDa to less than 8 kDa. Based on these results it can be assumed that the pHMGCL used 
in the present study (containing > 20 molar % of hydrophilic HMG units) degrades even 
faster, as we also observed for related copolymers of HMG with lactide (pLHMGA)55. In-
deed, measuring the dry weight of post-release scaffolds and comparing that with the 
initial weight of scaffolds, showed that PCL, PCL/pHMGCL (1:1), and PCL/pHMGCL (1:2)  
  Burst Release (0-4 hrs) Phase 1 (4hrs- 10 days) Phase 2 (10- 35 days) 
Group 1 21.0 ± 1.2 19.2 ± 1.8 2.1 ± 2.1 
Group 2 34.9 ± 1.3 26.8 ± 2.1 8.4 ± 2.3 
Group 3 27.2 ± 0.8 42.9 ± 6.8 7.4 ± 5.1 
Table 4. Percentage of BSA released from coaxial scaffolds as burst (0-4 hrs), phase 1 (4 hrs-
10 days), and phase 2 (10-35 days). Data are presented as means ± standard deviations  
(n=3 samples from the same scaffold). 
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scaffolds lost 0.3±0.4, 17.5±4.5, and 26.0±4.0 percent of their initial weight in 35 days. 
Since the weight of incorporated protein (BSA) is negligible compared to the weight of 
scaffolds, this mass loss cannot be related to the protein release and is therefore indica-
tive of polymer degradation. SEM images of post-release scaffolds confirmed that PCL 
fibers were intact after 35 days (Figure 6, A and B), while fibers of scaffolds containing 
pHMGCL in the shell showed signs of degradation as observed by fibers fragmentation 
(Figure 6, C-F). Investigating the thermal properties of scaffolds after 35 days of protein 
release showed that crystallinity of scaffolds composed of pHMGCL/PCL (as reflected by 
ΔH) was notably increased while the crystallinity of PCL scaffolds was unchanged (Table 
3). This increase in ΔH can be attributed to the preferential hydrolytic degradation of 
amorphous regions in the pHMGCL structure, resulting in crystallization of CL segments 
of the pHMGCL/PCL blend that were initially present in amorphous regions of the  
material.  
 
Figure 6. SEM images of BSA-loaded nanofibrous scaffolds after 35 days incubation in MilliQ-water at 37 °C.  
Scale bar is 30 µm (left) and 10 µm (right). White arrows show degraded fibers. 
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Increasing the weight fraction of hydrophilic pHMGCL in the fibers shell from 0% in PCL 
scaffold to 50 and 67% in PCL/pHMGCL scaffolds (1:1 and 1:2, respectively) resulted in a 
significant increase in amount of released protein after 10 days (PCL vs. 1:1 and 1:2 
blend: p<0.05 and p<0.001, respectively) and after 35 days (PCL vs. 1:1 and 1:2 blend: 
p<0.05 and p<0.01, respectively). In addition, increasing the pHMGCL weight fraction in 
the blend from 50% in 1:1 scaffold to 67% in 1:2 scaffold, resulted in a significantly in-
creased release of protein after 10 days (p<0.05), however, the cumulative release after 
35 days was not significantly different (p>0.05). 
Overall, it can be concluded that the protein release from PCL scaffolds is likely governed 
by diffusion via nanopores in the fibers shell, which have a size (slightly) bigger than the 
hydrodynamic diameter of BSA (less than 5 nm)48, while the protein release from 
pHMGCL/PCL scaffolds is likely controlled by a combination of diffusion and shell degra-
dation. 
3.4. VEGF Bioactivity 
As the biological half-life of VEGF is very short (30 min)56, administration of this growth 
factor intravenously requires high doses and/ or multiple injections56, 57. However, ad-
ministration of large amounts of VEGF should be avoided as it results in catastrophic 
pathological vessel formation at non-targeted sites56. Therefore, it is important to devel-
op a polymeric matrix which is capable of slow releasing this protein at the defect site for 
TE application (e.g. bone regeneration). Previous research revealed different approaches 
to prepare fibrous scaffolds with VEGF release, including physical adsorption58, blending 
protein with polymer solution for scaffolds preparation59, as well as coaxial electrospin-
ning with VEGF encoding plasmid in the core part60. Amongst different approaches, we 
are particularly interested in coaxial electrospinning because this approach has great 
potential in preserving proteins during the electrospinning process due to different feed-
ing capillary channels into one nozzle to generate composite nanofibers with a core–shell 
structure50. In addition, it provides homogeneous protein distribution throughout the 
fibers, and proteins can be delivered in a controlled manner due to the shell barrier61. In 
this study, we prepared VEGF loaded nanofibrous scaffolds from PCL/pHMGCL 1:2 solu-
tion using BSA in the core as protein stabilizer62. This type of scaffold was chosen based 
on the in vitro release results which showed faster and higher overall release of the pro-
tein (Figure 5). Although the data are obtained from BSA as a model protein, one can 
assume that the loading efficiency and release profile of VEGF are comparable to the 
ones of BSA due to their similarity in size46. 
The bioactivity of released VEGF was analyzed by observing the growth of HUVECs cul-
tured on the scaffolds loaded with VEGF (S+VEGF) in the assay medium, which contains 
no essential growth component for HUVEC growth. The scaffold without VEGF (S) was 
used as control. Furthermore, as a previous study indicated that HUVEC could proliferate  
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in the AM with sustained supplementation of VEGF (12.5 ng/ml)63, we set up the group 
S+SVEGF as reference for HUVECs growth on the scaffolds. In addition, S+TVEGF was set up 
to distinguish the burst release effect on the cell growth. The DNA content of each group 
at different time intervals was related to the control group S+SVEGF, and the relative DNA 
content of HUVECs on post-seeding day 1, 4 and 7 is presented in Figure 7. This figure 
shows that all groups displayed similar DNA content at day 1, indicating similar cell 
attachment and growth after cell seeding. After 4 days, HUVECs cultured on S showed 
significantly lower DNA content compared to S+SVEGF (p<0.05), whereas no statistical 
difference was observed among other three groups. After 7 days, the relative DNA con-
tent from S+VEGF group was 4 fold higher than S group, which was significantly different 
(p<0.05). Since the DNA content is positively correlated with the number of viable cells, it 
can be concluded that the VEGF-releasing scaffolds supported more viable HUVECs 
growth and proliferation compared to bare scaffolds up to 7 days, which most likely is 
attributed to the bioactive VEGF released from coaxial scaffolds. In addition, no statistical 
differences were observed from HUVECs cultured on VEGF releasing scaffolds (S+VEGF) 
and VEGF supplemented medium, suggesting that the released VEGF had similar bioac-
tivity compared to those having VEGF freshly added in the medium. Similar results were 
recently reported by Jia et al.64, in which VEGF was loaded with dextran as the core com-
ponent of poly(lactide-co-glycolide) (PLGA) coaxial electrospun scaffolds and it was  
Figure 7. Relative DNA content of human umbilical vein endothelial cells (HUVECs) on scaffolds (n=3) 
on day 1, 4 and 7 post-seeding. Five groups in the experiment are: (S): Naïve scaffolds in AM; 
(S+VEGF): Scaffolds loading with VEGF in AM; (S+TVEGF): Naïve scaffolds in AM supplemented with 
total amount of VEGF (1.6 μg); (S+SVEGF): Naïve scaffolds in AM supplemented with 12.5 ng/ml VEGF; 
(TCP+SVEGF): Tissue culture plates in AM supplemented with 12.5 ng/ml VEGF. Relative DNA amount 
as compared to (S+SVEGF) and expressed as fold of DNA content (Mean ± SD).  
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shown that the released VEGF preserved its bioactivity and supported HUVECs growth up 
to 5 days.  
Furthermore, the cell proliferation was also confirmed by SEM. As demonstrated in Fig-
ure 8a, spreading of HUVECs was observed on VEGF-releasing scaffolds (S+VEGF) on day 
4, whereas the cells grown on the naïve scaffolds (S) were clustered. Moreover, on day 7, 
obviously more cell confluence was observed on VEGF-releasing scaffolds (S+VEGF) than 
the other groups, which confirmed 
the trend of aforementioned DNA 
content results presented in  
Figure 7. It is also worthwhile to 
mention that on day 4, the HUVECs 
in S+VEGF group showed a good 
attachment on scaffolds, as evi-
denced by confocal microscopic im-
ages (Figure 8b). Moreover, it 
showed similar confluence as 
S+TVEGF. However, on day 7, S+VEGF 
group showed apparently more con-
fluence than other groups, albeit 
that the cells were patchy on the 
scaffolds, which is probably due to 
the large surface volume of electro-
spun scaffolds as well as the limited 
number of the cells. These results 
suggest that the cell growth was sup-
ported by the sustained release of 
bioactive VEGF from coaxial scaffolds 
up to day 7.  
Taken together, the current study 
demonstrates that the released pro-
angiogenic factor VEGF remained 
biologically active up to 7 days, sug-
gesting coaxial electrospinning is fa-
vorable for growth factor release 
with well maintenance of bioactivity. 
Although in vitro data suggested 
promising potential of using growth 
factor loaded core/shell fibers for TE 
Figure 8. Morphology of human umbilical vein endothelial 
cells (HUVECs) cultured on scaffolds. (a) SEM pictures of HU-
VECs cultured on different groups after 4 and 7 days. Scale 
bar is 10 µm. (b) Representative confocal images of HUVECs 
cultured on scaffolds loading with VEGF in AM (S+VEGF) after 
4 days.(i) DAPI staining for nuclei UV-visualization (Blue); (ii) 
Alexa-fluor 568 conjugated phalloidin for actin (Red); (iii) the 
merger of DAPI and actin staining. Autofluorescence caused 
by polymeric fibrous scaffolds was observed at different track. 
(Scale bar is 20 µm) 
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ments are necessary to fully understand the relationship between the dosage and re-
lease profile of loaded growth factor and corresponding biological responses. 
4. Conclusions 
The current study describes the preparation and characterization of VEGF-loaded nano-
fibrous electrospun scaffolds based on blends of a hydroxyl-functionalized polyester 
(pHMGCL) and PCL by means of coaxial electrospinning. DSC analysis showed that these 
two polymers are miscible at a molecular level. It was shown by contact angle measure-
ments that scaffolds containing pHMGCL exhibited significantly higher surface hydro-
philicity compared to those based on PCL only. BSA as a model protein was loaded into 
these fibers and it was shown that the in vitro release of this protein is likely governed by 
combination of diffusion and degradation. Scaffolds composed of pHMGCL showed an 
enhanced protein release as compared to PCL scaffolds, likely due to enhanced hydroly-
sis rate of pHMGCL/PCL blend while PCL scaffolds did not degrade in the time frame in-
vestigated. It has shown previously that the increased hydrophilicity of pHMGCL scaffolds 
results in a considerable increase in adhesion of human mesenchymal stem cells seeded 
onto these scaffolds comparing to their counterpart PCL scaffolds. In the present study, it 
was demonstrated that loaded VEGF in pHMGCL containing scaffolds preserved its bioac-
tivity to support HUVECs growth up to 7 days. Therefore, these bioactive electrospun 
scaffolds based on blends of pHMGCL and PCL are capable of releasing VEGF in a sus-
tained manner and can be considered as attractive candidates for TE applications. 
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1. Introduction 
In view of the biomedical application of biomaterials, nanofibrous scaffolds composed of 
biodegradable polymers gain increasing popularity, due to their morphological similari-
ties to the native extracellular matrix1. Among the multiple techniques used for nano-
fiber fabrication, e.g. phase separation and self-assembly, electrospinning is the most 
popular and cost-effective method to produce ultrathin polymeric fibers, which can be 
easily employed in the laboratory and scaled up to industrial levels2. Regarding polymers 
used for electrospinning, poly(lactide-co-glycolide) (PLGA) is one of the most preferred 
ones and already approved by Food and Drug Administration (FDA) as a constituent of 
many biomaterial-based devices owing to its adjustable biodegradability and biocompati-
bility. 
Although PLGA-based nanofibrous scaffolds are expected to have a promising application 
future in wound healing3, cardiac tissue regeneration4, as well as guided bone regenera-
tion (GBR) membranes5, emerging concern exists regarding biocompatibility issues relat-
ed to PLGA degradation products after implantation. It has been shown that during PLGA 
degradation, the accumulation of acidic degradation products (i.e. lactic and glycolic ac-
id) decreases the pH in the surrounding tissue, which can trigger inflammatory and for-
eign body reactions in vivo6, 7. Upon clinical application, these reactions resulted in obvi-
ous symptoms, such as suddenly emerging pain, swollen tissues, and even persistent 
fistula8. Furthermore, recent research indicated that the high surface-to-volume ratio of 
nanofibrous scaffolds can even alter the tissue reaction to implanted PLGA-based materi-
als toward an inferior level level9, 10. Consequently, it is necessary to comprehensively 
investigate the biocompatibility characteristics related to PLGA-based nanofibrous 
scaffolds for biomedical application.  
Biocompatibility is defined as “the ability of a biomaterial to perform its desired function 
with respect to a medical therapy, without eliciting any undesirable local or systemic 
effects in the recipient or beneficiary of that therapy, but generating the most appropri-
ate beneficial cellular or tissue response in that specific situation, and optimizing the 
clinically relevant performance of that therapy”11. In general, the host tissue reacts to an 
implant by initiating an inflammatory response that consists of blood clot formation and 
the recruitment of macrophages, neutrophils, and lymphocytes to the site of implanta-
tion via several steps12, 13. First, macrophages recognize proteins adsorbed to the bio-
material surface and may adhere to the surface via specific cell surface receptors inter-
acting with those adsorbed proteins; then, the secretion of active cytokines and growth 
factors, especially by macrophages, further orchestrates the cellular response to the bio-
material; in case of a persistent inflammatory response, activated macrophages may fuse 
to form foreign body giant cells (FBGCs) at the tissue/biomaterial interface13. In view of 
these steps, it is clear that (i) the cellular reaction to the materials, and (ii) cytokine lev- 
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els/balance are two important factors that determine the outcome of biocompatibility9. 
In other words, macrophages and foreign body giant cells (FBGCs) are considered as key 
determinants for the biocompatibility of implanted materials at a cellular level, while 
cytokines are involved at a molecular level by orchestrating cell recruitment and  
behavior9. 
In view of the biological aspects of the host tissue response, it is accepted that a compre-
hensive understanding of biocompatibility issues related to implanted materials should 
be based on a sound evaluation of both cellular reactions and cytokine expression after 
implantation. However, a quite obvious limitation exists in current research regarding to 
biocompatibility issues of PLGA-based nanofibrous scaffolds based on our literature sur-
vey. In previous attempts to improve the biocompatibility of PLGA, titania nanoparti-
cles14, tripolyphosphate (TPP) nanoparticles15, and demineralized bone particles (DBPs)6 
were incorporated into PLGA scaffolds, all of which have shown in vitro effects by neu-
tralizing the acidic degradation products of PLGA scaffolds to some extent. However, few 
studies presented direct evidence indicating that this neutralization indeed improved the 
host tissue response in vivo. Among these few cases, Yoon et al.6 reported that DBP/
PLGA composite scaffolds evoked significantly less inflammation and fibrous capsule for-
mation compared to pure PLGA scaffolds upon subcutaneous implantation in rats.  
Unfortunately, the authors only evaluated the biological response for a period of up to 5 
days after implantation, which is too short to observe effects of PLGA degradation on 
biocompatibility issues. Furthermore, a very small number of studies focused on in vivo 
cytokine expression in response to implanted materials. Previous work of Brodbeck et al. 
revealed that in vivo gene expression of interleukin-1β (IL-1β), tumor necrosis factor-α 
(TNF-α), transforming growth factor-β (TGF-β), and interleukin-10 (IL-10) played an 
important role in directing the process between wound-healing and inflammation16. 
Nevertheless, to our knowledge, almost no information is available so far about the 
expression profile of cytokines in protein level related to the biocompatibility of 
biodegradable polymers. 
In view of this, the current study aimed to evaluate i) the biocompatibility of PLGA elec-
trospun nanofibrous scaffolds in both virgin and pre-degraded state, and ii) the effect of 
incorporated nano-apatitic particles (nAp) on degradation and biocompatibility of such 
scaffolds. To that end, PLGA was blended with poly(ε-caprolactone) (PCL) to prepare 
electrospun scaffolds to warrant the integrity of the electrospun scaffolds, as pure PLGA 
electrospun scaffolds are known to shrink substantially at 37°C 17, 18. Nano-apatitic parti-
cles (nAp) were chosen as a neutralizing additive due to their alkaline properties and 
similarities to the mineral component in bone. Our hypothesis was that nAp incorpora-
tion in PLGA improved the tissue response by neutralizing the acidic degradation  
products. 
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2. Materials and methods 
2.1. Materials 
PLGA 5050 (Purasorb® PDLG 5010) was purchased from Purac Biomaterials BV 
(Gorinchem, the Netherlands). Granular PCL (Mn 80 kDa) and docusate sodium salt (AOT) 
(purity≥99.0%) were purchased from Sigma–Aldrich (St. Louis, USA). Nano apatitic pow-
der (Budenheim, Tri-Cafos P/C53-80; A80308A, MV 500 (T-C-P)) was kindly provided by 
Prof. Dr. Marc Bohner (RMS Foundation, Bettlach, Switzerland). Organic solvents 2,2,2-
trifluoroethanol (TFE) (purity ≥ 99.8%) and 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) 
(purity ≥ 99.0%) were obtained from Acros (Geel, Belgium) and Sigma−Aldrich, respec-
tively. 
2.2. Scaffold preparation 
Four groups of electrospun scaffolds were prepared (see Table 1) and named as nX based 
on the theoretical weight percentage of nAp in the prepared scaffolds. For the electro-
spinning solution for bare scaffolds (n0), polymers (PLGA/PCL=3/1(w/w)) were dissolved 
at a concentration of 16% w/v in 90% TFE in deionized H2O mixed with HFIP (v/v=1/1). 
For the electrospinning solutions containing nAp, a previously described method with 
modifications was used19. In brief, the amount of nAp was defined according to the 
weight ratio of nAp and polymers, and nAp powder was suspended in the solvent by ul-
trasonic and vigorous stirring before adding the polymers. AOT salt (0.05% w/v) was used 
as a surfactant and dissolved in the solvent to obtain stable particle suspension in the 
polymer solution as previously described19. 
 
  SCAFFOLDS 
  n0 n10 n20b n30b 
PLGA (g) 1.2 1.2 1.5 1.5 
PCL (g) 0.4 0.4 0.5 0.5 
nAp (g) -- 0.18 0.5 0.86 
AOT (mg) -- 5.0 5.0 5.0 
Solvent HFIP/90%TFE 
(1:1) 
HFIP/90%TFE 
(1:1) 
HFIP/90%TFE 
(1:1) 
HFIP/90%TFE 
(1:1) 
Total volume (ml) 10 10 10 10 
Theoretical nAp % -- 10.0 20 30.0 
Actual nAp % a -- 10.9 22.1 31.2 
nAp loading efficiency 
(Actual%/Theoretical%) 
-- 1.09 1.10 1.04 
Table 1. The composition of 10 ml electrospinning solution and obtained 
nAp loading efficiency for different groups 
a Actual nAp (%) was obtained from TGA results. 
b In order to achieve similar fiber diameter in four groups, n20 & n30 were prepared with PLGA/
PCL=3/1(w/w) at a concentration of 20% w/v.  
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2.3. Scaffold characterization 
The morphology of the fabricated scaffolds was observed by a high-resolution field emis-
sion scanning electron microscope (FESEM; JEOL, SM3010, Tokyo, Japan), operated at an 
acceleration voltage of 3.0 kV. The fiber diameters were measured from the SEM micro-
graphs obtained at random locations (n = 100) using Image J software (National Institutes 
of Health, Bethesda, USA) based on SEM micrographs. 
Transmission electron microscopy (TEM, JEOL 1010, Tokyo, Japan) was used to visualize 
nanoapatite incorporation. The TEM samples were prepared by directly depositing the  
electrospun fibers onto the Formvar-coated copper grids. 
Fourier transform infrared spectrometry (FTIR; Spectrum One, Perkin−Elmer, USA) was 
used to analyze the chemical structure of the scaffolds with nAp incorporation over a 
range of 520−4000 cm-1 at a resolution of 4 cm-1. X-ray diffraction (XRD) was used to ob-
serve the crystallographic structure of the scaffolds (PW3710, Philips, The Netherlands) 
with Cu Kα radiation (45 kV, 40 mA). The scanning range was from 20 to 40° with a step 
size of 0.02°. The nAp powder used for scaffold preparation was also examined by FTIR 
and XRD to provide reference.  
To verify the actual content of nAp in the composite membrane, thermogravimetric anal-
ysis (TGA) was carried out from room temperature to 600 °C using a TGA instrument Q50 
(New Castle, DE, USA) at a heating rate of 10 °C/min in air. 
2.4. In vitro degradation 
Prior to initiation of the degradation experiment, the scaffolds containing 15 mg PLGA 
each were treated with argon plasma cleaner (PDC-001, Harrick Scientific Corp., USA) for 
4 min with the radio frequency power set at 30W under vacuum condition to improve 
hydrophilicity. After that, they were incubated in 2 ml phosphate buffer saline (PBS; pH 
7.4) at 37°C under shaking condition (60 rpm). The PBS solution was not changed 
throughout the 56-day in vitro degradation experiment. The pH of the solution with or 
without scaffolds was measured at selective time intervals using a pH meter (n=3).  
At the end of the degradation experiment, the molecular weight (Mw) of degraded 
polymers from one out of three samples in each group was determined by means of gel 
permeation chromatography (GPC) using a 2695 Waters Aliance system and a Waters 
2414 refractive index detector. Two PL-gel 5 µm mixed-D columns fitted with a guard 
column (Polymer Labs, Mw range of 0.2−400 kDa) were used. The columns were calibrat-
ed with polystyrene standards of known molecular weights using Analytical Grade (AR) 
tetrahydrofuran (THF). The flow rate was 1 ml/min at 30°C. The concentration of samples 
was approximately 5 mg/ml and the injection volume was 50 µl. As the scaffolds in the 
current study were prepared by the blends of PLGA and PCL, the original molecular 
weight for each polymer was also examined by GPC as reference. 
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2.5. Design of the in vivo evaluation 
Fifteen healthy 8-week-old male Wistar rats (~250 g) were used as experimental animals. 
The protocol was approved by the Animal Ethical Committee of the Radboud University 
Nijmegen Medical Center (Approval no: RU-DEC 2011-038) and national guidelines for 
the care and use of laboratory animals were applied. 
Based on the in vitro degradation data, n0 and n30 were enrolled for a 4-week in vivo 
evaluation. In order to evaluate the effect during the entire PLGA degradation period (~7 
weeks), pre-degraded n0 and n30 (i.e. incubated in sterile PBS (pH 7.4) for 3 weeks with-
out changing medium) were included in the animal experiment. Prior to initiation of the 
animal experiment, all scaffolds (1.5×1.5 cm2) were sterilized by γ-irradiation (Isotron, 
Ede, Nederlands) and then used for both direct implantation (D-system) and cage 
implantation (C-system) to obtain histological and exudates samples, respectively. The 
cages were prepared as described previously16 and sterilized by autoclaving. Empty cages 
were implanted as controls. Table 2 shows an overview of the experimental groups for in 
vivo evaluation. 
 
2.6. Animal surgery 
The animals were anesthetized with isoflurane, and their backs were shaved and steri-
lized with alcohol and iodine scrub. Four paravertebral incisions (2 cm each) per rat were 
made approximately 1 cm lateral to the vertebral column to expose the dorsal subcutis. 
Subcutaneous pockets were created by blunt dissection. The anterior pockets were used 
for implantation of scaffolds following C-system, whereas the posterior pockets were 
used for corresponding scaffolds following D-system (Figure 1). After insertion of an im-
plant, the skin was closed using skin staples (Agraves®, InstruVet C.V., Cuijk, the Nether-
lands). A total of 48 scaffolds (n=6 for each experimental group/implantation system) 
plus 6 empty cages were distributed over 15 rats according to a randomization scheme. 
Sample code Cage implantation 
(C-system) 
(anterior pockets) 
Direct implantation  
(D-system) 
(posterior pockets) 
n0 n=6 n=6 
n30 n=6 n=6 
p-n0 (3-week pre-degraded n0) n=6 n=6 
p-n30 (3-week predegraded n30) n=6 n=6 
Negative control Empty cage − 
Table 2. Experimental groups of scaffolds and numbers of samples (n) for in vivo evaluation 
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2.7. Sample retrieval and histological processing 
At week 1 and 4 post-surgery, exudate samples were collected from the cage implant 
systems using 25 gauge needles. The collected exudates were further centrifuged at 
1000 rpm at 4°C to isolate supernatants, which were kept at -80°C till further analysis. 
Immediately after exudate collection at week 4 post-surgery, the animals were eu-
thanized using CO2 suffocation, and the tissue–covered specimens were retrieved. The 
samples from C-system implantation were lysed in 1 ml TRIzol® reagent (Invitrogen, USA) 
after PBS rinsing. The samples from D-system implantation were fixed in 10% formalin, 
dehydrated in a graded series of ethanol and embedded in paraffin, after which 6 μm 
sections were cut in a transversal direction using a standard microtome (RM 2165; Leica, 
Germany). The sections were cut from at least three arbitrary regions perpendicular to 
the long axis of the tissue capsule. Paraffin sections were stained with hematoxylin/eosin 
(HE).  
Figure 1. Implantation scheme for in vivo evaluation (a), and (b)scaffolds in cage and direct implantation 
system. (a) Four subcutaneous pockets were made per rat, as shown as sites 1-4. The anterior pockets 
(sites 1&2) were used for samples in cage system (C-system). The posterior pockets (sites 3&4) were 
used for corresponding samples in direct implantation system (D-system). Scaffolds from the different 
groups were indicated as different colors in the scheme, and different groups were randomized in 15 
rats. If an empty cage was implanted in anterior pocket, no scaffold was implanted in the corresponding 
posterior pocket. (b) Scaffolds were cut into small squares (1.5×1.5 cm2) for both direct and cage implan-
tation system. The cages were prepared by surgical-grade stainless steel wire mesh cages (1.5 cm in 
length, 0.8 cm in diameter, 0.25-mm wire diameter and 0.8-mm opening width with 58% open area), as 
previously described 16 
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2.8. Immunohistochemistry  
For the identification of macrophages and FBGCs in the paraffin sections, CD68 immuno-
histochemical staining and tartrate-resistant acid phosphatase (TRAP) staining were per-
formed. For CD68 staining, the sections were treated with 10% H2O2 in methanol to inac-
tivate endogenous peroxidase, and post-fixed with 10% formaldehyde in PBS. After three 
times washing with 0.075% glycine in PBS, the sections were heated in citrate buffer (pH 
6.0) for 10 min at 70 °C. After rinsing with PBS, the sections were pre-incubated with 10% 
normal donkey serum (NDS, Chemicon, USA) followed by the overnight incubation of 
mouse anti-rat CD68, (1:200; Serotec, DPC, the Netherlands) at 4 °C. Subsequently, the 
sections were rinsed with PBS, incubated with biotinylated secondary antibody donkey-
anti-mouse IgG (1:500; Jackson Labs, USA) for 1 h, rinsed with PBS, and treated with 3,3-
diaminobenzidine (DAB). For TRAP staining, the sections were pre-incubated 0.2M Tris-
MgCl2 buffer (pH 9.0) for 2 h at 37 °C. After rinsing with distilled water, the sections were 
incubated in acidic phosphate medium (pH 5.0) consisting of hexazotized pararosaniline 
(4 ml), Naphthol AS-BI Phosphate (25 mg), N,N-Dimethylformamide (2.5 ml), veronal 
buffer (12.5 ml) and MgCl2 (0.5g) for 1 h at 37 °C. After staining, the sections were coun-
terstained with hematoxyline for 10 s, rinsed in water, dehydrated and mounted with 
DPX (BDH Laboratory Supplies, England). 
2.9. Histological evaluation 
All sections were photographed with the Zeiss Imager Z1 together with the AxioCam 
MRc5 camera using the AxioVision 4.6.3 software (Carl Zeiss Microimaging GmbH, Ger-
many). Histological evaluation on all sections was performed by two independent exam-
iners (W.J and J.J.B) based on the obtained images. For the analyses of HE stained sec-
tions, a refined histomorphometric grading scale was used (Table 3)20. The performed 
quantitative evaluation of the fibrous capsule in each section was based on four different 
areas (image size: 678×510 μm2) of entire fibrous capsules surrounding the scaffolds as 
previously described21. 
2.10. Measurement of cytokines in exudates 
The exudates extracted from cages were assayed for cytokines with a bioplex bead array 
(Bio-Rad: Hemel Hempstead, UK) using rat inflammation cytokine 10-plex magnetic bead 
assay kit (Millplex®,Cat# RCYTOMAG-80K-10, Millipore, USA) according to the manufac-
turer’s instructions. Ten different cytokines were detected, including the chemokine 
growth-regulated oncogene-KC (GRO-KC, CXCL1), monocyte chemotactic protein-1 (MCP
-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endotheli-
al growth factor (VEGF), as well as cytokines TNF-α, IL-1β, IL-4, IL-6, IL-10 and IL-13. Cyto-
kine concentrations (pg/ml) were determined from fluorescence intensities (FI)  
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Table 3. Histological grading scale for tissue response 
compared to a linear standard curve generated from standards of known concentration 
provided by the manufacturer. 
2.11. Real-time polymerase chain reaction (PCR) 
The total RNA of the infiltrated cells was isolated from the scaffolds in C-system using 
TRIzol® reagent according to manufacturer’s instructions. In brief, samples were mixed 
vigorously to lyse the cells followed by centrifugation at 10,000 g for 10 min at 4 °C. The 
supernatants were transferred to a new tube and 200µL chloroform was added, mixed, 
incubated for 3 min and centrifuged at 10,000 g for 15 min. The resulting aqueous layer 
was collected, mixed with 500µl isopropanol and RNA was pelleted by centrifugation at 
10,000 g for 15 min. The pellet was washed with 70% ethanol and RNA was finally dis-
solved in 27µl deionized water. The total RNA concentration was measured using a 
Nanodrop (Nanodrop Technologies, USA). The reverse transcriptase (RT) reaction was 
performed to obtain cDNA by using SuperscriptTM III First-strand Synthesis System 
(Invitrogen, USA) according to manufacturer’s protocol as previously described22. 
Gene expression was evaluated for interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-
α), transforming growth factor-β (TGF-β), and interleukin-10 (IL-10). The expression lev-
els were analyzed versus the housekeeping gene beta-actin (β-Act) as previously de-
scribed23. The forward and reverse primer sequences for each gene are listed in Table 4. 
Relative mRNA expression was quantified using the comparative Ct (∆Ct) method and 
 Score 
Histological grading scale for capsule quality  
Capsule tissue is fibrous, not dense, resembling connective or fat tissue in the non-injured 
regions 4 
Capsule tissue is fibrous but immature, showing fibroblasts and little collagen 3 
Capsule tissue is granulous and dense, containing both fibroblasts and many inflammatory cells 2 
Capsule tissue consists of masses of inflammatory cells with little or no signs of connective 
tissue organization 1 
Cannot be evaluated because of infection or other factors not necessarily related to the materi-
al 0 
Histological grading scale for capsule thickness  
1-4 fibroblasts  4 
5-9 fibroblasts 3 
10-30 fibroblasts 2 
>30 fibroblasts 1 
Not applicable 0 
Histological grading for cell infiltration  
Only fibroblasts contact the surface    4 
Scattered macrophages and leucocytes are present 3 
One layer of macrophages and leucocytes are present 2 
Multiple layers of macrophages and leucocytes present 1 
Cannot be evaluated 0 
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Table 4. Forward and reverse primer sequences 
 
 
 
 
 
 
 
 
 
 
2.12. Statistical analysis 
Data were expressed as mean ± standard deviation. For fiber diameter and pH measure-
ments, statistical analysis was performed with a one-way ANOVA and post-hoc Tukey 
Multiple Comparisons test. For histological evaluation, a non-parametric ANOVA 
(Kruskal−Wallis) with post Dunn’s multiple comparison test was applied. The statistic 
analysis was performed using Graphpad Instat software (Instat® 3.05, Graphpad Software 
Inc., USA). For cytokine concentrations measured in exudates, a paired t-test was per-
formed to detect the difference of each cytokine concentration related to time intervals. 
To compare the difference in cytokine concentrations between groups at the same time 
interval, a non-parametric ANOVA (Kruskal−Wallis) with post-hoc multiple comparison 
test was applied using SPSS 18.0 (SPSS, Chicago, Illinois) and statistical package R (http://
www.R-project.org)24. 
3. Results 
3.1. Scaffold characterization 
The nanofibrous scaffolds with different amounts of nAp were prepared by electrospin-
ning, and their morphologies were examined using SEM and TEM. SEM images (Figure 
2a) showed a uniform fiber structure for electrospun fibers of each composition with 
similar average fiber diameters ranging from 731 to 780 nm (p>0.05). TEM (Figure 2b) 
demonstrated that most nAp particles were embedded within the fibers and only some 
were exposed at the fiber surface. 
The FTIR spectra of the different scaffolds are shown in Figure 2c. Typical bands attribut-
ed to PO4
3- can be observed from the spectrum of reference nAp powder. The bands at 
1089 and 1027 cm-1 can be assigned to the triple degenerated γ3 anti-symmetric 
stretching of P–O band, and the bands at 601, and 563 cm-1 can be attributed to the tri-
ple degenerated γ4 vibration of O–P–O bond25. The bands at 628 cm-1 can be assigned to 
the libration mode of OH- group26. Identical bands for O–P–O bonds and OH- group can 
only be observed from the scaffolds with nAp incorporation (n10, n20, and n30). 
 
Primers Forward (5’→3’) Reverse (5’→3’) 
IL-1β CTGTGACTCGTGGGATGATG GGGATTTTGTCGTTGCTTGT 
TNF-α ACTCCCAGAAAAGCAAGCAA CGAGCAGGAATGAGAAGAGG 
TGF-β ATACGCCTGAGTGGCTGTCT TGGGACTGATCCCATTGATT 
IL-10 AATAACTGCACCCACTTCCC CAACCCAAGTAACCCTTAAAGTC 
β-Act TTCAACACCCCAGCCATGT TGTGGTACGACCAGAGGCATAC 
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The corresponding XRD patterns of different scaffolds are depicted in Figure 2d. As a ref- 
erence, the pattern of nAp powder indicated the Bragg peaks at 25.9°, 31.8°, 32.9° and 
34.1° 2ѳ, which respectively correspond to the characteristic reflections of 002, 211, 300 
and 202 of an apatitic structure19. The characteristic peaks of nAp at 25.9° and 34.1° 
were observed in the XRD patterns of scaffolds with nAp incorporation, while both other 
characteristic peaks were masked by peaks contributed by the polymer, as can be deter-
mined from the XRD pattern of the bare polymer scaffolds.  
The actual content of nAp incorporated in the scaffolds was evaluated by TGA, and the 
nAp loading efficiency was between 1.04 and 1.10 (Table 1). 
3.2. In vitro degradation of scaffolds  
The in vitro degradation of polymeric scaffolds incubated in PBS at 37°C under dynamic 
(60 rpm) conditions was monitored by the pH change of PBS during a 56-day degradation 
period and GPC measurements for the scaffolds after that period. 
As shown in Figure 3a, a fast pH decrease from pH 7.4 to around pH 5 (day 0-day 4) was 
observed for all types of scaffolds upon immersion in PBS, followed by a phase with rela-
tively stable pH until week 3. Thereafter, pH-levels slowly continued decreasing until the 
end of the degradation study (week 8). For n0, the final pH-value of the solution de-
creased to 2.58±0.03. Compared to n0, the composite scaffolds showed an nAp amount-
dependent effect on final pH-levels: final pH values for n10, n20, and n30 were signifi-
cantly higher than n0 (p<0.05; 3.59±0.01, 4.03±0.01, and 4.28±0.05, respectively), and 
they were significantly different from each other (p<0.01). 
GPC was performed to examine the molecular weight (Mw) of polymers in the scaffolds 
after an 8-week degradation study. GPC results showed that the Mw of PLGA in the bare 
scaffolds (n0) could not be detected, and the Mw of PCL decreased from 105.6 to 26.9 kD. 
Compared to the n0, scaffolds with nAp incorporation showed an nAp amount-
dependent higher post-degradation Mw of PLGA and PCL (Figure 3b). 
Figure 3. In vitro degradation behavior of scaffolds. 
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3.3. Descriptive histology of host tissue response 
The host tissue response to bare and composite scaffolds in virgin (n0 & n30) and pre-
degraded state (p-n0 & p-n30) was evaluated after a 4-week subcutaneous implantation 
period. Representative sections (HE-staining) of different scaffolds implanted in the D-
system are presented 
in Figure 4.  
Histological observa-
tion showed that fi-
brous encapsulation 
occurred for all types 
of scaffolds, and en-
dogenous cells which 
mainly include fibro-
blasts and leucocytes 
infiltrated at the inter-
face between the 
scaffold and the fibrous 
capsule.  
The presence of multi-
nuclear cells was  
observed in the sec-
tions of n0 (Figure 4), 
whereas these were 
not observed in the 
histological sections of 
the other types of 
scaffolds.  
Histological grading 
results (Figure 5) based 
on the HE-stained sec-
tions showed that in-
corporation of nAp 
significantly (p<0.001) 
decreased cell infiltration 
between the fibrous cap-
sule walls and the 
scaffolds remnants for 
both virgin and pre- 
 
Figure 4. HE staining of different groups of scaffolds after 4-week subcutane-
ous implantation. The left column showed HE stained sections from 4-week 
subcutaneously implanted scaffolds. The fibrous capsule wall was indicated 
by black arrow (à), and the scaffold remnant was indicated as “S”. Magnified 
images in the blue squared area were displayed in the right column, where 
multiple multinuclear cells (indicated by white arrows) can be observed 
between the fibrous capsule layers and scaffold interface in HE stained sec-
tion of n0.  
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degraded scaffolds. In contrast, similar capsule quality and thickness were observed for 
all types of scaffolds, which mainly consisted of multiple layers (5−9 layers) of fibroblasts 
with little collagen structure. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 shows CD68- and TRAP-staining, performed to confirm macrophage infiltration 
and FBGCs formation. An apparently increased CD68(+) staining was observed for n0 
(Figure 6a) and p-n0 (Figure 6c), whereas the scaffolds with nAp incorporation in both 
virgin (n30; Figure 6b) and pre-degraded (p-n30; Figure 6d) status showed less CD68(+) 
cell infiltration. Furthermore, n0 showed evidently most TRAP(+) cells in the vicinity of 
the scaffold (Figure 6e), while only limited TRAP(+) cells were observed for p-n0 and n30 
(Figure 6f&g). Hardly any TRAP(+) cells were observed for p-n30 (Figure 6h). 
3.4. Expression of inflammatory cytokines 
At protein level, cytokine expression was examined from the exudates samples extracted 
from the implants in the C-system after 1 week and 4 weeks of implantation. From the 
ten different cytokines that were analyzed, concentrations of GM-CSF, IL-4, IL-6, IL-10 
and IL-13 were below the detection limit (8 pg/ml). Irrespective of marginal significant 
differences as indicated in Figure 7, the cytokine expression of GRO-KC, MCP-1 and VEGF 
was relatively high for all groups after 1 week and a significant decrease (p<0.05) after 4 
weeks. In contrast, the expression of TNF-α and IL-1β was relatively low for all groups 
after 1 week and increased after 4 weeks. 
Figure 5. Histological grading of different groups of scaffolds after 4-week subcutaneous implantation. 
Histological grading analysis indicated that the incorporation of nAp significantly (p<0.001) reduce 
macrophages infiltration between the fibrous capsule walls and the interface of degrading scaffolds in 
both virgin and pre-degraded status.  
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At gene level, the relative gene expression of IL-1β, TNF-α, TGF-β, and IL-10 from the 
infiltrated cells that attached to the materials in the C-system after 4 weeks of implanta-
tion were analyzed using qPCR. As the empty cage does not contain the material, there-
fore, no gene values were obtained from this group. As shown in Figure 8, IL-1β and IL-10 
expression was similar for all groups. However, compared to n0, gene expression of TNF-
α was significantly decreased in p-n0 (p<0.05), and gene expression of TGF-β was signifi-
cantly increased in n30 (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
4. Discussion  
The aim of this study was to evaluate the effect of nAp incorporation into PLGA-based 
nanofibrous scaffolds on degradation and biocompatibility characteristics. Our hypothe-
sis was that nAp incorporation into the nanofibrous scaffolds would neutralize acidic 
degradation products, and hence could slow down scaffold degradation and improve the 
tissue response. For this purpose, four groups of PLGA/PCL blended (w/w=3/1) polymeric 
electrospun scaffolds were prepared with 0−30 wt% nAp incorporation (n0−n30). The 
generated scaffolds were characterized, and enrolled in an in vitro degradation study. 
Subsequently, n0 and n30, in a virgin and pre-degraded state, were subcutaneously im-
planted for 4 weeks using both direct and cage implantation to evaluate the in vivo tissue 
response. Our main findings showed that the incorporation of nAp evokes an nAp 
amount-dependent buffering effect during degradation. Further, nAp incorporation de-
creased polymer degradation, as shown by a higher post-degradation polymer Mw. Re-
garding biocompatibility, the current study indicated that nAp incorporation significantly 
improved the tissue response during 4-week of subcutaneous implantation, as evidenced  
Figure 8. Relative gene expression of IL-1β, TNF-α, TGF-β, and IL-10 from the cells infiltrated in the 
scaffolds after 4 weeks of implantation. Data was expressed as 2-∆∆Ct and 95% confidence interval relative 
to the n0 group (n=6). Values were normalized with β-Act. 
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by less infiltration of inflammatory cells as well as less FBGCs formation surrounding the 
scaffolds. However, only marginal differences in cytokine expression were observed be-
tween all groups. 
The current study confirmed the buffering effect of nAp on pH decline during the degra-
dation of PLGA-based scaffolds. In principle, the pH decline during in vitro degradation 
can be attributed to the release of acidic PLGA degradation products (i.e. lactic acid and 
glycolic acid), as PCL degradation results in non-acidic free caprolactone and its cyclic 
dimer and trimer27. In this study, a fast pH decrease occurred within the first few days for 
all groups, followed by a phase with relatively stable pH till week 3, and thereafter anoth-
er obvious pH drop. This result corroborates earlier findings about the degradation be-
havior of electrospun PLGA nanofibers28. Furthermore, the pH change during PLGA deg-
radation is positively related to the amount of acidic degradation products released dur-
ing different stages of PLGA degradation 28. Our results also revealed that the embedded 
nAp particles reduced polymer degradation in an nAp amount-dependent manner, which 
resulted in higher polymer Mw after 56-day in vitro. Similar findings were previously re-
ported when a strong alkaline salt (i.e. sodium tripolyphosphate) was used instead of 
nAp15. However, it is more interesting to notice from the current study that the acidic 
degradation products derived from PLGA-based scaffolds can also be neutralized by nAp 
particles, which represent weak alkaline components that are well known for their simi-
larity to the inorganic phase in bone matrix, and capability to support osteoblast-like cell 
proliferation and differentiation19. 
It has been confirmed in this study that the nAp incorporation improves the host tissue 
response to PLGA-based nanofibrous scaffolds in both virgin and pre-degrade state, by 
showing significantly less infiltration of macrophages as well as apparent less FBGCs for-
mation after 4 weeks of subcutaneous implantation. We attributed this observation to 
the lower amount of soluble degradation products and their distribution throughout the 
implant vicinity. Such findings are consistent with previous research, which indicated 
that the determining factor for the foreign body reaction of degradable implantable ma-
terials is the physical presence of particulate degradation products or the transient 
chemical characteristics of the degrading milieu with the capacity to stimulate inflamma-
tory cells, especially macrophages and giant cells11. In contrast to previous research, 
which evaluated in vivo responses of PLGA up to 5 days after subcutaneous implanta-
tion6, the current study involved 3-week pre-degraded scaffolds (p-n0 and p-n30) in sub-
cutaneous implantation (4 weeks) to cover the entire degradation period of PLGA-based 
nanofibers, which is up to 7 weeks (leading to 20% of mass loss) as previously reported28. 
Those pre-degraded scaffolds (p-n0 and p-n30) showed similar histological response, 
compared to their corresponding virgin state scaffolds (n0 and n30, respectively), indi-
cating that the inflammatory reaction caused by the degradation products existed during 
the entire material degradation period. 
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The current study further analyzed the effect of nAp incorporation on in vivo cytokine 
expression profiles in order to explore the molecular mechanism related to the histologi-
cal results. Despite differences in the histological observations, similar cytokine expres-
sion (gene and protein level) was observed for all four experimental groups, albeit that 
marginal differences were observed at gene level for TNF-α and TGF-β, and for GRO-KC 
at protein level after 1 week of implantation. The probable reason for this observation is 
that the ‘normal’ foreign body reaction resulting from the empty cage already induces a 
basal level of inflammation, which concealed partial effect of the samples in the cages to 
the surrounding tissues in terms of cytokine expression29. Nevertheless, the histological 
observations from direct implantation system, which avoid masking effects of responses 
to the cages, demonstrate the resultant effect of nAp incorporation on improved tissue 
responses. 
In this study, we have shown that by incorporating nAp into the PLGA-based scaffolds, 
polymer degradation can be slowed down, and that the inflammatory reaction initiated 
by the acidic degradation products could also be effectively reduced in vivo. PLGA has 
long been widely used to develop different types of medical devices (e.g. scaffolds, drug 
carriers, wound healing materials, etc.). To avoid future adverse inflammatory reactions 
upon biomedical application of PLGA-based devices, of the incorporation of a weak alka-
line salt such as nAp, instead of previously reported strong alkaline salt15, appears suffi-
ciently effective to diminish potential in vivo adverse tissue reaction to PLGA and its deg-
radation products. Furthermore, different from alternative bulk hydroxyapatite, which 
shows slow in vivo degradation30, the nAp particles undergo a relative fast dissolution 
because of the nanoscale particle size and increased interfacial surface area31. The disso-
lution of nAp does not generate any toxic chemicals apart from Ca2+ and PO4
3-, which are 
naturally found in hard tissues as well as in blood31. In consequence, the usage of nAp 
particles presents one of the most viable options to improve the tissue response of PLGA
-based devices from the safety issue point of view.  
5. Conclusions 
The results of the current study show that the incorporation of nAp can slow down the 
degradation of PLGA-based materials in an nAp amount-dependent manner. In view of 
biocompatibility of PLGA-based materials, the current study showed that nAp incorpora-
tion significantly improves the tissue response during 4-week of subcutaneous implanta-
tion, by showing less infiltration of inflammatory cells as well as less FBGCs formation 
surrounding the scaffolds. However, no effects of nAp-incorporation on cytokine expres-
sion were observed. 
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Summary and address to the aims 
Bone tissue engineering presents a potential alternative strategy to repair large bony 
defects, particularly large bone gaps and composite defects in the craniomaxillofacial 
region. Conventional bone tissue engineering approaches involve pre-culture of oste-
oprogenitor cells on a scaffold, followed by implantation of the cell/scaffolds complex 
into defect site. In this cell-based approach, exogenously delivered osteoprogenitor cells, 
relying on growth factors secreted by donor tissue, contribute to the bone tissue regen-
eration process, whereas the scaffolds simply provide physical support for the cells to 
allow tissue ingrowth. Although so far cell-based approaches represent the ultimate chal-
lenge for tissue engineering approaches1, it is still far from feasible to translate this ap-
proach from laboratory to clinical application in the near future from a regulatory and 
ethical point of view. In consequence, there is an increasing demand to generate bioac-
tive scaffolds that can provide not only physical support for cells, but also a local release 
of biomolecules (e.g. growth factors, cytokines, etc) to stimulate endogenous tissue re-
generation without using exogenously delivered cells. 
Recently, electrospinning has emerged as a popular technique to prepare tissue engi-
neering scaffolds due to its relative simplicity regarding the generation of fibrous 
scaffolds with nano- or submicron-scale dimensions that morphologically resemble the 
natural extracellular matrix. In addition, electrospinning generates ultrathin fibers with a 
large specific surface area, which enables an effective incorporation and delivery of bio-
molecules. These characteristics render electrospinning with superiority in preparation 
of bioactive scaffolds over other scaffold preparation techniques. 
The aim of this thesis was to fabricate bioactive electrospun scaffolds with biomolecule 
incorporation to achieve optimal bone regeneration. Chapter 1 gives a general introduc-
tion on bone tissue engineering, electrospinning technique, as well as a description of 
the aims of this thesis. Each following chapter discusses a separated study. This summary 
addresses the aims as described in the first chapter in successive order. 
1. What is the current state of the art in local delivery of biomolecules for bone regener-
ation? 
Chapter 2 highlights recent advances in local delivery of biomolecules from synthetic 
biomaterials to repair bony defects in craniomaxillofacial (CMF) region in both normal 
and compromised healing conditions. 
There are two major types of biomolecules which are frequently used to the clinical 
treatment of CMF bone defects based on a molecular weight threshold (5kDa): (i) large 
biomolecules and (ii) small biomolecules. Large biomolecules include inflammatory cyto-
kines- and chemokines, morphogenetic and angiogenic factors. For instance, stromal cell 
derived factor-1 alpha (SDF-1α) is a powerful chemokine involved in cell recruitment in a  
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variety of tissues; bone morphogenetic proteins (BMP-2,4,7) play important roles in oste-
ogenic differentiations of skeletal cells; vascular endothelial growth factor (VEGF) 
isoforms are involved in the regulation of the interaction between angiogenesis and os-
teogenesis. On the other hand, small molecules, including antibiotics, AMPs, antitumor 
drug, siRNA and shRNA, as well as anti-osteoporotics, are rapidly emerging in recent 
years as an interesting adjunct for upgrading the clinical treatment of CMF bone regener-
ation under compromised healing conditions. 
Furthermore, Chapter 2 provides a perspective on the efficacy of biomolecule delivery in 
CMF bone regeneration by reviewing presently available reports of pre-clinical studies 
using various animal models, in which calvarial defects, mandibular and alveolar bony 
defects and sinus elevation are included. Most of the preclinical studies have so far been 
focused on the morphogenetic molecules and angiogenic molecules delivery, and quite 
limited research efforts involved delivery of small molecules. 
2. What are current available methods to functionalize electrospun scaffolds with bio-
molecules, and what are pros and cons for different methods? 
Within the past five years, electrospun scaffolds have gained an exponentially increasing 
popularity in tissue regeneration area because of their ultrathin fiber diameter and large 
surface-volume ratio, which is favorable for biomolecule delivery. Chapter 3 reviews cur-
rent techniques that can be used to prepare bioactive electrospun scaffolds, including 
physical adsorption, blend electrospinning, coaxial electrospinning, and covalent immo-
bilization. In addition, Chapter 3 analyses the existing challenges (i.e. protein instability, 
low gene transfection efficiency, and difficulties in accurate kinetics prediction) to 
achieve biomolecule release from electrospun scaffolds, which necessitate further re-
search to fully exploit the biomedical applications of these bioactive scaffolds. 
3. Can electrospun scaffolds be functionalized with SDF-1α by physical adsorption to 
achieve cell recruitment? 
As described earlier, physical adsorption is the easiest method to functionalize electro-
spun scaffolds with biomolecules. In Chapter 4, we prepared electrospun scaffolds using 
polymer blends of poly(ε-caprolactone) (PCL) and type B-gelatin. Furthermore, we func-
tionalized scaffolds with stromal cell derived factor-1α (SDF-1α) via physical adsorption in 
order to obtain cell recruitment capacity for guided bone regeneration (GBR) applica-
tions. The results of Chapter 4 showed that PCL/gelatin electrospun scaffolds with SDF-
1α adsorption provided a diffusion-controlled SDF-1α release profile. Furthermore, the 
scaffolds loaded with different amounts of SDF-1α (50−400 ng) significantly induced 
chemotactic migration of BMSCs in vitro without dose-dependent effects. Eight weeks 
after implantation in rat cranial defects, SDF-1α loaded scaffolds yielded a 6-fold increase 
in the amount of bone formation compared to the bare membranes, albeit that contribu- 
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tion of in vivo BMSCs recruitment to the bone regeneration could not be ascertained. In 
conclusion, the results of Chapter 4 indicate the potential for using SDF-1α loaded PCL/
gelatin electrospun scaffolds as a bioactive GBR membrane, which is beneficial for opti-
mizing clinical application of GBR strategies. 
4. What is the superior method to generate bioactive electrospun scaffolds with sus-
tained release of biomolecules, in respect of spinnability, release profiles, and bioactivity 
preservation? 
Although physical adsorption is the easiest method to load biomolecules, this approach 
provides a large burst release, which might be a disadvantage for those biomolecules 
demanding a long-term biological effect. In view of this, it was necessary to figure out an 
optimal method to fabricate electrospun scaffolds with sustained release of biomole-
cules. So far, blend electrospinning and coaxial electrospinning represent two main alter-
natives to fabricate electrospun scaffolds with a sustained release profile. The aim of 
Chapter 5 was to compare both techniques with respect to processing set-up, scaffold 
characteristics, release kinetics, and biological activity of the loaded protein. Bovine se-
rum albumin was used as a model protein to determine release profiles, while alkaline 
phosphatase was used to determine protein activity after the electrospinning process. 
Coaxial electrospinning resulted in uniform fiber morphology with a core–shell structure, 
and a homogeneous protein distribution throughout the core of the fibers. In contrast, 
blend electrospinning formed bead-like fibers with a heterogeneous protein distribution 
in the fibers. The coaxial scaffold exhibited more sustained release profiles than the com-
parative blend scaffold, and the additive poly (ethylene glycol) (PEG) in the coaxial 
scaffold accelerated protein release. Both electrospinning processes decreased the bio-
logical activity of the incorporated protein, but coaxial electrospinning with PEG as an 
additive showed up to 75% preservation of the initial biological activity. Consequently, 
Chapter 5 concluded that coaxial electrospinning was superior compared to blend elec-
trospinning for the preparation of nanofibrous scaffolds with a uniform fibrous structure, 
protein distribution and sustained protein release kinetics as well as high preservation of 
the protein activity. 
5. What is the application potential for coaxial electrospun nanofibrous scaffolds with 
growth factor release? 
In Chapter 6, we fabricated nanofibrous scaffolds based on blends of a hydroxyl function-
alized polyester poly(hydroxymethylglycolide-co-ε-caprolactone) (pHMGCL) and poly(ε-
caprolactone) (PCL), loaded with bovine serum albumin (BSA) as a protein stabilizer and 
vascular endothelial growth factor (VEGF) as a potent angiogenic factor by means of a 
coaxial electrospinning technique. The scaffolds were characterized by scanning electron 
microscopy (SEM), fluorescence microscopy (FM), and differential scanning calorimetry  
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(DSC). The scaffolds displayed a uniform fibrous structure with a fiber diameter around 
700 nm. The release of BSA from the core of the fibers was studied by high performance 
liquid chromatography (HPLC) and it was shown that the coaxial scaffolds composed of 
blends of pHMGCL and PCL exhibited faster release than the comparative PCL scaffolds. 
VEGF was incorporated in the core of the scaffolds and the effect of the released protein 
on the attachment and proliferation of endothelial cells was investigated. It was shown 
that the incorporated protein preserved its biological activity and resulted in initial high-
er numbers of adhered cells. Thus, Chapter 6 indicated that coaxially electrospun 
scaffolds based on blends of pHMGCL/PCL loaded with VEGF can be considered as a 
promising candidate for tissue engineering applications. 
6. What are biocompatibility and degradation characteristics of PLGA-based nanofibrous 
electrospun scaffolds? 
Regarding polymers used for electrospinning, poly(lactide-co-glycolide) (PLGA) is one of 
the most preferred ones and already approved by the Food and Drug Administration 
(FDA) as a constituent of many biomaterial-based devices owing to its adjustable biodeg-
radability and biocompatibility. However, increasing concerns exists regarding biocom-
patibility issues related to PLGA degradation products after implantation. The aim of 
Chapter 7 was to evaluate the effect of nano-apatitic particles (nAp) incorporation on the 
degradation characteristics and biocompatibility of PLGA-based nanofibrous scaffolds. 
Composite PLGA/PCL blended (w/w=3/1) polymeric electrospun scaffolds with 0−30 wt% 
of nAp incorporation (n0−30) were prepared. The obtained scaffolds were firstly evaluat-
ed by morphological, physical and chemical characterization, followed by an in vitro deg-
radation study. Further, n0 and n30 in both virgin and 3-week pre-degraded status were 
subcutaneously implanted in rats, either directly or in stainless steel mesh cages, to eval-
uate in vivo tissue response. The results showed that the incorporation of nAp yields a 
nAp amount-dependent buffering effect on pH-levels during degradation and delayed 
polymer degradation based on molecular weight analysis. Regarding biocompatibility, 
nAp incorporation significantly improved the tissue response during a 4-week subcutane-
ous implantation period, showing both less infiltration of inflammatory cells (monocyte/
macrophages) and less foreign body giant cells (FBGCs) formation surrounding the 
scaffolds. Similar cytokine expression (gene and protein level) was observed for all 
groups of implanted scaffolds, although marginal differences were found for TNF-α and 
TGF-β at gene level as well as GRO-KC at protein level after 1 week of implantation. In 
conclusion, the results of Chapter 7 indicated that hybridization of the weak alkaline salt 
nAp in PLGA-based electrospun scaffolds is effective to decrease the in vivo adverse tis-
sue response to PLGA materials, which is beneficial for optimizing final clinical applica-
tion of different PLGA-based biomedical devices. 
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Closing remarks and future perspectives 
Since the first patent on electrospinning process was filed in 19342, electrospinning has 
been fully developed and widely used in filtration and texture manufacturing industry. 
However, outside those types of industry, there was little interest in electrospinning or 
electrospun nanofiber until the mid-1990s3. In recent years, electrospinning has emerged 
as a cost-effective technique to generate porous scaffolds with a biomimetic characteris-
tic due to the fibers that have similarity in geometry to fibrous components in the extra-
cellular matrix (ECM). Currently, most of the research still stays within laboratory level 
and quite far away from large-scale application. The current naïve situation of translating 
bioactive electrospun scaffolds into clinical application might be mainly attributed by 
challenges arising from two aspects: (1) in vitro release kinetics detection, and (2) in vivo 
dosing prediction. 
In previous studies, the in vitro release kinetics was investigated based on different 
methods, including radioiodination, HPLC and enzyme-linked immunosorbent assay 
(ELISA). In this thesis, we explored two methods to detect in vitro biomolecules release 
profile based on different loading approach. In Chapter 4, we used 125I radioiodination 
method to detect the release of SDF-1α which was physically adsorbed on the electro-
spun scaffolds. In contrast, in Chapter 5&6, since the protein was incorporated inside the 
core-shell structure fibers and it is not applicable to involve radioiodinated protein dur-
ing electrospinning due to local safety regulatory issues, HPLC was applied to detect in 
vitro release kinetics of BSA, which was used as a model protein to generally predict re-
lease profile for other loaded growth factors4-8. In addition to radioiodination and HPLC, 
ELISA is another frequently used method to detect in vitro release of therapeutic pro-
teins, such as fibroblast growth factor (FGF)9 and bone morphogenetic protein-2 (BMP-2)
10. 
Among the different detection methods, radioiodination and ELISA are most frequently 
used to detect the release kinetics of therapeutic proteinaceous molecules. However, 
there is emerging concern about the reliability of ELISA to detect growth factor release. 
Piskounova et al reported that after 4 weeks of measurement, roughly 80% of BMP-2 
was released based on radioiodination11, whereas less than 12% of BMP-2 was measured 
from the same samples using ELISA method12. Such obvious deviation might be attribut-
ed to the weak points of ELISA-based methods. In principle, ELISA only recognizes the 
“sound protein” with specific epitope to which antibodies can bind, and such epitope is 
apparently fragile to physical and chemical environments of delivery system13. In addi-
tion, protein loss during sampling and dilution, as well as low affinity towards protein 
aggregates may also contribute to the under estimation of total release. In consequence, 
the accurate detection of growth factor release is a big challenge for current biomole-
cules delivery, and there is great necessity to optimize the current physical/chemical  
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detection methods to comprehensively understand the release behavior of loaded 
growth factors. 
As aforementioned, radioiodination is the most reliable method to detect the release 
profile of proteinaceous molecules, because it recognizes the radionuclides of iodine that 
are directly conjugated with target molecule, and the radioactivity is positively related to 
the total mass of the loaded biomolecules. However, some inherent practical concerns 
hinder the general use of this method. Firstly, since tyrosines are the sites of radioio-
dination14, it would be rather challenging to label the proteins and peptides containing 
few or no tyrosines as sites for iodination. Secondly, some molecules are inactivated 
when their tyrosines are iodinated. For instance, iodination of tyrosine residue A19 or 
B16 leads to the inactivation of insulin15. In view of this, there is a great necessity to im-
prove the design of labelling technique structure-reactivity relationships, and such im-
provement will be beneficial for the comprehensive understanding and wide application 
of radioiodination method.  
Another important issue for clinical application of biomolecules loaded electrospun 
scaffolds is to predict an optimal dosing for in vivo application, which is not only of scien-
tific interest, but a pre-requisite for an efficient improvement of the safety of the phar-
maceutical and therapeutic treatments. The prediction of in vivo optimal dosing is 
strongly dependent on quantification of (1) the in vivo release kinetics and (2) the biolog-
ical activity of loaded protein. Unfortunately, limited information is available so far re-
garding the in vivo release. Several previous studies investigated the in vivo growth fac-
tor release profile by using carrier free protein for radioiodination in order to achieve a 
specific radiolabeling16, 17. However, most of commercially available growth factors for 
clinical application are mixed with multiple kinds of additives to improve the stability and 
shelf-life, which yield an open question to determine whether these additives which po-
tentially affect the delivery system (e.g. osmotic pressure, pH, etc.) will alter the in vivo 
release profile. On the other hand, biomolecules, particularly the therapeutic proteins, 
have a complex conformational structure and are fragile to the surrounding physical/
chemical environment (e.g., pH, humidity, etc) during sample preparation, processing 
and storage processes. Therefore, the biological activity of proteinaceous biomolecules 
can be affected by any conformation changes and aggregations, which will influence the 
effective dosing when they are applied in vivo. Consequently, further in vivo studies are 
needed to investigate the influence of protein conformational changes and aggregation 
on the biological activity. 
In summary, bioactive electrospun scaffolds with biomolecules incorporation present a 
promising acellular approach for tissue regeneration. On one hand, the flexibility of ob-
tained electrospun scaffolds render them feasible for many applications which includes 
GBR membranes as addressed in this thesis, as well as potential scaffolds for interface  
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tissue regeneration such as periosteum, ligament, and joint tissue. On the other hand, 
the high surface-volume ratio owing to the ultrathin fiber diameter enables electrospun 
scaffolds as an effective carrier to load various kinds of biomolecules via different meth-
ods to synchronize tissue regeneration process. In order to translate such a promising 
approach from bench to bed, extensive research efforts are needed to achieve (1) a con-
trolled release kinetics and (2) optimal in vivo dosing.  
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Samenvatting en evaluatie van de doelstellingen 
Bot tissue engineering is een potentieel alternatieve strategie om grote botdefecten, met 
name grote bot lacunes en composiet gebreken, in de craniomaxillofacial regio te her-
stellen. De conventionele bot tissue engineering aanpak omvat in vitro kweek van oste-
oprogenitorcellen op een dragermateriaal, gevolgd door implantatie van een cel/scaffold 
construct in een defect. Deze cel-gebaseerde benadering met exogeen aangeleverde 
osteoprogenitorcellen gaat uit van effecten van groeifactoren, gesecreteerd door donor-
weefsel, welke bijdragen aan het botregeneratieproces, waarbij de dragermaterialen 
eenvoudige fysieke dragers zijn voor de cellen om weefselingroei mogelijk te maken. 
Hoewel tot nu toe cel-gebaseerde benaderingen de ultieme uitdaging voor tissue engi-
neering vertegenwoordigen1, is het nog verre van haalbaar, vooral vanuit een re-
gelgevend en ethisch oogpunt, om deze aanpak te vertalen van laboratorium naar 
klinische toepassing in de nabije toekomst. Bijgevolg is er een toenemende vraag naar 
biologisch actieve dragermaterialen, die niet alleen als fysieke drager voor cellen kunnen 
fungeren, maar ook een lokale afgifte van biomoleculen (bijvoorbeeld groeifactoren, 
cytokines, enz.) bewerkstelligen om endogene weefselregeneratie te stimuleren zonder 
exogeen aangeleverde cellen. 
Onlangs heeft electrospinning zich ontpopt als een populaire techniek om tissue engi-
neering scaffolds te maken vanwege de relatieve eenvoud met betrekking tot de gener-
atie van vezelige materialen met nano-of submicron-schaal dimensies, die morfologisch 
lijken op de natuurlijke extracellulaire matrix. Bovendien genereert electrospinning ul-
tradunne vezels met een groot specifiek oppervlak, dat een effectieve opname en afgifte 
van biomoleculen mogelijk maakt. Deze kenmerken zorgen ervoor dat electrospinning 
superioriteit heeft voor het maken van bioactieve scaffolds ten opzichte van andere 
scaffold preparatie-technieken. 
Het doel van dit proefschrift was om bioactieve elektrogesponnen scaffolds te fabriceren 
met biomolecuul incorporatie om een optimale botregeneratie te bereiken. Hoofdstuk 1 
geeft een algemene inleiding op bot tissue engineering, electrospinning, alsmede een 
beschrijving van de doelstellingen van dit proefschrift. Elke volgende hoofdstuk be-
spreekt een aparte studie, waarvan hieronder de doelstellingen en resultaten samen-
gevat zijn. 
1. Wat is de huidige stand van de techniek voor de lokale afgifte van biomoleculen voor 
botregeneratie? 
Hoofdstuk 2 belicht recente ontwikkelingen in de lokale afgifte van biomoleculen van 
synthetische biomaterialen om botdefecten in het craniomaxillofaciale (CMF) gebied in 
zowel normale en gecompromitteerde omstandigheden te herstellen. 
Er zijn twee belangrijke klassen van biomoleculen die vaak worden gebruikt voor de  
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klinische behandeling van CMF botdefecten, gebaseerd op molecuulgewicht 
(drempelwaarde 5 kDa): (i) grote biomoleculen en (ii) kleine biomoleculen. Grote biomol-
eculen omvatten inflammatoire cyto- en chemokines, morfogenetische en angiogene 
factoren. Zo is stromal-derived factor-1 alpha (SDF-1α) een krachtig chemokine be-
trokken bij cel rekrutering in verschillende weefsels, spelen botmorfogenetische eiwitten 
(BMP-2, 4, 7) een belangrijke rol in de osteogene differentiatie van skeletcellen en zijn 
vasculaire endotheliale groeifactor (VEGF) isovormen betrokken bij de regulering van de 
interactie tussen angiogenese en osteogenesis. Anderzijds worden kleine moleculen, 
zoals antibiotica, AMPs, antitumor drug, siRNA en shRNA, evenals anti-osteoporotics, de 
laatste jaren meer en meer gezien als een snel groeiend hulpmiddel voor het verbeteren 
van de klinische behandeling van CMF botregeneratie onder gecompromitteerde gene-
zingsomstandigheden. 
Bovendien geeft Hoofdstuk 2 een kijk op de werkzaamheid van afgegeven biomoleculen 
in CMF botregeneratie door de herziening van op dit moment beschikbare literatuur van 
pre-klinische studies met behulp van verschillende diermodellen, waarbij calvariale, 
mandibulaire en alveolaire botdefecten en sinushoogte werden inbegrepen. De meeste 
pre-klinisch onderzoeken tot nu toe waren gericht op de afgifte van morfogenetische 
moleculen en angiogene moleculen en een slechts beperkte hoeveelheid onderzoeksin-
spanningen richtte zich op afgifte van kleine moleculen. 
2. Wat zijn de huidige beschikbare methoden om elektrospun scaffolds te functionalis-
eren met biomoleculen, en wat zijn voor-en nadelen voor de verschillende methoden? 
In de afgelopen vijf jaar hebben electrospun scaffolds een exponentieel toenemende 
populariteit gekregen in het gebied van weefselregeneratie vanwege hun ultradunne 
vezeldiameter en grote oppervlakte/volume verhouding, hetgeen gunstig is voor bio-
molecuul afgifte. Hoofdstuk 3 bespreekt huidige technieken, die kunnen worden ge-
bruikt om bioactieve electrospun scaffolds te verkrijgen, waaronder fysische adsorptie, 
blend electrospinning, coaxiale electrospinning en covalente immobilisatie. Daarnaast 
worden in Hoofdstuk 3 de bestaande uitdagingen (d.w.z. eiwit instabiliteit, lage-gen 
transfectie-efficiëntie, en moeilijkheden in nauwkeurige kinetiek voorspelling) 
geanalyseerd om biomolecuul afgifte te bereiken van elektrospun scaffolds, waarvoor 
verder onderzoek noodzakelijk is om biomedische toepassingen van deze bioactieve stei-
gers volledig te kunnen benutten. 
3. Kunnen elektrospun scaffolds worden gefunctionaliseerd met SDF-1α door fysieke 
adsorptie en celrecrutering bewerkstelligen? 
Zoals eerder beschreven, is fysische adsorptie de meest eenvoudige manier om elektro-
spun scaffolds te functionaliseren met biomoleculen. In hoofdstuk 4 hebben we elektro-
spun scaffolds gemaakt met behulp van mengsels van polymeren van poly(ε-caprolacton)  
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(PCL) en type B-gelatine. Verder hebben we gefunctionaliseerde scaffolds gemaakt met 
SDF-1α via fysische adsorptie om celrecruterende capaciteit voor guided bone regenera-
tion (GBR) toepassingen te verkrijgen. De resultaten van hoofdstuk 4 tonen dat PCL/
gelatine elektrospun scaffolds met SDF-1α adsorptie een diffusie-gecontroleerd SDF-1α 
afgifteprofiel hebben. Bovendien werden verschillende hoeveelheden SDF-1α (50-400 
ng) gebruikt, welke allen aanzienlijke chemotactische migratie van BMSCs in vitro in-
duceerden zonder dosisafhankelijke effecten. Acht weken na implantatie in craniale de-
fecten in ratten, lieten SDF-1α loaded scaffolds een 6-voudige toename zien in de hoev-
eelheid botvorming ten opzichte van de kale scaffolds, zij het dat bijdrage van in vivo 
gerekruteerde BMSCs aan botregeneratie niet kon worden vastgesteld. Kortom, de re-
sultaten van Hoofdstuk 4 tonen duidelijk het potentieel van SDF-1α geladen PCL/gelatine 
electrospun scaffolds als bioactieve GBR membraan, hetgeen gunstig is voor het optimal-
iseren van klinische toepassingen van GBR strategieën. 
4. Wat is de beste methode om bioactieve electrospun scaffolds te genereren met gereg-
uleerde afgifte van biomoleculen t.a.v. spinbaarheid, afgifteprofielen en behoud van bio-
activiteit? 
Hoewel fysieke adsorptie de meest eenvoudige manier is om biomoleculen te laden, 
biedt deze aanpak een grote burst release, hetgeen een nadeel kan zijn voor deze bio-
moleculen, welke een lange-termijn biologisch effect dienen te realiseren. Daarom was 
het noodzakelijk om een optimale methode te zoeken voor het maken van electrospun 
scaffolds met gereguleerde afgifte van biomoleculen. Tot nu toe vertegenwoordigen mix 
electrospinning en coaxiale electrospinning twee belangrijke alternatieven voor het 
maken van elektrospun scaffolds met een vertraagd afgifte profiel. In Hoofdstuk 5 had 
als doel om beide technieken te vergelijken met betrekking tot verwerking, afgifteki-
netiek en biologische activiteit van het biomolecuul. Albumine werd gebruikt als een 
modeleiwit om afgifteprofielen te bepalen, terwijl alkalische fosfatase werd gebruikt om 
eiwit activiteit te bepalen na het elektrospinproces. Coaxiale electrospinning resulteerde 
in een uniforme vezelmorfologie met een kern-mantel structuur en een homogene ei-
witverdeling in de kern van de vezels. Anderzijds werden via mix electrospinning 
‘druppelvormige’ vezels gevormd met een heterogene eiwitverdeling in de vezels. De 
coaxiale scaffolds vertoonden een meer constant afgifteprofiel dan de mix scaffolds en 
het additief poly(ethyleenglycol) (PEG) in de coaxiale scaffolds versnelde de eiwit afgifte. 
Beide electrospinningprocessen verlaagden de biologische activiteit van het opgenomen 
eiwit, maar coaxiale electrospinning met PEG als additief resulteerde in 75% behoud van 
de oorspronkelijke biologische activiteit. Bijgevolg werd uit hoofdstuk 5 geconcludeerd 
dat coaxiale electrospinning superieur is aan mix electrospinning t.a.v. de bereiding van 
nanofiber scaffolds met een uniforme vezelstructuur, homogene eiwitverdeling, con-
stante eiwit afgiftekinetiek en hoog behoud van de eiwitactiviteit. 
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5. Wat zijn de toepassingsmogelijkheden voor coaxiale elektrospun nanofiber scaffolds 
met groeifactor release? 
In hoofdstuk 6 werden nanofibrous scaffolds vervaardigd gebaseerd op mengsels van 
een hydroxyl gefunctionaliseerde polyester poly(hydroxymethylglycolide-co-ε-
caprolacton) (pHMGCL) en poly(ε-caprolacton) (PCL), geladen met bovine serum albu-
mine (BSA) als proteïnestabilisator en vascular endothelial groeifactor (VEGF) als een 
krachtige angiogene factor door middel van coaxiale electrospinning. De scaffolds 
werden gekarakteriseerd middels scanning elektronenmicroscopie (SEM), fluorescenti-
emicroscopie (FM) en differentiële scanning calorimetrie (DSC). De scaffolds vertoonden 
een uniforme vezelstructuur met een vezeldiameter van ~700 nm. De afgifte van BSA uit 
de kern van de vezels werd bestudeerd via high-performance vloeistofchromatografie 
(HPLC) en er werd aangetoond dat de coaxiale scaffolds bestaande uit mengsels van PCL 
en pHMGCL snellere afgifte realiseerden dan vergelijkbare PCL scaffolds. VEGF was opge-
nomen in de kern van de scaffolds en het effect van het vrijgekomen eiwit op de 
hechting en proliferatie van endotheelcellen werd onderzocht. Er werd aangetoond dat 
het opgenomen eiwit zijn biologische activiteit behoudt en dat afgifte resulteert in 
grotere aantallen hechtende cellen en meer celgroei. Aldus gaf hoofdstuk 6 aan dat co-
axiale electrospun scaffolds gebaseerd op mengsels van pHMGCL/PCL en geladen met 
VEGF kunnen worden gezien als een veelbelovende kandidaat voor tissue engineering 
toepassingen. 
6. Wat zijn biocompatibiliteit en degradatie karakteristieken van PLGA-gebaseerde nano-
fiber elektrospun scaffolds? 
Binnen de polymeren die voor electrospinning gebruikt worden, is poly(lactide-co-
glycolide acid) (PLGA) een van de meest geprefereerde, te meer vanwege reeds door de 
Food and Drug Administration (FDA) goedgekeurde devices met PLGA als bestanddeel en 
door de variabele biologische afbreekbaarheid en biocompatibiliteit. Echter, een toene-
mende bezorgdheid bestaat omtrent biocompatibiliteit kwesties in verband met PLGA 
afbraakproducten na implantatie. Het doel van hoofdstuk 7 was om het effect van apa-
tiet nano-deeltjes (nAP) incorporatie te evalueren op de degradatie en biocompatibiliteit 
van PLGA-gebaseerde nanofiber scaffolds. Composiet PLGA/PCL (w/w = 3/1) electrospun 
scaffolds met 0-30 % nAP (n0-30) werden bereid. De verkregen scaffolds werden eerst 
beoordeeld via morfologische, fysische en chemische karakterisering, gevolgd door een 
in vitro degradatiestudie. Verder werden n0 en n30 in zowel nieuwe als 3-week pre-
aangetaste toestand subcutaan geimplanteerd in ratten, hetzij rechtstreeks, hetzij in 
roestvrijstalen gaas kooien, om de in vivo weefselreactie te evalueren. De resultaten 
toonden dat de opname van nAP een hoeveelheid-afhankelijk bufferend effect op zowel 
de pH-niveaus tijdens degradatie als een vertraagde polymeerafbraak gebaseerd op mo-
leculaire gewicht bewerkstelligde. Met betrekking tot de biocompatibiliteit, verbeterde  
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nAP incorporatie aanzienlijk de weefselreactie tijdens een 4-weekse subcutane im-
plantatie periode, met minder infiltratie van inflammatoire cellen (monocyten/
macrofagen) en minder vreemd lichaam reuzencellen (FBGC's) formatie rond de 
scaffolds. Een vergelijkbare cytokine expressie (gen en eiwitniveau) werd waargenomen 
voor alle groepen geïmplanteerde scaffolds, hoewel marginale verschillen werden ge-
vonden voor TNF-α en TGF-β op genniveau en GRO-KC op eiwitniveau na 1 week im-
plantatie. Concluderend werd gesteld dat de resultaten van hoofdstuk 7 aangegeven dat 
hybridisatie van het alkalische zout nAP in PLGA-gebaseerde electrospun scaffolds 
effectief is om de in vivo nadelige weefselreactie op PLGA materialen te verminderen, 
wat gunstig is voor het optimaliseren van klinische toepassingen voor verschillende PLGA
-gebaseerde biomedische devices. 
Slotopmerkingen en toekomstperspectief 
Sinds het eerste patent op het elektrospinproces werd ingediend in 19342, is electrospin-
ning volledig ontwikkeld en op grote schaal gebruikt in de filtratie en textuur industrie. 
Echter, afgezien van die soorten van industrie, was er weinig belangstelling voor electro-
spinning of elektrospun nanovezels tot het midden van de 90-er jaren3. In de afgelopen 
jaren is gebleken dat electrospinning een kosteneffectieve techniek is om poreuze 
scaffolds te genereren met biomimetische kenmerken veroorzaakt door de vezels die 
overeenstemmen qua geometrie met vezelige componenten in de extracellulaire matrix 
(ECM) van weefsel. Momenteel bevindt het onderzoek zich nog steeds grotendeels op 
laboratorium niveau en derhalve vrij ver van grootschalige toepassing. De huidige situ-
atie t.a.v. het vertalen van bioactieve elektrospun scaffolds naar klinische toepassingen 
kan vooral worden toegeschreven aan de uitdagingen die voortvloeien uit twee as-
pecten: (1) in vitro vrijgavekinetiek detectie, en (2) in vivo dosering voorspellingen. 
In voorgaande studies werd de in vitro afgiftekinetiek onderzocht op basis van verschil-
lende methoden, zoals radioiodinatie, HPLC en enzyme-linked immunosorbent assays 
(ELISA). In dit proefschrift onderzochten we twee methodes om in vitro een biomole-
culen afgifteprofiel te bestuderen op basis van een verschillende aanpak. In hoofdstuk 4 
hebben we gebruik gemaakt 125I radioiodinatie om de release van fysisch-geadsorbeerde 
SDF-1α aan de elektrospun scaffolds te bestuderen. Daarentegen werd in hoofdstukken 
5 en 6, omdat het eiwit is opgenomen in de kern-mantelstructuur van de vezels en deze 
opzet niet geschikt is voor radioactief gejodeerde eiwitten wegens lokale veiligheid re-
gelgevingskwesties, HPLC toegepast voor detectie van in vitro afgiftekinetiek van BSA, 
welk werd gebruikt als model eiwit4-8. Naast radioiodinatie en HPLC, is ELISA een veelge-
bruikte methode voor het bestuderen van in vitro afgifte van eiwitten, zoals fibroblast 
groeifactor (FGF)9 en bot morfogenetische proteïne-2 (BMP-2)10. 
Binnen de verschillende detectiemethoden worden radioiodinatie en ELISA het meest 
gebruikt om de afgiftekinetiek van therapeutische eiwitachtige moleculen te detecteren.  
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Er is echter bezorgdheid ontstaan over de betrouwbaarheid van ELISA voor de detectie 
van groeifactor afgifte. Piskounova et al. melden dat na 4 weken gemeten, ongeveer 80% 
van BMP-2 werd afgegeven op basis radioiodinatie11, terwijl minder dan 12% BMP-2 af-
gifte werd gemeten van dezelfde monsters met ELISA12. Zulke duidelijke afwijkingen kun-
nen worden toegeschreven aan de zwakke punten van ELISA-gebaseerde methoden. In 
principe herkent ELISA alleen het specifieke epitoop van een eiwit waaraan antilichamen 
kunnen binden en dergelijke epitopen zijn blijkbaar kwetsbaar in fysische en chemische 
omgevingen13. Bovendien kan eiwitverlies tijdens bemonstering en verdunning, evenals 
lage affiniteit voor proteïneaggregaten, ook bijdragen aan de onderschatting van de to-
tale release. Bijgevolg is de nauwkeurige detectie van groeifactor release een grote 
uitdaging voor de huidige biomoleculen release, en bestaat er een grote noodzaak om de 
huidige fysieke/chemische detectiemethoden te optimaliseren om volledig het release 
gedrag van geladen groeifactoren volledig te begrijpen. 
Zoals vermeld is radioiodinatie de meest betrouwbare methode om het afgifteprofiel van 
eiwitachtige moleculen te detecteren, omdat het gebaseerd is op detectie van radionu-
cliden die direct geconjugeerd zijn aan het doelmolecule en de radioactiviteit positief 
gerelateerd is aan de totale hoeveelheid van de geladen biomoleculen. Sommige inher-
ent-praktische overwegingen belemmeren het algemene gebruik van deze methode. 
Enerzijds zijn tyrosinen de sites van radioiodinatie14 en is het derhalve niet mogelijk om 
eiwitten en peptiden met weinig of geen tyrosines te conjugeren met een radiolabel. 
Daarnaast worden sommige moleculen geïnactiveerd wanneer hun tyrosines worden 
geconjugeerd. Een voorbeeld is de jodering van tyrosine residuen A19 of B16, hetgeen 
leidt tot de inactivering van insulin15. Hierdoor is er een grote noodzaak om het design 
van labeling techniek te relateren aan structuur-activiteit en daarmee een verbetering 
teweeg te brengen voor een diepgaand begrip en brede toepassing van radioiodinatie 
methodes. 
Een ander belangrijk punt voor klinische toepassing van biomolecuul-geladen electro-
spun scaffolds is te voorspellen wat de optimale dosering is voor in vivo toepassingen, 
hetgeen niet alleen van wetenschappelijk belang, maar ook voorwaarde is voor een 
efficiënte verbetering van de veiligheid van farmaceutische en therapeutische behande-
lingen. De voorspelling van in vivo optimale dosering is sterk afhankelijk van kwantificer-
ing van (1) de in vivo afgiftekinetiek en (2) de biologische activiteit van geladen eiwitten. 
Helaas is slechts beperkte informatie beschikbaar tot nu toe met betrekking tot de in 
vivo afgifte. Verschillende eerdere studies onderzochten in vivo groeifactor afgiftepro-
fielen met dragervrij proteïnes voor radioiodinatie om een specifieke radiolabeling te 
bereiken16,17. Echter, de meeste in de handel verkrijgbare groeifactoren voor klinische 
toepassing zijn gemengd met verschillende soorten additieven om de stabiliteit en houd-
baarheid te waarborgen, waarbij onduidelijkheid bestaat of deze additieven invloed heb-
ben op het afgiftesysteem (bijvoorbeeld osmotische druk, pH, enz.) en dus het in vivo  
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afgifteprofiel. Anderzijds hebben biomoleculen, in het bijzonder de therapeutische ei-
witten, een complexe structuur en conformationele kwetsbaarheid t.a.v. de omringende 
fysisch-chemische omgeving (bijv. pH, vochtigheid, enz.) tijdens de voorbehandeling, 
verwerking en opslag. Daarom kan de biologische activiteit van eiwitachtige biomole-
culen worden aangetast door conformatie-veranderingen en aggregaties, die de 
effectieve dosering beïnvloeden wanneer ze worden toegepast in vivo. Derhalve is het 
voor verder in vivo onderzoek nodig om de invloed van eiwit conformatie-veranderingen 
en -aggregatie op de biologische activiteit te onderzoeken. 
Kortom, bioactieve elektrospun scaffolds met biomolecuul incorporatie representeren 
een veelbelovende a-cellulaire aanpak voor weefselregeneratie. Aan de ene kant is de 
flexibiliteit van de verkregen elektrospun scaffolds interessant en aanwendbaar voor vele 
toepassingen die GBR membranen omvat, zoals beschreven in dit proefschrift, alsook 
voor toepassingen op het gebied van interface weefselregeneratie, zoals periost en liga-
ment weefsel. Anderzijds is het door de hoge oppervlakte-volumeverhouding vanwege 
de ultradunne vezeldiameter mogelijk electrospun scaffolds een effectieve drager te 
laten zijn om verschillende soorten biomoleculen te laden via verschillende methoden 
om het weefselregeneratie proces te sturen. Om zo'n veelbelovende benadering van 
laboratorium naar bed te vertalen is uitgebreid onderzoek nodig om (1) een gecon-
troleerde afgiftekinetiek en (2) een in vivo optimale dosering te bereiken. 
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骨组织工程技术成为临床修复大面积骨缺损，尤其是颅颌面复杂性骨缺损一种
新兴途径。论文第一章介绍了骨组织工程的概念和研究现状。传统的骨组织工程技
术包括以下几个步骤，从宿主体内分离具有成骨潜力的前体细胞，并将其接种到在
组织工程支架上进行预培养；将培养成熟的细胞/支架复合体移植进入缺损部位，
实现组织修复。在这一过程中，外援性的前体细胞在修复过程中起着主要作用，而
组织工程支架则主要对接种的细胞和缺损部位的修复提供物理支撑作用。近年来，
越来越多的临床和实验表明，理想的组织工程支架不应该仅仅起着物理支架作用，
同时还应该起到局部释放生物活性分子的作用，以刺激宿主内源性组织积极参与修
复过程。 
论文第二章概述了局部控释生物活性分子修复颅颌面骨缺损的相关研究进展。
根据分子量大小（5kDa），生物活性分子可以广义的分为生物大分子和生物小分
子。生物大分子主要包括炎症趋化因子，形态决定因子和成血管因子。它们在调控
成骨细胞趋化（例如SDF-1α），分化（例如BMP-2,4,7），以及骨组织血管形成
（例如VEGF）过程中发挥重要作用。生物小分子则包括生长因子小分子多肽，抗炎
因子，抗肿瘤因子以及抗组织疏松因子。它们在调控病理性骨修复过程中发挥重要
作用。 
目前，利用生物材料制备生物活性分子的控释系统在体内主要应用于以下三类
缺损，分别是：颅骨缺损，下颌骨及牙槽骨缺损，以及上颌窦提升。绝大多数体内
应用目前尚属于动物实验阶段。其真正的其临床应用，需要在载药载体的设计，保
存所加载因子的生物学功能的保存，以及体内的释放曲线调控等方面做更多更系统
的研究。 
制备组织工程支架的方法有很多，其中静电纺丝技术因为可以生成与天然的细
胞外基质物理结构高度相似的纳米/微米纤维，于近年来受到越来越多科研人员的
关注。同时，电纺丝纤维极其细小的纤维直径（纳米/微米级别）增大了整个支架
的表面积，使其成为了生物活性分子的有效载体。目前主要有四种方法可以制备复
合生物活性分子的电纺纤维支架：物理吸附，混合电纺，同轴电纺，以及化学改
性。论文第三章分析比较了这四种方法在复合生物活性分子领域中的应用以及各自
的优缺点和面临的挑战。此外，论文的四至七章分别应用了物理吸附，混合电纺，
以及同轴电纺制备出复合了不同生物活性分子的电纺纤维支架，并分别评价了支架
的理化性能，药物释放曲线和体内外生物学表现。 
应当指出的是，尽管静电纺丝技术创始于1934年，并且已经充分发展并应用于
工业，但是在生物活性分子释放领域中的应用还依旧停留于实验室评价阶段。造成
这一现象的主要原因可能来源于以下两方面的研究瓶颈： 体外释放曲线的检测，
以及体内剂量的预测。前者主要面临的挑战来自于现有试验技术手段的局限性。以
往的研究结果现实，为了检测生活活性分子的体外释放曲线，最常用的技术手段包
括酶联免疫技术和放射性同位素标记技术。然而近年来越来越多的研究结果质疑利
用酶联免疫技术来检测蛋白释放曲线的可靠性，因为蛋白的抗原抗体结合位点有可
能在支架制备过程中，或者蛋白释放过程，以及样本的存储检测过程中被破坏，因 
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而无法被检测到。 
相比之下，放射性同位素直接标记目标蛋白的酪氨酸，因而在检测目标蛋白的
释放曲线方面能提供更可靠的结果。但这一方法的局限性在于如果目标蛋白不含有
或含有极少量的酪氨酸，那么同位素标记便有可能不成功。此外，有些蛋白分子的
生物活性靶点包含酪氨酸，同位素标记则有可能导致其生物活性的丧失。另外一个
重要挑战来自于预测生物活性分子的体内优化剂量。体内剂量的准确预测依赖于准
确估计生物活性分子的体内释放曲线和体内生物学活性。然而体内复杂的理化环
境，以及生物活性分子复杂多变的理化特性都能影响其在体内的生物学行为，因此
给准确预测体内生物活性分子的优化剂量带来了挑战。 
总而言之，复合生物活性分子的电纺纤维支架代表了一种新兴的组织修复手
段。一方面，电纺纤维支架良好的柔韧性以及可塑性使其在引导型组织修复，以及
交界组织修复（例如牙周膜，韧带，关节等）中具有良好的应用前景。另一方面，
超细纤维直径所带来的巨大表面积使得电纺纤维支架能够有效加载并释放多种生物
活性分子，以促进组织修复。为了更好的将这一技术从实验室转化向临床，未来需
要更多的研究以阐明生物活性分子的控释以及体内剂量的优化。 
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